Targeted quantitative proteomics in the NF-κB signalling pathway and the ubiquitin-proteasome system by Beaudette, Patrick Edmund
  Dissertation 
 
Targeted quantitative proteomics in the NF-κB signalling 
pathway and the ubiquitin-proteasome system 
 
zur Erklarung des akademischen Grades 
(Dr. rer. nat.) 
 
im Fach Biologie/Molekularbiologie 
 
eingereicht an der 
Lebenswissenschaftlichen Fakultät 
der Humboldt-Universität zu Berlin 
von 
 
Patrick Edmund Beaudette, MSc. 
 
 
 
Präsident der Humboldt-Universität zu Berlin 
Prof. Dr.-Ing. Dr. Sabine Kunst 
 
Dekan der Lebenswissenschaftlichen Fakultät 
Prof. Dr. Bernhard Grimm 
 
 
Gutachter: 
1. Prof. Dr. Thomas Sommer 
2. Prof. Dr. Claus Scheidereit 
3. Prof. Dr. Achim Leutz 
 
Datum der Einreichung: 26.06.2017 
Datum der Promotion: 13.11.2017 
  
1			Introduction	
	 2	
Table of Contents 
 
1			Introduction	...................................................................................................................	4	
1.1			The	NF-B	signalling	pathway.	....................................................................................	4	
1.2			Canonical	versus	non-canonical	NF-B	signalling	mechanisms	......................	5	
1.3			Co-regulated	signal-induced	processing	of	both	NF-B	precursors.	..............	6	
1.4			The	NF-B	precursors	and	partial	proteasomal	processing.	............................	9	
1.5			A	brief	history	of	mass	spectrometry	and	protein	analysis.	............................	10	
1.6		Peptide	versus	whole	protein	MS.	..............................................................................	11	
1.7			Mass	analyzers	in	proteomics.	...................................................................................	11	
1.8			Development	of	shotgun	proteomics.	......................................................................	12	
1.9			Stable	isotopes	and	quantitative	proteomics.	.......................................................	13	
1.10			Protein-protein	interaction	and	post-translational	modifications.	...........	14	
1.11			Undersampling	and	the	need	for	targeted	MS	analysis.	.................................	15	
1.12			Selected-reaction	monitoring	mass	spectrometry.	..........................................	17	
2			Aim	of	this	study.	.......................................................................................................	18	
3			Results.	..........................................................................................................................	19	
3.1			SRM-MS	quantitation	in	the	non-canonical	NF-B	pathway.	.........................	19	3.1.1			Design	and	development	of	selected	reaction	monitoring	methods:	Criteria	for	peptide	selection.	...........................................................................................................................	19	3.1.2			Chemical	synthesis	of	peptide	candidates	permits	optimization	and	refinement	of	SRM	parameters.	......................................................................................................	20	3.1.3			Evaluation	of	synthetic	peptide	candidates	by	their	MS	performance.	............	21	3.1.4			Benchmarking	the	performance	of	the	SRM-MS	methods	.....................................	29	3.1.5			Considerations	in	preparing	protein	lysate	for	MS	analysis.	................................	31	3.1.6			Proof	of	concept:	Challenging	the	SRM-MS	methods.	..............................................	33	3.1.7			Extended	WT	MEF	stimulation.	.........................................................................................	42	3.1.8			Dynamic	SILAC	SRM-MS	analysis	of	MEF	LTR	stimulation	time	course	reveals	distinct	precursor	and	product	populations.	............................................................	44	3.1.9			Inhibition	of	the	ribosome,	proteasome,	or	VCP-p97	blocks	accumulation	of	
de	novo	M-Arg-6	products.	................................................................................................................	47	3.1.10			Mathematical	modelling	of	the	LT-dependent	processing	of	the	precursors	predicts	signal-dependent	processing	of	a	p100-p105	complex.	....................................	50	3.1.11			Expansion	of	SRM-MS	analysis	to	the	broader	NF-B	pathway.	....................	56	
3.2			The	Protein-protein	interaction	network	of	NF-B	precursor	p100.	.........	61	3.2.1			Determination	of	p100	interactome	by	immunoprecipitation.	...........................	61	
3.3			MS	screening	for	radiation-induced	interactors	of	NEMO/IKK .	.................	67	3.3.1			Optimization	of	immunoprecipitation	and	MS	conditions	to	improve	enrichment	of	NEMO.	..........................................................................................................................	68	
3.4			Analyzing	polyubiquitination	by	mass	spectrometry.	.......................................	73	3.4.1			Ubiquitin	linkage	profiling	by	SRM-MS.	.........................................................................	73	3.4.2			Polyubiquitin	and	parkin.	.....................................................................................................	75	3.4.3	Ubiquitin	and	protein	kinase	A	signalling.	......................................................................	78	
4			Discussion	....................................................................................................................	81	
4.1			Inception	and	evolution	of	proteomics.	..................................................................	81	
4.2			Targeted	proteomics	for	analytically	challenging	scarce	protein	species.	.	83	
4.3			Critical	facets	of	the	SRM-MS	method	development	process.	..........................	85	
4.4			The	advantages	of	SRM-MS	over	Western	blotting.	............................................	87	4.4.1			SRM-MS	vs.	Western	blotting:	Quality	of	the	assay.	.................................................	88	
1			Introduction	
	 3	
4.4.2			SRM-MS	vs.	Western	blotting:	Quality	of	the	results.	...............................................	89	
4.5					Dynamic	SILAC	SRM-MS	analysis	of	LT-R	stimulated	MEF	cells.	..............	91	
4.6					Modelling	predicts	a	signal-responsive	precursor	complex.	.........................	92	
4.7					Protein-protein	interaction	analysis	of	p100	and	IKK/NEMO.	.................	94	
4.8					Polyubiquitination	in	cell	signalling	networks.	.................................................	97	4.8.1					Linear	ubiquitination	and	parkin.	..................................................................................	98	4.8.2					Novel	regulation	of	protein	kinase	A	signalling.	......................................................	98	
4.9					Quantitative	proteomics	and	unbiased	biology.	................................................	99	
4.10				Caveats	of	absolute	quantitation.	........................................................................	100	
4.11					Concluding	remarks.	...............................................................................................	102	
5					Summary	..................................................................................................................	104	
6	 Zusammenfassung	.................................................................................................	105	
7					Materials	and	methods.	.......................................................................................	107	
7.1					Materials.	.......................................................................................................................	107	7.1.1					Chemicals.	..............................................................................................................................	107	7.1.2					Enzymes.	.................................................................................................................................	108	7.1.3					Laboratory	equipment	.....................................................................................................	108	7.1.4					Instrumentation.	.................................................................................................................	108	
7.2					Methods	..........................................................................................................................	109	7.2.1					Solid-phase	peptide	synthesis	of	candidates	for	NF-B	assay.	.....................	109	7.2.2					Quantified	SpikeTides	TQL	peptide	standards.	.....................................................	109	7.2.3					StageTips	for	peptide	enrichment	and	desalting.	.................................................	110	7.2.4					Preparation	of	cell	pellet	for	enzymatic	digest.	.....................................................	110	7.2.5					Bradford	determination	of	protein	concentration.	..............................................	111	7.2.6					NanoDrop	determination	of	peptide	concentration.	...........................................	111	7.2.7					SDS-PAGE	preparatory	gel	prior	to	in-gel	enzymatic	digestion.	....................	111	7.2.8					In-gel	protein	digest.	.........................................................................................................	111	7.2.9					In-solution	protein	digest.	..............................................................................................	112	7.2.10					LC-SRM-MS	analysis	of	NF-kB	in	MEF	cells.	.........................................................	112	7.2.11					LC-MS/MS	measurement	of	peptides	derived	from	in-gel	digestion	of	immunoprecipitations,	and	bioinformatic	analysis	of	raw	data.	...................................	113	7.2.12					In-house	manufacture	of	reversed-phase	analytical	columns	with	emitters.	....................................................................................................................................................................	114	
7.3					Collaborator	contributions:	cell	culture,	immunoprecipitations,	and	
mathematical	modelling.	....................................................................................................	114	
8						Appendices	.............................................................................................................	115	
8.1	 Abbreviations	...............................................................................................................	115	
8.2	 List	of	Figures	...............................................................................................................	118	
8.3	 List	of	Tables	.................................................................................................................	120	
8.4				Publications	...................................................................................................................	121	
8.5					Acknowledgements	....................................................................................................	122	
8.6					Eidesstattliche	Erklärung	........................................................................................	123	
9					References	...............................................................................................................	124	
 
 
  
1			Introduction	
	 4	
1   Introduction 
1.1   The NF-κB signalling pathway.  
Investigating the NF-κB family of transcription factors is compelling due to their 
involvement in the regulation of a wide variety of biological activities, helping to 
modulate the immune response, inflammation, cell growth and tissue development 
according to a number of stimuli	 1. Several different signalling systems converge on 
the NF-κB pathway in order to elicit the desired transcriptional response, the 
outcome being tailored to the particular tissue with the appropriate gene regulation. 
For such a central system with expansive effects, it is unsurprising that faulty 
regulation has been linked to numerous pathologies, such as Hodgkin’s lymphoma 
and other malignancies and disorders	2,3	4. A better understanding of the dynamics of 
NF-κB activation is therefore essential for the intelligent design of therapeutic 
interventions. This transcription factor family is comprised of RelA/p65, RelB, c-Rel, 
p50 and p52, which form various homo- and heteromeric dimers that are the 
functional units in gene regulation	 5	 6.	Each protein shares a Rel homology domain 
(RHD) that mediates this dimerization, as well as binding to DNA and promoting 
nuclear localization. In the absence of stimulation these dimers are sequestered in 
the cytoplasm in an inactivated form, achieved by binding to an inhibitory protein of 
the IκB family, a group of proteins bearing an Ankryin Repeat Domain (ARD) that 
masks the nuclear localization signal	 6. The cytoplasmic IκB family includes IκBα, 
IκBβ and IκBε, as well as the precursor proteins p100 and p105	 7.	Regarding the 
precursors p100 and p105, the C-terminal half contains the inhibitory ARD, while the 
N-terminal half are the NF-κB transcription factors p52 and p50, respectively. Upon 
activation of the pathway the inhibitory IκB proteins are degraded, freeing the 
associated dimers to translocate to the nucleus where they can bind to promoter 
regions of their target genes and recruit co-activators and the transcriptional 
machinery. Activation of the NF-κB pathway occurs when different stimuli trigger a 
signalling cascade that leads to phosphorylation of the IκB molecule at specific 
serine residues via the IκB kinase (IKK) complex 8 9, a critical hub comprising two 
types of kinases, IKKα and IKKβ, bound to a regulatory subunit IKKγ/NEMO	 10,11. 
Phosphorylation is closely followed by ubiquitination and proteasome-mediated 
degradation of the relevant IκB.  
 
1			Introduction	
	 5	
1.2   Canonical versus non-canonical NF-κB signalling 
mechanisms 
Depending on the nature of the stimuli and the response required, two types of NF-
κB pathways can be triggered, the canonical or the non-canonical, each 
differentiated by their mechanisms and kinetics. Canonical signalling is activated 
rapidly and propagates transiently until feedback mechanisms, such as NF-κB 
mediated upregulation of IκBs, blunt and terminate the response12. Canonical 
activation depends upon the regulatory ubiquitin binding behaviour of NEMO that 
activates the IKKβ kinase activity. NEMO facilitates an interaction with IκBα13 and 
thereby promotes its phosphorylation, ubiquitination and ultimate degradation and the 
liberation of its associated dimers, typically RelA/p50.  
By contrast the non-canonical signalling pathway is distinguishable by its slow and 
steady activation and persistence, appropriate kinetics considering the governing 
signals are related to development, including B-cell maturation, bone metabolism and 
lymphoid organogenesis14. Activation of the non-canonical pathway is primarily 
through ligand binding to the tumor necrosis factor (TNF) receptor family, such as 
lymphotoxin β receptor (LTβR), BAFFR, CD40, RANK and TNFR25,9. Non-canonical 
signal propagation does not require NEMO but rather depends on the NF-κB 
inducing kinase (NIK), an enzyme that is suppressed at very low basal levels in the 
absence of stimulus by TRAF-cIAP mediated K48 polyubiquitination and proteasomal 
degradation15,16. Pathway stimulation disrupts the TRAF-cIAP complex, promoting an 
elevation of NIK levels by new protein synthesis17-19. Elevated levels of NIK result in 
phosphorylation of the activation loop of IKKα, which in turn phosphorylates C-
terminal serine residues on the NF-κB precursor p100, triggering subsequent SCFβ-
TrCP-catalyzed formation of K48 polyubiquitin chains15,16. In a very curious step, only 
the inhibitory ARD-containing C-terminal half of p100 is degraded by the proteasome, 
while the N-terminal product, now known as p52, escapes destruction and can 
translocate to the nucleus, usually in a dimer with RelB20,21 . It was believed that the 
other NF-κB precursor, p105, undergoes spontaneous proteasomal processing to 
form p50, and upon canonical pathway activation, such as with lipopolysaccharide or 
TNFα, undergoes phosphorylation and ubiquitination events that ultimately lead to its 
complete degradation	22	23	24. Signal-induced processing of endogenous p105 has not 
been previously observed.  
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Figure 1.1 Signaling via the noncanonical NF-κB pathway. 
Binding of lymphotoxin β to the lymphotoxin β receptor (LTβR), leading to a cascade of NIK 
and IKKα-mediated phosphorylations that results in polyubiquitinated p100 being converted to 
the transcriptionally active p52 by a specific proteasomal truncation, with p105 being 
processed to p50 in parallel. Active NF-κB dimers are liberated and translocate to the nucleus 
to effect the transcriptional response to the external stimulus.
1.3   Co-regulated signal-induced processing of both NF-κB 
precursors.  
Non-canonical signalling induces the partial proteasomal processing of the precursor 
p100 to the product p52 via a signalling cascade relying on NIK and IKKα. We have 
recently published data demonstrating that the other NF-κB precursor, p105, 
responds in parallel to a non-canonical stimulus, an agonist of LTβR, and undergoes 
signal-dependent proteasomal truncation to the active product p5025. Figure 1.1 
provides a simplified overview of non-canonical activation of the precursors p100 and 
p105. A western blot analysis of the precursors in cytoplasmic extract following non-
canonical activation via the lymphotoxin β receptor (LTβR) is shown in Figure 1.2A, 
where one can observe the slow decrease of precursor band over time. Non-
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canonical signal responsiveness also appears to be linked, as p105 loses its ability to 
respond to LTβR stimulation in murine embryonic fibroblast (MEF) cells where p100 
has been knocked out, undergoing no signal-induced decrease in protein levels over 
time (Figure 1.2B, right panel). Conversely, when it is p105 that has been genetically 
deleted, the kinetics of p100 processing are enhanced, being processed to p52 more 
rapidly and to a greater extent (Figure 1.2B, left panel). We could show in
coimmunoprecipitation studies  that the two precursors routinely co-purify, suggesting 
a physical interaction and possible association within the context of a complex. This 
observation is further supported by the fact that the two species co-migrate during 
gel-filtration chromatography, eluting in the same high-molecular-weight fractions 
(Figure 1.2C). While the data in Figure 1.2 is a component of the publication 
stemming from my thesis project, it is introduced now as it was instrumental in 
shaping the scope of my work, and its inclusion here is designed to aid the reader in 
understanding the project’s landscape upon my entry into it. A better understanding 
of the co-dependent processing of the NF-κB precursors may shed light on the 
broader regulatory aspects of non-canonical signalling.  
A.
 
NE 
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B. 
                    
C. 
Figure 1.2 Western blot analysis of LTβR-induced MEF cells.  
A. Wild-type MEF cells were induced by treatment with an anti-LTβR agonist (AC.H6) and 
cells sampled over 12 h. Shown are Western blots of p100/p52 (top) and p105/p50 (middle) in 
cytoplasmic extracts, and Western blots of p50 and p52 in nuclear extracts (bottom). 
B. Wild-type and p105 KO MEF cells were induced by treatment with an anti-LTβR agonist 
(5G11B). Cells were sampled over 8 h and cytoplasmic extracts immunoblotted for p100 and 
p105. 
C. Gel filtration chromatography of stimulated (α-LTβR) and unstimulated (uns) wild-type MEF 
lysate, with collected fractions analyzed by immunoblotting for p100 and p105. 
*All MEF cell culture, LT stimulation, gel filtration and immunoblotting performed by Dr. Buket 
Yilmaz. 
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1.4   The NF-κB precursors and partial proteasomal processing. 
One crucial link between the precursors is the fact that they both undergo 
proteasomal processing, destruction of their C-terminal half up to a specific peptide 
bond. The precision of this action is at odds with the usual function of the proteasome, 
a hydrolytic destruction chamber from which no intact protein emerges26. In fact, its 
processing of p100 and p105 is the rare instance of such a function in mammals; 
another transcription factor Gli3 also undergoes a proteasomal truncation.  Its 
analogue in Drosophila is a transcription factor of the Cubitus interruptus (Ci) family 
undergoing a proteasome-mediated C-terminal truncation that serves to reverse its 
role from being a transcriptional activator to a repressor27. In a process with obvious 
parallels to the NF-κB precursor, Ci155 is cleaved to form Ci75 after undergoing 
phosphorylation and ubiquitination. Regulation of this proteasome-mediated action 
has been linked to Ter94, an ATPase associated with diverse cellular functions. (AAA 
ATPase). The mammalian ortholog of Ter94 is called VCP/p97, a hexameric ATPase 
capable of generating mechanical force from ATP hydrolysis and acting on its 
substrates through a family of UBX-domain containing adapter proteins28,29. It plays a 
role in different degradative pathways, such as ubiquitin-fusion degradation (UFD) 
and endoplasmic-reticulum-associated degradation (ERAD)	 30, and is also essential 
for reformation of the nuclear envelope during the cell division cycle31. Within the NF-
κB universe itself, p97 has been linked to the degradation of IkBα in the canonical 
pathway32, a process involving sequential phosphorylation and ubiquitination events. 
Investigating p97’s effect on the precursor processing in the non-canonical NF-κB 
signalling pathway is therefore a worthy venture, and the recent discovery of a 
reversible, competitive small molecule inhibitor of p97 known as DBeQ provides a 
convenient tool for better exploring any mechanistic links33.  
Up to this point the study of partial proteasomal processing of the NF-κB precursors 
has been achieved largely through traditional molecular biology approaches, with 
stimulus-derived concentration changes detected by Western blotting methods. The 
present project proposes to adapt targeted proteomic methods based on selected-
reaction monitoring (SRM) mass spectrometry (MS) in order to measure temporal 
concentration changes of the NF-κB precursors and their products in the presence of 
non-canonical pathway stimulation, namely activation of the LTβR. SRM-MS is used 
in conjunction with nanoflow high-performance liquid chromatography (HPLC) that 
enables absolute quantitation of peptides in a complex biological matrix34. Copy 
numbers of proteins can be determined and precise concentration fold-changes 
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calculated. SRM-MS offers a very high degree of specificity and sensitivity, a vastly 
improved mode of detection that has only been made possible in the last decade due 
to advances in the field of mass spectrometry-based proteomics35.  
1.5   A brief history of mass spectrometry and protein analysis. 
When J.J. Thomson discovered electrons with his cathode ray tube and measured 
their mass-to-charge ratio 120 years ago36, the era of mass spectrometry was born. 
In the beginning its use was relegated largely to physicists and was essential in 
several fundamental scientific findings, such as the discovery of stable isotopes in 
the 1920s37. Up until the 1950s the major practical application was found in the 
petroleum industry to profile hydrocarbons in distillation fractions38, with the first 
peptide sequencing paper appearing in 1959 to usher in a biochemical age for this 
technology39. In this paper the non-volatility of peptides was finally overcome through 
a reductive derivatization of carbonyl groups into polyaminoalcohols, which could 
then form gas-phase ions after harsh, fragment-inducing electron impact (EI) 
ionization. While this ionization was successful only with di- and tripeptides it was still 
a major breakthrough. When cleverly combined with Edman degradation and early 
DNA sequencing, whole protein sequences were elucidated in this way, albeit with 
painstaking effort and time 40-42. Further advances in ionization technology, from 
chemical ionization (CI)	 43 to fast atom bombardment (FAB) 44 enabled larger 
peptides to be ionized without derivatization. From this early point, the protease 
trypsin was used to convert full-length proteins into lower molecular weight, MS-
amenable peptides. The development of electrospray ionization (ESI) at Yale 
University in 1989 by John Fenn and colleagues was a massive leap forward and the 
most important milestone yet in protein mass spectrometry, a method to gently 
convert large biomolecules into gas-phase ions directly from the liquid phase, with 
minimal fragmentation 45,46. ESI represented significant gains in ionization efficiency 
and ion transfer into the mass analyzer and, importantly, ionizing directly from the 
liquid phase meant that ESI could be coupled directly to an HPLC separation.  The 
molecular weight limitations imposed by other ionization methods were also 
effectively removed, as the ESI process generates multiply-charged ions, meaning 
even large biomolecules have a mass-to-charge ratio compatible with the detection 
limits of most mass analyzers.  
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1.6  Peptide versus whole protein MS. 
While the ESI process can ionize an intact protein47, digesting whole proteins into 
peptides offers superior analytical benefits. Peptides are much more uniform in their 
physicochemical profiles, particularly their size, solubility and hydrophobicity48. The 
majority of a protein’s peptides will not be modified by a glycosylation chain, a 
common variable-length post-translational modification (PTM) resulting in a single 
species presenting many mass-to-charge ratios, a process dividing the intensity 
across many channels and reducing sensitivity. In terms of MS analysis, peptides 
have superior ionization potential, leading to improved signal response and sensitivity 
compared to proteins, and their fragment spectra are easier to interpret49. The 
complexity of a whole cell tryptic digest is staggering, a solution with potentially a 
million unique analytes. Fortunately peptides are also very amenable to 
chromatography, with reverse-phase C18 columns routinely employed to resolve 
them in-line with the MS analysis50.  
 
1.7   Mass analyzers in proteomics. 
As ionization technology was advancing, so too were the mass analyzing 
technologies at the heart of a mass spectrometer. Room-sized magnetic sector 
instruments51 were superseded by triple-quadrupole instruments that placed a 
collision cell between two mass analyzing quadrupoles, facilitating mass analysis on 
both intact and fragmented molecules52,53. The first quadrupole selects an ion of 
interest and filters out all remaining signals. The transmitted ion enters the collision 
cell where it strikes molecules of nitrogen or argon at high speed, causing internal 
molecular bonds to break. Ion fragments then enter the third quadrupole where a 
mass spectrum is recorded. Called tandem mass spectrometry, or MS/MS, it 
provides spectra rich in structural information. In the case of peptides, fragmentation 
along the peptide bond backbone means that, with some experience, the amino acid 
sequence of the peptide can be inferred. Other mass analyzers used in biochemistry 
include time-of-flight (TOF), converting an ion’s transit time in a drift tube to a mass-
to-charge ratio, offering high resolution and fast scanning across the mass range54. 
Ion trapping mass analyzers could enrich ions both before and after fragmentation 
and thereby increased the sensitivity of the scans, and multiple levels of 
fragmentation (MSn) allow for deeper structural characterization of molecules55. The 
current apex of ion-trapping technology is the Orbitrap, an analyzer first commercially 
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released in 2000 that now dominates the proteomic landscape56,57. It consists of a 
spindle-shaped electrode within a cylindrical electrode. Trapped ions orbit around the 
spindle with a motion dependent on their mass-to-charge ratio. This motion is 
detected as an image current which is then converted by Fourier transform into a 
mass spectrum58. The quadrupole and the Orbitrap are the two most important mass 
analyzers being used in proteomics. Table 1.1 below compares their relative merits48. 
 
Property Quadrupole  
 
Orbitrap 
 
m/z range 100-1250 50-1800 
Resolution 500-1500 15,000-250,000 
Mass accuracy 20 ppm 0.5 ppm 
Speed Slow, 2000 Da/s Fast, 12,000 Da/s 
Ion transmission 
efficiency 
High  High 
Expense $ $$$ 
Table 1.1 Comparison of triple-quadrupole and Orbitrap mass analyzers. 
 
1.8   Development of shotgun proteomics. 
The completion of the Human Genome Project ushered in an era where the 
completed genomes of humans and other organisms made accessible all of the 
protein sequences encoded in their DNA, whether or not these gene products had 
been previously observed 59,60. Using the genome, one can make a database of the 
complement of peptides all of its proteins would yield when subjected to a tryptic 
digest. Experimental MS spectra of peptides derived from an experimental tryptic 
digest of an unknown protein could be matched to those predicted by the DNA 
sequence in a method called Peptide Mass Fingerprinting (PMF), the concept being 
that a tryptic digest of a given protein yields a mix of tryptic peptide masses uniquely 
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characteristic of that protein61-63. While far faster than the classical Edman 
degradation, this technique worked only for relatively pure samples, such as a band 
excised from a polyacrylamide gel. A technique applicable to complex samples of 
many digested proteins in solution that relied on MS/MS spectra of tryptic peptides 
soon followed. Peptide Fragment Fingerprinting (PFF) matches the experimentally 
observed fragments of a tryptic peptide in an MS/MS spectrum with a database of in 
silico predicted MS/MS spectra derived from a database64,65. This approach, termed 
“shotgun” or “bottom-up” proteomics could be applied to complex samples such as 
whole cell lysates digested with trypsin. Shotgun proteomics completely transformed 
protein biology and led to an explosion of discovery, as identifying proteins no longer 
required tedious efforts to first isolate them for traditional sequencing.  
 
1.9   Stable isotopes and quantitative proteomics. 
Early shotgun proteomics efforts were satisfied with identifying as many proteins in a 
sample as possible, but soon strategies to reliably quantify proteins arising from 
different cells or samples dominated the literature66. Understanding how protein 
expression levels are altered between tissues, according to an external stimulus or in 
a disease state, holds great promise for illuminating mechanistic questions. However 
it is vital that such differences were not simply an artefact of the analysis, such as 
sample preparation or instrument response, and incorrectly assigned a biological 
meaning. An internal standard is needed that can normalize a peptide’s intensity to 
account for technical variations that often arise. Tagging or labelling molecules with 
stable isotopes proved to be an excellent answer, adding neutrons to peptide 
molecules so a portion of the hydrogen (1H), carbon (12C), nitrogen (14N) or oxygen 
(16O) atoms are replaced by a heavier stable isotope (2H or D, 13C, 15N, and 18O)	67-70.	
Assuming sufficient resolution, two peptides with identical amino acid sequences but 
slightly different neutron content could be resolved in a mass spectrum, giving two 
mass-to-charge ratios. Aside from this incremental mass difference, the two species 
are otherwise identical, co-eluting in a chromatographic separation and ionizing with 
the same potential. As an internal standard, isotope-coded peptides can correct for 
technical variations in an LC-MS/MS analysis - injection volume, instrument response, 
chromatography – and highlight true differences in protein levels between samples 
founded in biology.  Incorporation of stable-isotopes can be done both chemically 
and metabolically. Chemical tags typically target a peptide’s primary amine groups, 
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found at the N-terminus and on lysine side-chains, on either intact proteins or on 
tryptic peptides. This can be done inexpensively for two or three parallel samples by 
dimethylating with formaldehyde via a reductive amination process71,72, or using 
commercial products offering higher levels of multiplexing with isobaric tags that 
release quantitation marker fragment ions upon MS/MS fragmentation73,74. For cells 
grown in culture, heavy-labelled amino acids can be incorporated into all proteins 
using the cell’s own translation machinery in a process called Stable Isotope Labeling 
of Amino acids in Cell culture (SILAC)	 75-78. SILAC exploits the principle that lysine is 
an essential amino acid that the cell obtains from the growth media. While arginine is 
not an essential amino acid, biosynthesis is limited and it is mostly obtained from diet 
79. Substituting heavy lysine and arginine amino acids into the culture media, SILAC 
ensures that every tryptic peptide will be labelled at its C-terminus. By labelling early 
in the processing workflow, technical variations related to chemical tagging can be 
avoided. The most recent method in quantitation gaining traction in the field does not 
use stable isotopes at all. Label-free quantitation (LFQ) relies on multiple repeat 
measurements of samples and is valid only when the technical inter-run variations 
are statistically less than any biologically-derived differences between samples being 
compared80,81. For each sample in the set, peptide signals in the form of high-
resolution extracted-ion chromatograms are integrated and averaged with the other 
peptides of a protein that have been detected across all samples, allowing the 
calculation of normalization factors for each sample to correct for technical variations 
in the analysis. The appeal of LFQ is the absence of additional chemical 
manipulations of the sample, and its application for biological systems where SILAC 
cannot be employed, for example in animal models and clinical samples82.  
 
1.10   Protein-protein interaction and post-translational 
modifications. 
With a sound strategy for normalization, quantitative shotgun proteomics is a very 
powerful approach for not only identifying thousands of proteins present within a 
given proteome, but for gaining biological insights into how proteins are differentially 
expressed under certain conditions such as disease. Coupled to 
immunoprecipitations, quantitative proteomics can be used to identify those proteins 
specifically enriched in a sample through direct or indirect association to the bait 
protein83-85. This provides evidence of an interaction that may or may not have 
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functional implications for both proteins, and can help discover protein complexes 
and define their membership	 86 87. Similar strategies can be used to examine 
differences in levels of a post-translational modification. Ciechanover wrote that 
“Timely and selective protein modification is a crucial feature of many modes of 
protein regulation”	88. This is particularly true with phosphorylation and ubiquitination, 
and there exist many examples in the literature identifying and quantifying these 
modifications	 89	 90	 91	 92	 93	 94. Polyubiquitination, the extension of the primary 
ubiquitination site by multiple ubiquitin molecules, plays an important role in signalling 
pathways, including both canonical and non-canonical NF-κB activation	 95	 96. The 
mode by which one ubiquitin molecule is attached to the next in the chain determines 
the fate of the substrate on which the chain is formed. Eight possibilities exist for the 
second and subsequent ubiquitin molecules to connect to the one before it, via 
primary amine groups on the seven internal lysines and the N-terminus of ubiquitin. 
Each linkage has a unique topology and particular linkages have come to be 
associated with particular functions, the classical being K48-linked polyubiquitin	97	98. 
This modification signals the destruction of a target protein and leads to its 
recruitment and hydrolysis at the proteasome	 99. Knowledge of the character of a 
polyubiquitin chain is important to understanding the purpose of a ubiquitination 
event on a specific target protein as well as exploring how the global linkage 
landscape is altered by perturbing the system	 100	 101. Linear polyubiquitin (or M1) 
chains form between the N-terminal amine of a conjugated ubiquitin and the C-
terminal acid group of the incoming ubiquitin molecule	 101. This chain type has been 
shown to play an essential role in certain modes of NF-κB activation	 102	 103, and 
depends on the ‘linear ubiquitin assembly complex’ (LUBAC) a ligase complex 
comprised of Sharpin, HOIL-1L and HOIP. 
 
1.11   Undersampling and the need for targeted MS analysis. 
Continuous innovation and development in mass spectrometry results in new 
instrumentation that collect spectra at a higher rate and achieve greater sensitivity 
being released every couple of years. Despite these advances, the sheer complexity 
of proteomic samples remains a significant analytical challenge, one that is further 
compounded by the vastly different expression levels of proteins across the 
proteome	 104. Termed the ‘dynamic range problem’, it refers to the fact that some 
proteins are expressed at high levels across tissues (e.g. mammalian VCP/p97 is 
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thought to comprise 1% of cytosolic protein	 105) while others are present at 
vanishingly low amounts	 106	 107. In mammalian cells, this range spans 6 orders of 
magnitude: for every copy of a rare protein, there are a million copies of the most 
abundant protein. In human plasma the problem is even more extreme, with a span 
of 10 orders of magnitude, or 10 billion of the most common protein molecules for 
every one of the least common	 108. Like the proverbial needle lost in a haystack, the 
peptides from the most abundant proteins dominate the sample while the least 
abundant are easily lost to obscurity	 109. In 2010, 50% of all MS/MS spectra found in 
public data repositories represented only 82 human proteins	 110. Unlike genomic 
research, there is no amplification scheme available to boost levels of rare proteins 
until they are in the detection range. As a consequence, these rare proteins are 
underrepresented in datasets, overlooked by instrumentation working beyond its 
capacity. The most common type of shotgun proteomics measurement is called a 
data-dependent analysis (DDA) and is structured as a Top 10 experiment	 48	 111. An 
initial full spectrum MS scan identifies the ten most intense peptide peaks currently 
eluting from the column at a given time. Following this survey scan, ten MS/MS 
scans of these selected peptides are acquired before the cycle repeats itself. To 
avoid redundancy a given signal cannot be selected again for MS/MS for a short 
duration to allow the elution to finish.  One issue with this approach is that ionization 
suppression effects between co-eluting peptides means that many weaker signals 
are never selected for MS/MS, with a bias towards the most abundant proteins that 
have higher MS intensities. Another is that despite the advances in instrumentation, 
even at a lofty MS/MS acquisition rate of 200 scans per minute, it is mathematically 
impossible to sequence every peptide from complex whole-cell digest samples. This 
problem is called undersampling and comes with the drawback that shotgun data 
sets suffer from a reproducibility problem: two back-to-back measurements of the 
same sample will not cover all of the same proteins or peptides	112. Naturally it is the 
least abundant proteins where this effect is felt most acutely, in which category the 
transcription factors such as the NF-κB family tend to fall. This poses a challenge for 
quantitative proteomics experiments when the same proteins must be measured 
across a large number of samples, such as those derived from a clinical study or 
from a time-course experiment.  
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1.12   Selected-reaction monitoring mass spectrometry. 
A different approach to MS analysis is required to alleviate this issue. When the 
analytical goal is to reproducibly quantify a pre-selected group of proteins in a sample 
and not the entire proteome, it is appropriate to employ a Targeted Proteomics 
approach, namely SRM-MS	 35	 113. Unlike a data-dependent shotgun analysis, 
targeted proteomics focuses the instrument’s attention on a predetermined group of 
peptides with known MS/MS fragmentation patterns that represent the proteins of 
interest in the study. The LC separation component does not change, but the type of 
MS mass analyzer does. LC-SRM-MS utilizes the mass filtering properties of a triple-
quadrupole (QQQ) MS instrument	114 to selectively monitor a specific peptide analyte. 
The first quadrupole filters all masses except that corresponding to the target peptide 
in its known charge state. The selected fragment ion is fragmented in the second 
stage by high-energy impacts with a collision gas	 115. Finally the third quadrupole 
filters and measures specific fragment ions derived from that peptide. This precursor 
ion/fragment ion pair is called a transition and several transitions per peptide are 
measured to improve the method’s selectivity. A series of transitions corresponding 
to multiple peptides are cycled through repeatedly and record multiple data points as 
a peptide elutes from the chromatographic column. The resulting chromatographic 
peaks can be integrated and the area under the curve used for relative quantitation. 
When heavy-isotope-labelled internal standard peptides are spiked into the sample, 
their signal forms the basis for absolute quantitation of the peptide analysis. The 
present project aims to adapt targeted proteomic methods based on SRM-MS 
detection in order to measure the concentrations of the NF-κB precursors and their 
processing products following LTβR stimulation. 
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2   Aim of this study. 
Activation of the non-canonical NF-κB signalling pathway is known to result in 
proteolytic processing of p100 by the proteasome to form p52. Our publication	25 has 
expanded this mechanism to include a stimulus-dependent processing of p105 to its 
transcriptionally active form p50, a process tightly-coupled to p100. The aim of the 
current study is to examine the processing and degradation of endogenous NF-κB 
precursors p100 and p105 in a time-resolved manner in murine embryonic fibroblasts 
(MEFs). To this end, traditional immunology-based detection methods are replaced 
with a targeted proteomics approach employing selected-reaction monitoring mass 
spectrometry (SRM-MS) to facilitate absolute quantitation of both the precursors 
p100 and p105 and their respective products p52 and p50. The strategy relies on the 
incorporation of stable isotopes into synthetic peptides for quantitation, and into 
proteins through metabolic labeling of cells in culture to distinguish pre- and post-
stimulation populations of proteins. Ultimately this absolute, time-resolved 
quantitative data will be used to challenge various mathematical models of this 
pathway activation mechanism to support or refute the hypothesis that the NF-κB 
precursors p100 and p105 form a complex that responds to the lymphotoxin β 
receptor activation signal in a concerted manner. Building upon this work, the protein-
protein interaction network of p100 will be investigated to identify other proteins with 
a functional role in the activation mechanism, particularly with respect to the 
proteasomal processing step. 
The canonical NF-kB pathway, in particular the DNA damage response, will be 
studied with non-targeted (i.e. data-dependent) proteomic methods. The protein-
protein interaction network of endogenous IKKΥ/NEMO will be unravelled in an effort 
to identify cytoplasmic partners of this important signalling hub that bind to an 
IKKΥ/NEMO complex in response to irradiation.  
Additionally, both targeted and non-targeted proteomics methods will be applied to 
determine the nature of polyubiquitin linkages present in a specific system. Here the 
goal is attaining a better understanding of parkin’s role in anti-apoptotic activity as 
well as mechanisms governing the regulation of protein kinase A (PKA) signalling 
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3   Results. 
 
3.1   SRM-MS quantitation in the non-canonical NF-κB pathway.  
 
3.1.1   Design and development of selected reaction monitoring 
methods: Criteria for peptide selection.  
Selection of an appropriate peptide to act as proxy for the quantitation of its parent 
protein is a critical first step in the development of a selected reaction monitoring 
method. Foremost, the chosen peptide(s) must represent an amino acid sequence 
that is unique, termed proteotypic. A proteotypic peptide is necessary for the 
unambiguous measurement of the target protein. Additional criteria impacting peptide 
selection are MS sensitivity, chromatography and number of potential isoforms. The 
ideal peptide exists in one form, meaning a single charge state and no chemical or 
post-translational modifications. Multiple isoforms of a peptide complicate 
quantitation, as multiple internal standards are required to tally the contributions 
made by each. Moreover as each form is likely to possess a discrete mass, the 
presence of multiple signals essentially divides the ion current amongst all of them, 
lowering the overall intensity and reducing sensitivity. The list below summarizes 
criteria most important for peptide selection	116: 
 
Peptide properties to avoid: 
• Methionine residues. 
• Annotated or suspected sites of post-translational modification. 
• Sequence motifs triggering missed cleavage events e.g -KR, -KK. 
• Short hydrophilic peptides. 
• Long hydrophobic peptides. 
 
Oxidation of methionine, post-translational modification and missed cleavages all 
result in multiple isoforms of the same peptide. Short, hydrophilic peptides are 
undesired as they are not well retained by reverse-phase chromatography and can 
elute too early in the gradient. Conversely, long hydrophobic peptides may elute too 
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late, and solubility problems may cause difficulty when using synthetic peptides as an 
internal standard.  
3.1.2   Chemical synthesis of peptide candidates permits optimization 
and refinement of SRM parameters. 
Selection of peptides according to the above guidelines is helpful for filtering out 
potentially problematic sequences. In silico prediction tools 117,118 can be helpful in 
narrowing the field of options, but empirical evidence is far more valuable as the MS 
performance of a particular peptide is challenging to predict. 
Solid-phase synthesis of peptides is achieved through coupling amino acid 
derivatives in the required order on a resin support using Fmoc protecting groups to 
block reactive moieties in the side-chains so that amino acids are joined together 
through the backbone carboxylic acid and primary amine groups. The schematic in 
Figure 2.1 shows an Fmoc-protected amino acid derivative being added to a growing 
peptide chain bound to a solid support. 
Figure 2.1  Solid-phase peptide synthesis using a Rink amide support. (adapted 
from Dan Cojocari/Wikipedia) 
For our purposes a Rink amide (hydroxymethyl-polystyrene) resin was employed, the 
resultant peptide products having an amidated C-terminus rather than a free acid 
group	 119. This trade-off is weighed against the gentler cleavage conditions (95% 
trifluoroacetic acid, TFA) to efficiently release the peptides from the resin.  While the 
amidated synthetic peptide is 1 Da heavier than its native counterpart it behaves 
+ Fmoc-protected amino 
acid 
95% TFA deprotection and 
cleavage from support 
Rink 
amide 
resin 
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virtually identically. Importantly, the peptide will adopt the same charge state and 
fragmentation patterns and therefore provide an opportunity for tuning and optimizing 
the MS instrument parameters in order to maximize the performance of the SRM 
method.  
Following the solid-phase synthesis procedure, the resins were washed thoroughly 
with Ethanol before elution with the TFA cleavage buffer. The peptides were 
precipitated from the eluate with cold methyl-t-butyl ether to afford several milligrams 
of white to off-white solid. A purity of 90% was assumed and the peptide products 
dissolved in 30% acetonitrile containing 0.1% formic acid to make stock solutions of 1 
mM. The reaction products were evaluated in the next step by MS characterization 
on a triple-quadrupole mass spectrometer, and the candidates with the most intense 
MS signal response were selected for further development.  
 
3.1.3   Evaluation of synthetic peptide candidates by their MS 
performance. 
The motion of a positively-charged gas-phase peptide ion within the vacuum of a 
mass spectrometer is manipulated by application of negative electrical potential and 
radiofrequency waves. Analogous to how light is bent and focused in a microscope 
with lenses and mirrors, the MS uses ring electrodes and quadrupoles to selectively 
transmit and focus beams of gas-phase ions. The schematic in Figure 2.2 illustrates 
the ion path of a triple-quadrupole mass spectrometer.  
 
Figure 2.2  Schematic representation of triple-quadrupole (QQQ) mass 
spectrometer.  
Mass filtering at Q1 selects the precursor peptide ion, which is transmitted to Q2 where it is 
fragmented by high-energy collision with nitrogen gas molecules. Mass filtering of the 
selected fragment mass in Q3 completes the circuit, generating a measureable ion current 
that is plotted. 
 
The triple quadrupole instruments used for this work, Sciex 5500 or 6500 Q-Traps, 
have a third quadrupole that can also function as a linear ion trap, trapping and 
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enriching precursor or fragment ions until they are scanned out to the detector. This 
functionality was used in method development to amplify the signal and increase the 
signal-to-noise. All peptides derived from the solid-phase synthesis were subjected to 
the following MS characterization. A synthetic tryptic peptide from p100 
(TPSPSGSLLR) will be used as an example to illustrate the process of method 
development.  The first step is confirmation of the expected mass of the synthetic 
peptide. The formula: m/z = (M+ nH)/n gives the mass (m) to charge (z) ratio for a 
given charge state, where n is the number of additional protons. Tryptic peptides 
generally have a minimum of two basic (i.e. proton accepting) sites, the N-terminal 
amine and the basic side-chain of the C-terminal lysine or arginine residue. In 
electrospray MS at acidic pH both sites are charged, meaning the majority of tryptic
peptides have a charge state of 2. Figure 2.3 shows an MS1 spectrum for the peptide 
TPSPSGSLLR collected by scanning a 100-1000 mass range at 1000 Da/s in the 
linear ion trap; the view has been zoomed to 30 Da of the x-axis to better show detail. 
The peptide has a calculated molecular weight of 1014.55 Da, so the observed value 
of 507.4 Th indicates that this peptide has two additional protons resulting in the 
double charge. (1013.55+2)/2 = 507.8 (observed mass offset from calculated mass 
due to deviation in calibration of the linear ion trap). The resolution of this scan is 
insufficient to fully resolve the isotopes of the peptide. 
 
Figure 2.3   Enhanced MS spectrum of the p100 peptide TPSPSGSLLR.  
In Figure 2.4 an enhanced resolution scan resolves the isotopes of the peptide to the 
baseline, with the higher-mass peaks corresponding to 12C atoms replaced by one or 
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two 13C atoms, the proportion dictated by the natural abundance of this isotope, 1.1%. 
“Enhanced resolution” is achieved by collecting ions in the linear ion trap and 
scanning a narrow mass range at a slow speed. The spacing of the isotope peaks 
provides another way to determine the charge state of the molecule by counting the 
number of isotopes occurring within a single unit of the m/z scale. 
  
Figure 2.4   Enhanced Resolution spectrum of the p100 peptide TPSPSGSLLR. 
The MS1 measurements complete the first entry in the SRM method, the observed 
precursor mass to be isolated by quadrupole 1. An MS/MS scan is performed next to 
establish the collision-induced dissociation (CID) fragmentation pattern of the peptide. 
Figure 2.5 shows an MS/MS spectrum of the precursor with an m/z of 507.4, the 
location of which is indicated on the spectra with an arrow. Collision with an N2 
molecule splits the peptide into two pieces and results in singly-charged fragments
flying through to the detector. When possible, incorporating fragments into the SRM 
method with m/z values greater than the precursor is advantageous, as it eliminates 
the possibility of singly-charged background ions interfering with the measurement.   
This is illustrated more dramatically in Figure 2.10, an MS/MS spectrum of p105 
peptide VGADLSLLDR. One can clearly observe that below the precursor m/z of 
529.8 the spectra is populated by more fragment ions of a higher intensity than in the 
higher mass ranges.  
With the successful acquisition of a good quality MS/MS spectrum, the fragment ions 
to be filtered in quadrupole 3 can be selected. From Figure 2.5A, the fragments 
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corresponding to y5, y6, y7 and y8 are at higher m/z than the precursor and have a 
high intensity, making them ideal candidates to use in an SRM transition. 
A.
B. 
Figure 2.5  
A. Schematic of a generic peptide with naming convention of N-and C-terminal fragment 
types following breakage of the indicated peptide bond.  
B. Product ion (MS/MS) spectrum of of p100 peptide TPSPSGSLLR with major fragments 
labeled according to convention. Arrow indicates m/z of precursor ion. 
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While a precursor and fragment mass are the minimum requirement of an SRM 
method, the existence of synthetic standards permits a more thorough method 
development by optimizing two key instrument parameters, the declustering potential 
(DP) and the collision energy (CE). Tuning these can allow for the maximum ion 
current through the system and therefore the greatest sensitivity, essential for the 
detection of low-abundance species. The declustering potential is a voltage applied 
at the orifice of the machine, where the electrosprayed ions at atmospheric pressure 
enter into the vacuum of the instrument, and it functions to break up the clusters of 
ions. Minimizing clusters is akin to maximizing the transmission of single ions, 
meaning the maximum amount of precursor ion can be transmitted through the first 
quadrupole. A declustering potential ramp from 50 to 300V was applied to the SRM 
transitions and the ion transmission monitored. Figure 2.6 shows the individual 
curves collected for each transition across this range, with the optimal value defined 
as the highest intensity, otherwise interpreted as the maximum ion current. One 
observes that the curves are relatively flat but that the maxima offer a 20-30% 
increase in signal strength relative to the mimima. For the p100 peptide 
TPSPSGSLLR a value of 150 V was selected as a common DP value for all 
transitions, indicated by a vertical dashed line in Figure 2.6.  
 
Figure 2.6   Declustering potential optimization. 
A solution of the p100 peptide TPSPSGSLLR was infused at 5 μL/min into the Sciex 5500 Q-
trap triple-quadrupole MS while the voltage applied at the orifice is ramped between 0 and 
300 V in 5V increments during continuous acquisition of the indicated SRM transitions. The 
vertical dashed line is the DP value selected for all measurements. 
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Tuning of the collision energy offers the greatest opportunity to increase the method 
sensitivity. Below the optimal value a portion of the precursor molecule remains 
unfragmented and therefore cannot contribute to the fragment current detected 
beyond Q3. Above the optimal value the higher energy imparted to the precursor can 
lead to more than one fragmentation event per molecule. The intensity of the 
monitored fragment ions could lose intensity due to such a secondary fragmentation, 
reducing the ion current and sensitivity. The collision energy was ramped from 5 to 
50 eV and the intensity for each transition measured across the range, with Figure 
2.7 showing just how crucial tuning this parameter is; only a 5 eV shift to either side 
of the maxima corresponds to loss of intensity of approximately 25%. The dashed 
gray line in the figure represents the collision energy calculated using a linear 
equation as in Skyline	120. While it is a reasonable estimation of the optimal value, it is 
clear that it oversimplifies fragmentation behaviour by only taking into account the 
precursor’s mass and charge state.   
Figure 2.7   Collision energy optimization for p100 peptide TPSPSGSLLR. 
A solution of the p100 peptide TPSPSGSLLR was infused at 5 μL/min into the Sciex 5500 Q-
trap triple-quadrupole MS while the kinetic energy imparted to the precursor ion is ramped 
between 5 and 80 eV in 1 eV increments during continuous acquisition of the indicated SRM 
transitions. The dashed vertical line is the calculated collision energy value. 
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The MS characterization of the peptides from p105, p52 and p50 were carried out in 
the same manner, with further examples given below for the p105 peptide 
VGADLSLLDR (Figure 2.8 – 2.12).  Table 2.1 indicates the sequence of each peptide, 
its position within the sequence, the precursor and fragment masses included in the 
method as well as the optimized collision energies.  
 
Figure 2.8 Enhanced MS scan of p105 peptide VGADLSLLDR. 
 
Figure 2.9 Enhanced resolution scan of p105 peptide VGADLSLLDR. 
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Figure 2.10 Product ion (MS/MS) spectra of p105 peptide VGADLSLLDR.  
Product ion (MS/MS) spectrum of p100 peptide VGADLSLLDR with major fragments labeled 
according to convention. Note increase in singly-charged background ions below precursor 
m/z of 529.4. 
 
Figure 2.11 Collision energy optimization for p105 peptide VGADLSLLDR. 
A solution of the p105 peptide VGADSLLDR was infused at 5 μL/min into the Sciex 5500 Q-
trap triple-quadrupole MS while the kinetic energy imparted to the precursor ion is ramped 
between 5 and 80 eV in 1 eV increments during continuous acquisition of the indicated SRM 
transitions. 
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Figure 2.12 Schematic of tryptic peptides and their relative sequence position 
chosen for SRM-MS analysis of NF-kB precursors and products.  
 
Peptide Protein Sequence 
position 
SRM transitions; Fragment ID, 
(CE in eV) 
QYAIVFR p52 284-290 448.75  >  534.33;  y4 (20) 
448.75  >  421.25;  y3 (21) 
448.75  >  605.37;  y5 (26) 
 
TPSPSGSLLR p100 810-819 507.78  >  729.43;  y7 (26) 
507.78  >  816.46;  y8 (25) 
507.78  >  632.37;  y6 (31) 
VFETLEAR p50 147-154 482.75  >  718.36;  y6 (21) 
482.75  >  589.32;  y5 (23) 
482.75  >  865.43;  y7 (20) 
VGADLSLLDR p105 600-609 529.79  >  603.34;  y5 (23) 
529.79  >  959.51;  y9 (20) 
529.79  >  831.45;  y7 (22) 
Table 2.1 SRM transitions for MS analysis of p100/p52 and p105/p50 protein 
species.  
 
3.1.4   Benchmarking the performance of the SRM-MS methods 
The next phase of method development involves measuring both the native and 
isotopically-heavy (Arg 10) peptide in a complex background of a whole-cell tryptic 
digest. The SRM-MS analysis of peptides is always coupled to a chromatography 
step. Most typically, a solution of tryptic peptides is injected onto a reversed-phase 
column and a gradient of increasing acetonitrile elutes peptides largely according to 
their hydrophobic properties. The SRM signal is recorded over time and manifests 
itself as a peak, with the integrated area under the curve a function of the amount of 
peptide injected. The ideal internal standard is a peptide analogue with an identical 
amino acid sequence but with additional neutrons incorporated in the lysine and 
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arginine residues that are by definition at the C-terminus of a tryptic peptide. Such a 
molecule is physicochemically indistinguishable from the native peptide, eluting at the 
same time and fragmenting in the same way, but resolved into a distinct signal by the 
MS. When a fixed amount of IS is injected together with the samples, the IS peak 
area can be utilized to normalize the signal of the native peptide and facilitate relative 
quantitation between samples. When the quantity of IS is known precisely, the signal 
can be used to apply an absolute quantitation of the native species. Such 
normalization is important in LC-MS experiments due to the number of variables that 
can waver between injections: volume of sample injected by the autosampler, drift in 
instrument response, and ionization suppression.  
For the SRM-MS method to be a viable quantitation tool, an experiment was 
designed to demonstrate that the MS detector responds linearly to increasing 
amounts of peptide.  High-purity synthetic peptides were purchased from JPT 
Peptide Technologies GmbH (Berlin, Germany) serially-diluted in a fixed background 
of a tryptic digest of MEF whole cell lysate. Such a digest presents a worst-case 
scenario with respect to sample complexity; an entire proteome cleaved into 
hundreds of thousands of unique peptide species. At any given point during the 
gradient elution, hundreds of peptides may be co-eluting, creating an environment of 
competition in the electrospray ionization process. A higher affinity for protons for 
some peptide suppresses the ionization of co-eluting species, preventing their 
conversion to gas-phase ions and reducing sensitivity for that particular target. Figure 
2.13 plots the ratio of the two signals, dividing the area under the curve (AUC) of the 
isotopically-heavy (with a 13C615N4 composition, or H-Arg-10) internal standard by the 
AUC of the native (12C614N4 composition, or L-Arg-0) peptide. Note that this is a 
reversal of the usual arrangement, where a fixed amount of heavy peptide is used to 
quantify the variable amounts of native peptide present in biological samples. The 
plots demonstrate several important details: the SRM method succeeds in detecting 
each of the targets in the complex sample, even down to 1 fmol of peptide injected in 
a complex background. Linear regression analysis of the plots gives R2 values 
approaching 1, indicating that the instrument responds linearly over this range of 
concentrations. Finally, these plots are helpful in determining an appropriate amount 
of internal standard to include in future measurements of MEF cells. The linearity of 
p105’s MS signal response (R2 = 0.94) is not as convincing as for the other peptides 
(R2 ≈ 0.99). This can be offset by carefully choosing the amount of internal standard 
to spike in. For an ideal quantitation the amount of internal standard is approximately 
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equal to the amount of native peptide present in the sample, resulting in a peak area 
ratio of 1. When both analyte and standard belong to the same order of magnitude, 
the linearity of signal response is less strained and the internal standard can be used 
to effect a single-point calibration. For all of the peptide targets, an internal standard 
amount of 5 fmols was chosen for the quantitation of MEF-derived samples as this 
satisfied the ratio criteria and a single concentration simplifies the sample preparation 
workflow. The SRM methods designed for the quantitation of NF-κB family members 
p100/p52 and p105/p50 have met the analytical requirements set forth and are ready 
to be tested in the context of larger biological experiments. 
 
 
Figure 2.13 Signal response curves for NF-κB peptides. 
Calibration curve prepared by spiking heavy (H-Arg-10) SpikeTide reference peptides into a 
fixed background of a tryptic MEF digest. Injected samples were resolved on a nanoflow 
chromatographic system (Eksigent) and on-line SRM-MS analysis was performed on a Sciex 
5500 Q-Trap triple-quadrupole in positive ion mode Plotted are the ratio of the H-Arg-10 
peptide signal divided by the endogenous L-Arg-0 peptide signal. 
 
 
3.1.5   Considerations in preparing protein lysate for MS analysis. 
Sample preparation in proteomics is a key step that will impact the success of any 
downstream measurement. For samples derived from cell culture, the objective is to 
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produce a reasonably concentrated protein solution free of undesirable cellular 
components. These include: 
1. Genomic DNA: This must be mechanically or enzymatically sheared into 
shorter (<500) base pair oligonucleotides or the solution becomes viscous. 
This viscosity reduces the fidelity of any liquid transfer steps, and lower 
diffusion rates decrease the efficiency of any chemical or enzymatic 
treatments. Additionally, intact DNA is highly-charged and can retain some 
peptides and proteins through ionic interactions. 
2. Lipids and small-molecule metabolites: When these compounds are not the 
target of analysis they only serve to create an additional analytical burden by 
contributing to sample complexity and ion suppression, and can negatively 
impact chromatographic behaviour (see Figure 2.23, p50 measurement 
following Wessel-Fluegge treatment) 
3. Detergents: While included in many molecular biology protocols to aid in the 
lysis and dissolution of plasma membranes, their presence during the 
electrospray process lowers surface tension and prevents formation of 
droplets. Detergents that are polymeric in nature (e.g NP-40, Triton X-100) 
can be a pervasive contaminant, dominating spectra and obscuring weaker 
peptide signals via ionization suppression effects across much of a gradient 
elution.  
In addition to excluding unwanted components, it is necessary to prevent post-lysis 
alterations to the proteome, a common problem when the compartmentalization of 
the cell is disrupted, leading to non-specific proteolysis or other post-translational 
modifications. Inclusion of phosphatase and deubiquitinase inhibitors (NaV, NaF, 
NEM) are tolerated though any resulting chemical modifications they cause must be 
taken into consideration for the mass shift they induce in a target. Protease inhibitors 
must be avoided, as they will severely inhibit the tryptic digest. A complete 
denaturation of the proteome can achieve the same goal, preventing random 
background proteolysis by disrupting the structure of the proteases.  
In the simplest form of proteomic sample preparation, in-solution digest, cells are 
lysed in a buffered solution of 6M urea/2M thiourea with the aid of vortexing and 
ultrasonication, the latter serving to shatter the genomic DNA as well. There is 
minimal loss of protein material, with the exception of membrane-bound proteins that 
are notoriously difficult to solubilize and are typically underrepresented in such a 
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preparation. Cell lysate can also be filtered using a gel matrix, such as in sodium 
dodecyl sulfate-polyacrylamide electrophoresis (SDS-PAGE). Small molecules (<500 
Da) are readily removed and the gel-embedded proteins can be stably manipulated 
by chemical modification and digestion. Tryptic digestion of the reduced and 
denatured proteome typically proceeds with fewer missed cleavages than an in-
solution preparation, but extracting the peptides for MS analysis following the 
digestion is problematic, with estimates of losses ranging up to 90% 121. 
The Wessel-Fluegge method 122 is a liquid-liquid extraction protocol designed to 
partition cellular biomolecules between polar (methanol/water) and non-polar 
(chloroform) phases. Protein and DNA precipitates align along the interface between 
the two immiscible liquid phases, while small-molecule metabolites and lipids 
partition to the polar and non-polar phases, respectively. Though some losses occur 
due to incomplete precipitation and re-solubilization, the Wessel-Fluegge technique 
combines the high-yield of the in-solution digest method with the cleaner background 
of the gel preparation. Changing to Wessel-Fluegge from the in-solution digest 
protocol was important in remedying an issue with the measurement of p50. When 
prepared by in-solution digest, the measured peak was weak, broad and tailing 
(Figure 2.23), a challenging peak to quantify accurately as the peak boundaries are 
less sharp and the wide elution window is more likely to include interfering co-eluters. 
The drastic improvement in peak shape and intensity seen in Figure 2.21 after a 
Wessel-Fluegge preparation is clear. One can speculate about the deleterious role 
that small molecules and lipids may have played in altering the chromatographic 
behaviour, but what is important is that a narrower peak coupled to a higher intensity 
makes the assay for p105 detection both more selective and sensitive. 
 
3.1.6   Proof of concept: Challenging the SRM-MS methods.  
The dynamics of LT-βR-triggered non-canonical NF-κB signalling have previously 
been explored by using Western blotting techniques. Figure 1.2 showed the effect of 
stimulation on the levels of p100 over time, as measured in cytoplasmic extract. After 
4 h of LTβR stimulation there is a sharp reduction in the intensity of the p100 band, 
even more pronounced at the 6h timepoint. A novel finding preceding this work is that 
p105 also responds to the non-canonical stimulus, the amount reducing markedly on 
a similar timescale as with p100. In the cytoplasmic compartment, the levels of p52 
and p50 do not appear to change.  When p105 is absent from the cell due to a 
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knock-out, p100 levels appear to decline at a faster rate and to a lower endpoint, with 
the band disappearing after 4h of stimulation. 
 
In this proof-of-concept experiment, the questions asked of the SRM-MS 
methodology are as follows:  
1. How selective is SRM-MS i.e. are there any interferences or artefacts 
influencing the measurement? 
2. Are the same trends observed for p100/p52 and p105/p50 that are seen in 
the Western blot analysis? 
3. Is SRM-MS detection as sensitive as Western blotting? 
 
As mentioned, a tryptic digest of a whole cell protein extract has a staggering 
complexity. The possibility exists of a co-eluting peptide presenting a similar mass in 
Q1 and yielding fragments of similar mass. The mass filtering is relatively coarse, 
isolating a 0.7 m/z window for transmission to Q2, so the selectivity achieved with 
such a complex sample is imperfect.  Co-eluting interferences might be dealt with by 
changing the chromatographic condition, manipulating the gradient’s duration and 
profile to achieve a separation of the two species. If the interference cannot be 
completely separated and forms a shoulder with the target peak, splitting the peak at 
the valley when integrating is sufficient for quantitation.  
MEF cell lines in which the various NF-κB precursors’ and products’ are not formed 
due to the applied knock-out provide an opportunity to examine the selectivity of the 
SRM-MS measurement; the absence of the target will make any co-eluting 
interference easier to observe. Please note that all cell material was provided by my 
collaborator Dr. Buket Yilmaz as pellets. The p100-/- and p105-/- MEF cell lines have 
the C-terminal coding region truncated but leave an intact N-terminal sequence of the 
precursor genes, so p52 and p50 are present. Nfkb2-/- and Nfkb1-/- are complete 
knockouts where neither the precursor nor the product are present in the cell.  
The Nfkb2-/- MEF cell line was probed by the p100 and p52 SRM methods. A heavy 
(H-Arg-10) internal standard was included to act as a positive control and elution time 
marker, pinpointing the precise elution time of the L-Arg-0 peptide. In Figure 2.14, the 
H-Arg-10 peptide is observed to elute at 19.1 min, as indicated by the three 
monitored transitions co-eluting as characteristic nesting peaks at that point. 
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Examining the same retention time window in the L Arg-0 trace of a wild-type MEF 
(Figure 2.15), the nesting peaks are observed at the same timepoint, while in the 
p100 KO MEF (Figure 2.16) there is no corresponding signal at this retention time, 
indicating both the expected absence of this species in the sample and 
demonstrating the selectivity of the SRM-MS detection method.  All of the traces 
shown below show that for each SRM transition being monitored, there is a 
significant ion current present during much of the gradient, with distinct 
chromatographic peaks indicating an eluting peptide that shares a precursor and 
fragment mass in common with the target peptide. This underlines the value for using 
a heavy internal standard to confirm the elution time. 
 
Figure 2.14 SRM-MS measurement of H-Arg-10 p100 peptide in wild-type MEF. 
Five fmols of H-Arg-10 SpikeTide internal standard in a fixed background of 5 μg of a tryptic 
digest of wild-type whole-cell murine embryonic fibroblasts measured by SRM-MS on a 5500 
Q-Trap. The dashed box indicates the SRM signals for H-Arg-10 TPSPSGSLLR.  
*MEF cell pellets provided by Dr. Buket Yilmaz. 
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Figure 2.15 SRM-MS measurement of L-Arg-0 p100 peptide in wild-type MEF. 
Five μg of a tryptic digest of wild-type whole-cell murine embryonic fibroblasts and measured 
by SRM-MS on a 5500 Q-Trap. The dashed box indicates the SRM signals for the L-Arg-0 
peptide TPSPSGSLLR. 
*MEF cell pellets provided by Dr. Buket Yilmaz. 
 
Figure 2.16 SRM-MS measurement of L-Arg-0 p100 peptide in p100-/- MEF. 
Five μg of a tryptic digest of p100-/- whole-cell murine embryonic fibroblasts measured by 
SRM-MS on a 5500 Q-Trap. The dashed box indicates the established elution window for the 
L-Arg-0 peptide TPSPSGSLLR. 
*MEF cell pellets provided by Dr. Buket Yilmaz. 
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Similarly for the other targets, the knock-out cell lines facilitated a demonstration of 
the selectivity of the SRM-MS methods. Figures 2.17 through 2.23 illustrate this in the 
detection of the peptides QYAIVFR (p52), VGADLSLLDR (p105) or VFETLEAR (p50). 
The absence of signal during the expected elution windows in the knockout cell lines 
is confirmation that the measurement of p100 and p52 is not subject to background 
interference co-eluting at the same time. The methods p105 and p50 were also 
proven selective in this manner; in both cases no signal was found in the retention 
window indicated by the elution of the spiked-in heavy peptide standard. 
Figure 2.17 SRM-MS measurement H-Arg-10 p52 peptide in Nfkb2-/- MEF. 
Five fmols of H-Arg-10 SpikeTide internal standard in a fixed background of 5 μg of a tryptic 
digest of nfkb2-/- whole-cell murine embryonic fibroblasts measured by SRM-MS on a 5500 Q-
Trap. The dashed box indicates the SRM signal for H-Arg-10 QYAIVFR.  
*MEF cell pellets provided by Dr. Buket Yilmaz. 
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Figure 2.18 SRM-MS measurement of L-Arg-0 p52 peptide in Nfkb2-/- MEF. 
Five μg of a tryptic digest of nfkb2-/- whole-cell murine embryonic fibroblasts measured by 
SRM-MS on a 5500 Q-Trap. The dashed box indicates the established elution window for the 
L-Arg-0 peptide QYAIVFR. 
*MEF cell pellets provided by Dr. Buket Yilmaz. 
Figure 2.19 SRM-MS measurement of H-Arg-10 p105 peptide in wild-type MEF. 
Five fmols of H-Arg-10 SpikeTide internal standard in a fixed background of 5 μg of a tryptic 
digest of wild-type whole-cell murine embryonic fibroblasts measured by SRM-MS on a 5500 
Q-Trap. The dashed box indicates the SRM signals for H-Arg-10 VGADLSLLDR.  
*MEF cell pellets provided by Dr. Buket Yilmaz. 
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Figure 2.20 SRM-MS measurement of L-Arg-0 p105 peptide in p105-/- MEF. 
Five μg of a tryptic digest of p105-/- whole-cell murine embryonic fibroblasts measured by 
SRM-MS on a 5500 Q-Trap. The dashed box indicates the established elution window for the 
L-Arg-0 peptide VGADLSLLDR. 
*MEF cell pellets provided by Dr. Buket Yilmaz. 
Figure 2.21 SRM-MS measurement of H-Arg-10 p50 peptide in Nfkb1-/-  MEF. 
Five fmols of HArg-10 SpikeTide internal standard in a fixed background of 5 μg of a tryptic 
digest of wild-type whole-cell murine embryonic fibroblasts measured by SRM-MS on a 5500 
Q-Trap. The dashed box indicates the SRM signals for H-Arg-10 VFETLEAR. 
*MEF cell pellets provided by Dr. Buket Yilmaz. 
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Figure 2.22 SRM-MS measurement of L-Arg-0 p50 peptide in Nfkb1-/-  MEF. 
Five μg of a tryptic digest of nfkb1-/- whole-cell murine embryonic fibroblasts measured by 
SRM-MS on a 5500 Q-Trap. The dashed box indicates the established elution window for the 
L-Arg-0 peptide VFETLEAR. 
*MEF cell pellets provided by Dr. Buket Yilmaz. 
Figure 2.23 SRM-MS measurement of L-Arg-0 p50 peptide in wild-type MEF 
after Wessel-Fluegge extraction. 
Five μg of a tryptic digest of Wessel-Fluegge-extracted wild-type whole-cell murine embryonic 
fibroblasts measured by SRM-MS on a 5500 Q-Trap. The dashed box indicates the SRM 
signals for L-Arg-0 VFETLEAR. 
*MEF cell pellets provided by Dr. Buket Yilmaz. 
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The bar graph in Figure 2.24 shows the absolute mass spectrometric quantitation of 
p100 and p52 in MEF whole cell lysate following activation of the non-canonical NF-
κB pathway by treatment with an anti-LT-βR antibody, 5G11b, as agonist	 123. Five 
micrograms of total protein was injected alongside 5 fmols of each H-Arg-10 labeled 
internal standard. The calculated peak area ratios underwent a correction for the 
contribution of p100/p105-derived p52/p50 peptides, via subtraction of the N-terminal 
peptide signals. SRM-MS analysis of stimulated wild-type MEF cells (Figure 2.24A, 
left) reveals a steady decrease in p100 with time, about 2.5 fold relative to the 
unstimulated sample after 6h, while p52 increases after 3h and is maintained at that 
level. An SRM-MS analysis of a similar LT-stimulation time course in p105-/- MEF 
cells (Figure 2.24A, right) supported the enhanced processing phenotype that was 
seen in the Western-blot analysis. After only 1.5 h p100 levels plummeted about 3-
fold, reaching a lower endpoint than in the wild-type MEF.  As expected, the sharper 
reduction in p100 is matched by an earlier and more pronounced increase in p52 
levels. 
A. 
 
B. 
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Figure 2.24 Absolute quantitation of p100, p52, p105 and p50 in MEF cells. 
A. Absolute quantitation of p100 and p52 in wild-type (left) and p105 KO (right) MEF 
cells by SRM-MS.  
B. Absolute quantitation of p105 and p50 in wild-type, p100 KO and nfkb2-/- MEF cells 
by SRM-MS. 
MEF cells of the indicated type were subjected to LTβR-stimulated non-canonical NF-κB 
activation by treatment with the receptor agonist 5G11B. Total p100, p105, p52 and p50 were 
quantified by SRM-MS over three replicate injections, with the average of six transitions 
plotted as the number of protein molecules per microgram of protein input. 
*All MEF cell culture and LT stimulation performed by Dr. Buket Yilmaz. 
 
 
In the previously seen Western blot of LTβR-stimulated p105-/- MEF cells in Figure 
1.2B it appears that the band for p100 has disappeared completely by the 3h mark, 
leading one to believe that the population of p100 has been entirely abolished in 
these cells. By SRM-MS, however, p100 remains visible, being readily detected even 
after 6h of stimulation. In comparison to anti-body-based detection of p100, the SRM-
MS method is more sensitive. 
 
3.1.7   Extended WT MEF stimulation.  
The proof-of-concept experiments satisfied all three questions set forth, the 
established SRM-MS methods were shown to be selective and capable of replicating 
the trends previously seen in the non-canonical system using traditional molecular 
biology techniques. The ability to detect p100 after 6h of stimulation showed the 
methods to have a greater sensitivity compared to Western blotting. With this 
confidence longer duration LT-βR stimulation time courses were conducted, 
extended to 12h. Figure 2.25 shows the results for both the precursors (p100, p105) 
and the products (p52, p50). The MEF cell culture and LT stimulation was performed 
by Dr Buket Yilmaz. For each time-point, three injections were performed and two 
transitions quantified for each, resulting in the six calculated peak ratios displayed as 
black dots. These data illustrate the low deviation amongst the measurements and 
the SRM-MS method encouragingly was able to detect both p100 and p105 following 
the full 12h of stimulation, with the plot illustrating that the levels of these precursors 
remain suppressed and do not begin to recover for the duration of the time course. 
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Conversely, the products p52 and p50 increase in concentration until 4 to 6h and 
then maintain these levels for the remainder of the time. Both of these findings are 
consistent with the known “slow and persistent” dynamics of non-canonical NF-κB 
signalling, with similar kinetics governing the loss of precursors and the rise of 
products. Most interesting is the absolute quantitative information given in these plots. 
The basal levels of the products and precursors are revelatory, with p100 proving to 
be about 3-fold more abundant than p105. Both products are found at the 0 timepoint, 
likely caused by background proteasomal processing. Interestingly, a similar number 
of the two products are activated in response to the stimulus.  Figure 2.26 presents 
the basal and 8h-stimulated concentrations of all of the proteins in nanomolar 
amounts, calculated by assuming an average MEF cell volume of 2 picolitres	124. 
 
 
Figure 2.25 Absolute quantitation of p100, p52, p105 and p50 in LT-stimulated 
wild-type MEF cells by SRM-MS. 
Wild-type MEF cells were stimulated with the LTβR-agonist antibody 5g11B to trigger non-
canonical activation and cells were sampled at the indicated time points. Cell pellets were 
processed by in-solution digestion with trypsin and subjected to SRM-MS analysis to 
quantitate the levels of p100, p52, p105 and p50, normalized to the amount of total protein 
injected. Each sample was measured three times and the top two most-intense transitions 
used for the quantitation, resulting in six data points per time point, seen as black dots. The 
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trend curves are the best fit obtained through the data points by performing a least-square fit 
to a parameterized exponential, logarithmic or hyperbolic function curve. 
*All MEF cell culture and LT stimulation performed by Dr. Buket Yilmaz. 
 
 
Figure 2.26 Basal and LTβR-stimulated concentration values from the absolute 
quantitation of NF-κB precursors and products in wild-type MEF cells.  
Wild-type MEF cells were either unstimulated or stimulated with the LTβR-agonist 5g11B to 
trigger non-canonical activation and cells sampled after 8 h and subjected to SRM-MS 
absolute quantitation. A MEF cell volume of 2 pL	 was used to calculate nanomolar 
concentrations, and the box-plot shows the spread of the values from the six transitions 
quantified over three replicate injections. 
*All MEF cell culture and LT stimulation performed by Dr. Buket Yilmaz. 
 
3.1.8   Dynamic SILAC SRM-MS analysis of MEF LTβR stimulation time 
course reveals distinct precursor and product populations. 
The extended LT-βR stimulation highlights the fact that this pathway remains “on” for 
many hours, with no indication of the precursors or products returning to their pre-
stimulus levels even after 12h. One of the many transcriptional targets downstream 
of the pathway are the NF-κB components themselves as part of a negative 
feedback loop designed to restore equilibrium. Quantitative real-time polymerase 
chain reaction (qRT-PCR) data has shown that the NFKB2 gene is significantly up-
regulated after about 6h25. The time scale of the response allows sufficient time for 
both gene transcription and subsequent protein translation, posing the question: what 
role do de novo-synthesized p100 and p105 play in the non-canonical signalling 
pathway? 
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SILAC is a quantitative proteomics approach well adapted to handle this query	 75. 
Cells grown in the presence of isotopically-coded amino acids will naturally 
incorporate them into proteins being synthesized. A special medium that has been 
deprived of lysine and arginine is supplemented with these molecules where 13C and 
15N atoms have replaced 12C and 14N, respectively, creating a small difference in 
mass that is easily distinguished by a mass spectrometer. All of the peptides that 
function as proxies for their parent proteins have an arginine at the C-terminus (see 
Table 1), therefore it was sufficient to only use arginine composed of 13C (Arg6). By 
replacing the Arg0 medium of the MEF cells at the time of stimulation with one with 
the Arg6 residues, new proteins synthesized subsequently will incorporate this form 
of the amino acid, while the proteins present prior to the stimulation will contain 
exclusively Arg0.  Our naming convention refers to the “light isotope” species as L-
Arg-0, while the “medium-heavy isotope” species is M-Arg-6. Spiking the “heavy 
isotope” synthetic H-Arg-10 internal standard peptide into the samples facilitates 
quantitation of both populations. This workflow is summarized in the schematic in 
Figure 2.27. Please note that MEF cell culture and LT stimulation was performed by 
Dr. Buket Yilmaz. 
 
Figure 2.27 Workflow schematic of the Dynamic SILAC LT stimulation 
experiment. 
Wild-type MEF cells were grown in light L-Arg-0 SILAC media and transferred to a medium-
heavy M-Arg-6 SILAC media with or without accompanying LTβR stimulation. Cells were 
sampled at multiple time points and proteins quantified by SRM-MS using H-Arg-10 internal 
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standard peptides from JPT. The sample spectra indicates how the mass spectrometer can 
resolve peptide species with the same sequence but variable isotopic compositions.  
 
The results of the Dynamic SILAC time course are presented in Figure 2.28 and 
show both the total protein levels as well as the contributions made by L-Arg-0 and 
M-Arg-6 populations in MEF cells undergoing LTβR stimulation. Examining the 
precursors p100 and p105, there is a decrease in the total protein levels (stacked 
bars) reaching a minimum after about 6 to 8 h. After 12 h, the original L-Arg-0 protein 
has been depleted to levels nearly below the detection limits of the assay. Newly-
synthesized precursors (M-Arg-6) are evident within the first hour, and reach a 
plateau after about 6 h. Upon inspection of the products p52 and p50, it is apparent 
that the levels of the original protein present prior to stimulation remain nearly 
constant, while the increase in the total levels of the precursors and of both products 
comes from the de novo synthesized protein. Taking these observations together, it 
would appear that the original precursor proteins are preferentially degraded by the 
proteasome, to such an extent that they have been largely removed from the system 
by 12 h.  Simultaneously, the de novo synthesized precursors appear to be 
preferentially processed by the proteasome, with the C-terminal half removed to yield 
the p52 or p50 products. Indeed, it is only the new protein material that results in an 
increase in the levels of the active transcription factors. This finding accounts for the 
late onset of the rise in the products, and therefore the transcriptional response to the 
stimulus itself, as new precursors are first synthesized and then processed. The 
Dynamic SILAC experiment has shown unequivocally that LTβR stimulation in MEF 
cells results in the precursors, at endogenous levels, are subjected to both complete 
degradation and specific proteolytic processing.  
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Figure 2.28 Quantitation of NF-κB precursors and products in the Dynamic 
SILAC LT-stimulation time course. 
Wild-type MEF cells initially grown in L-Arg-0 SILAC media were moved into M-Arg-6 SILAC 
media containing the stimulation antibody 5G11b to trigger noncanonical activation. Cells 
were sampled at the indicated time points and processed for SRM-MS analysis in triplicate. L-
Arg-0 (blue bars) and M-Arg-6 (orange bars) peptide contributions to total protein levels 
(stacked bars) of the precursors p100 and p105 and their products p52 and p50 are plotted, 
normalized to the unstimulated case at t=0.  
*The MEF cell culture and LT stimulation was performed by Dr Buket Yilmaz. 
 
3.1.9   Inhibition of the ribosome, proteasome, or VCP-p97 blocks 
accumulation of de novo M-Arg-6 products. 
The partial proteasomal processing of the precursors p100 and p105 to give rise to 
the active transcriptional machinery is one of the most curious features of the non-
canonical pathway. What mechanism exists to block complete proteolytic destruction 
at a precise site? The involvement of an ATPase, Ter94, in the regulated 
proteasomal processing of the Drosophila transcription factor Ci	 27 was sufficiently 
similar to cast suspicion upon its mammalian counterpart, p97. Immunoprecipitation 
experiments (Figure 2.29A) revealed that p97 is associated with both precursors 
under resting and stimulated conditions in wild-type MEF cells, and with each cursor 
individually when the other was knocked out. A mutant p97 that had an inactive 
ATPase domain impaired the production of p52 relative to the wild-type in a NIK-
overexpression system, in which p100 processing is constitutively “on” in the 
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absence of any upstream stimulation. The small-molecule inhibitor DBeQ 33 provides 
a convenient way of investigating the role p97 plays in the non-canonical pathway of 
a healthy wild-type MEF cell. Incorporating inhibition of p97 into the established 
Dynamic SILAC system used previously means the effect of p97 ATPase inhibition 
can be explored in the two populations of proteins, the pre-existing (L-Arg-0) and 
those synthesized de novo following stimulation (M-Arg-6). As evidenced in Figure 
2.29B, the most pronounced effect was on the generation of M-Arg-6 products. 
DBeQ treatment dramatically reduced the accumulation of the M-Arg-6 p52 and p50 
species, while having minimal effect on the L-Arg-0 p52 and p50 populations, which 
remained constant (Figure 2.29C). 
A.
B. 
C. L-Arg-0 p50 L-Arg-0 p52 
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Figure 2.29 Dynamic SILAC SRM-MS evaluation of the influence of p97 ATPase 
activity on M-Arg-6 precursor processing. 
A. Immunoprecipitation of either p100 and p105 copurifies p97, as detected by Western 
blotting 25. Immunoblots courtesy of Dr. Buket Yilmaz. 
B. Similar to Figure 2.28 above, wild-type MEF cells initially grown in L-Arg-0 SILAC media 
were stimulated by 5G11b in the presence or absence of the p97 inhibitor DbeQ after being 
moved to M-Arg-6 SILAC media and cells sampled at the indicated timepoints for absolute 
SRM-MS quantitation. Shown are the effects p97 inhibition has on the levels of M-Arg-6 
products p52 and p50. 
C. Wild-type MEF cells subjected to Dynamic SILAC as above with SRM-MS quantitation of L-
Arg-0 product species, with or without LTβR stimulation, and with or without p97 inhibition 
with DBeQ. 
*The MEF cell culture and LT stimulation was performed by Dr Buket Yilmaz. 
 
The Dynamic SILAC methodology provides a way to study in detail effects of 
inhibition at other critical points of the non-canonical signalling pathway.  Upstream 
protein synthesis required to generate NIK following TRAF-cIAP complex disruption 
can be blocked with cycloheximide (CHX), preventing tRNA translocation and 
nascent protein elongation at the ribosome. Figure 2.30 shows that in the context of 
precursor processing, ribosome inhibition essentially obliterates any generation of the 
M-Arg-6 p50 and p52 species, while the pre-existing L-Arg-0 products were largely 
unaffected.  A similar outcome is attained via direct inhibition of the proteasome with 
MG132 treatment, an inhibitor blocking the hydrolytic activity,	whereby M-Arg-6 p52 
and p50 generation is blocked while no effect is exerted on the pre-existing L-Arg-0 
p52 and p50 molecules. 
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Figure 2.30 Effect of ribosome or proteasome inhibition on NF-κB precursor 
processing. 
Wild-type MEF cells initially grown in L-Arg-0 SILAC media were left stimulated or 
unstimulated by LTβR agonist 5G11b in the presence or absence of either the ribosome 
inhibitor cycloheximide (CHX) or the proteasomal inhibitor MG-132 after being moved to M-
Arg-6 SILAC media and cells sampled at the indicated timepoints for absolute SRM-MS 
quantitation. Shown are the effects CHX or MG-132 inhibition has on the levels of M-Arg-6 
(upper 4 panels) or L-Arg-0 (lower 4 panels) products p52 and p50. 
*The MEF cell culture and LT stimulation was performed by Dr Buket Yilmaz. 
 
3.1.10   Mathematical modelling of the LT-dependent processing of the 
precursors predicts signal-dependent processing of a p100-p105 
complex. 
Compelling evidence exists that the NF-κB precursors p100 and p105 exist together 
in a complex and that they respond to an LTβR stimulation of the non-canonical 
response in an interdependent manner. One precursor is always found with the other 
in endogenous co-immunoprecipitation experiments and elute together in a high 
molecular weight fraction on a sucrose density gel. Most compelling are the 
processing phenotypes when one or the other precursor is eliminated: in a p100 
knock-out, p105 fails to respond to the stimulus, while in a p105KO MEF, p100 
responds more intensely, being processed with more rapid kinetics. 
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The absolute quantification of the products and precursors over a 12h LTβR 
stimulation time course and the resolution of the two protein populations represents a 
data set that forms the foundation for mathematical modelling efforts designed to 
gain insight into the signal-responsiveness of a proposed p100-p105 complex.  
The SILAC SRM-MS analysis yielded the intriguing result that two distinct 
populations of precursor exist based on the way they responded to the stimulus. The 
blue section of the stacked bar graphs in Figure 25 indicate that the majority of the L-
Arg-0 p100 and p105 are degraded completely, while the de novo M-Arg-6 p100 and 
p105 are diverted largely into the processing pathway, being converted to M-Arg-6 
p52 and p50, respectively, by specific proteasomal hydrolysis.   
Compiling these findings, mathematical models comprising free or unbound p100, 
p105, p52 and p50, in addition to the purported p100-p105 complex, were proposed 
and have been summarized schematically in Figure 2.31. The four models are 
differentiated by the outcome pathway stimulation has on the p100-p105 complex. 
Please note that the generation of mathematical models was done in collaboration 
with Dr. Bente Kofahl, Dr. Katherina Baum and Dr. Jana Wolf. 
Model 1 (M1) The complex is unresponsive to the stimulus and forms a dead end 
that only dissociates into free p100 and p105. 
Model 2 (M2) The p100-p105 complex is degraded in response to stimulus. 
Model 3 (M3) The p100-p105 complex undergoes proteasomal processing to form 
the products p52 and p50 upon pathway stimulation. 
Model 4 (M4) The p100-p105 complex is both processed and degraded in response 
to the stimulus. 
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Figure 2.31 Proposed mathematical models of NF-κB precursor complex
processing. 
Proposed mathematical models describing the possible fates of a p100-p105 complex as well 
as the individual precursors and products. Included reactions are the de novo synthesis, 
degradation and processing of the precursors, either as independent entities or within a 
complex, and the degradation of products.  
*Mathematical modeling performed by Dr. Bente Kofahl, Dr. Katherina Baum and Dr. Jana 
Wolf. 
The processes shown in the schematic include precursor synthesis, degradation
(turnover) and processing as singular entities, as well as formation of the complex 
and processing or degradation events acting on the complex as a whole. The model 
was intentionally designed to describe one aspect of the system, how a p100-p105 
complex would respond to stimulation. Therefore the details and kinetics of the 
upstream events resulting in this stimulation have been omitted; for the purposes of 
this model the system is either “ON” or “OFF”. Likewise, events downstream of the 
processing/degradation of the individual precursors or complex have also been left 
out.  Every arrow in the models is governed by a kinetic parameter, these parameters 
were estimated using an iterative computational process using the absolute 
concentrations found in the SRM-MS measurements over the duration of the time 
course, for both the stimulated and unstimulated condition. It should be noted that the 
SRM analysis cannot distinguish between free p100 and p105 and that bound 
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together in a complex, therefore these values are represented as being summed 
together: “p100 + p100-p105” and “p105 + p100-p105”.  
After fitting the data to the four models and obtaining the estimates of the relevant 
kinetic parameters, a determination of their relative quality was calculated using the 
Akaike Information Criterion (AICc)	{Akaike:1973wv}{Burnham:2004wc}. The ΔAICc 
value is a calculation of the differences in the AICc and is a useful metric for ranking 
the models in order of likelihood. Such a ranking is displayed in Figure 2.32, which 
indicates that model M3 is the most probable, at 83%, while M2 and M4 trail behind 
at 10% and 8% respectively. In model M3 the p100-p105 complex is processed to 
products in a stimulus-dependent manner. Model M2 (complex degraded in response 
to stimulus) and model M4 (complex both processed and degraded in response to 
stimulus) have been ranked as being significantly less likely but cannot be absolutely 
ruled out. The likelihood of model M1, with a completely unresponsive dead-end 
p100-p105 complex, has been entirely rejected by this calculation.  
        
Figure 2.32 Calculated Akaike weights for Models M1 to M4.  
The higher Akaike weight indicates the more probable model. Model M3 predicts a 
stimulus responsive p100-p105 complex.  
*Mathematical modeling performed in collaboration with Dr. Bente Kofahl, Dr. Katherina Baum 
and Dr. Jana Wolf. 
With a complete set of estimated kinetic parameters, the proposed models can now 
be used to perform simulations to predict the outcome. Figure 2.33A shows the 
simulations for the top ranked model M3 overlaid with the actual experimental values 
determined by the SILAC SRM-MS approach. Precursor and product are divided into 
their two populations, L-Arg-0 and M-Arg-6, and the simulated and observed values 
are in remarkably good agreement. Both of these populations have been summed to 
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give the total values in Figure 2.33B, with the results mirroring the established 
temporal changes in the p100, p105, p52 and p50 levels following the LTβR 
stimulation. A further form of validation is achieved by running simulations for model 
M3 in which important players are deleted to reflect the MEF knock-out systems 
tested. The p105 KO simulation (in which p105 levels are set to 0) replicated the 
altered p100 dynamics with respect to the wild-type that we have observed 
previously by Western blot and SRM-MS (Figure 2.33C). This can be rationalized by 
no p105 being present to ‘absorb’ its portion of the stimulus, resulting in 
proportionately more stimulus being available for the activation of p100, hence it 
being processed at a higher rate.  
A.
B. 
3			Results.	
55	
C. 
Figure 2.33 Model simulations of LTβR stimulation by the model M3.   
A. Simulated time courses of stimulated or unstimulated MEF cells generated by Model M3 
(solid lines) and overlaid with the experimental data (points), separated according to the 
protein species, L-Arg-0 in blue, de novo M-Arg-6 in orange. The 95% confidence intervals of 
the parameters are given by the shaded areas. SRM-MS analysis does not differentiate 
between individual precursors and precursor participating in complex formation, hence [p100 
+ p100-p105] and [p105 + p100-p105] represent the total contributions. 
B. Simulated time course as given in A, but with the L-Arg-0 and M-Arg-6 protein levels  
summed to give the total amounts. 
C. The p105 KO MEF phenotype is simulated by applying a proportionally larger stimulus to 
p100. Plotted versus a stimulation of wild-type MEF to demonstrate the enhanced kinetics of 
p100 processing.  
*Mathematical modeling and simulations performed in collaboration with Dr. Bente Kofahl, Dr. 
Katherina Baum and Dr. Jana Wolf. 
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3.1.11   Expansion of SRM-MS analysis to the broader NF-κB pathway. 
The SRM-MS analysis of the precursors p100 and p105 (and their respective 
products, p52 and p50) proved to be a worthwhile venture. Importantly, it mirrored 
the established trends previously observed using Western blot detection while 
exceeding its’ limits of detection. The use of stable isotopes facilitated not only 
absolute quantitation, but through Dynamic SILAC also dissected the contributions 
made through de novo protein synthesis. Absolute values were critical in establishing 
a predictive mathematical model covering the mechanics of precursor complex 
formation and proteasomal processing.  
Expansion of the SRM-MS technique to include additional players in the NF-κB 
signalling pathway would therefore be of great value in providing more quantitative 
detail than has been seen previously, and contribute to a mathematical model of 
broader scope comprising these additional players. The primary targets are the core 
NF-κB transcription factors. In addition to bolstering the methods for p100 and p105 
by monitoring more peptides, peptides representing Rel A, Rel B and c-Rel will be 
included. As the IKK complex plays a central regulatory role in many signalling 
modes, SRM-MS detection methods for peptides from IKKα, IKKβ and IKKγ/NEMO 
would also be valuable. Additional targets include IκBα, GAPDH and Histone H2B. 
The inclusion of peptides for a cytoplasmic protein (GAPDH) and a nuclear protein 
(Histone H2B) is intended as a quality control for measurements in these cell 
fractions, to assess cross-contamination between the compartments. The histone 
peptide has another utility, as a signal for normalization of other protein 
concentrations in a similar manner as presented in Mann’s Histone Ruler paper	 125.  
As the quantity of histone proteins (in nucleosomes) is fixed relative to the amount of 
genomic DNA, one can interpret their signal as a proxy for total cell number, a useful 
conversion in cases where counting cell pellets is difficult.  
Prospective tryptic peptides were selected from the protein sequences according to 
the criteria presented earlier. Synthetic peptides (JPT Peptide Technologies, GmbH) 
were used to develop SRM-MS detection methods. After dissolving the peptides into 
the acetonitrile/ABC buffer, they were infused into the MS with the aid of a syringe 
pump and MS and MS/MS spectra acquired. These spectra established critical 
parameters, both the peptide’s observed mass-to-charge (m/z) ratio and the 
fragmentation pattern following CID. Ramping of collision energies was again 
employed to select the optimal values for each transition to ensure maximum 
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sensitivity. Previous experience with optimization of the declustering potential proved 
these curves to be rather flat, so a single value of 130 V was chosen for all peptides 
in the method, maintaining constant conditions at the ion source for the entire 
analysis.  
Table 2.2 includes the necessary SRM parameters for 26 (plus 2 oxidized forms of 
peptides) representing 12 proteins. Isotopically-heavy SpikeTide TQL peptides were 
ordered from JPT, with the C-terminal Lys and Arg residues substituted for 13C615N2 
and 13C615N4 versions. In order to maximize applications for the methods, a peptide 
was chosen that had the same sequence in both human and mouse wherever 
possible, with mouse-only sequences indicated in parantheses beside the protein 
name. Where a sequence contains a cysteine residue, C[alk] indicates that the 
method assumes a quantitative conversion of the free thiol group to the alkylated 
form via reaction with 2-chloroacetamide. Methionine-containing peptides include two 
entries, one each for the unoxidized and oxidized (Mox) version, with Q1 and Q3 
masses adjusted to account for the addition of a single oxygen atom (atomic mass 
15.9994). This allows an estimate to be made of the contribution the oxidized 
peptides make to the population.   
 
Q1	 Q3	 Protein/Peptide/z/Fragment	ID	 DP	(V)	 CE	(eV)	
561.3	 963.5	 NfkB2/ASDGSFSLPLK/+2/y9	 130	 20.9	
561.3	 848.5	 NfkB2/	ASDGSFSLPLK.+2	y8	 130	 23.4	
561.3	 704.4	 NfkB2/ASDGSFSLPLK/+2/y6	 130	 21.3	
427.2	 653.3	 NfkB2/SLVDTYR/+2/	y5	 130	 17.4	
427.2	 554.3	 NfkB2.SLVDTYR.+2/y4	 130	 19	
427.2	 439.2	 NfkB2/SLVDTYR/+2	y3	 130	 29	
402.7	 691.4	 NfkB2/LFGLAQR/+2/y6	 130	 22.7	
402.7	 544.3	 NfkB2/LFGLAQR/+2/y5	 130	 22.1	
402.7	 487.3	 NfkB2/LFGLAQR/+2/y4	 130	 22.7	
466.3	 631.4	 NfkB1/NWATLAQK/+2/y6	 130	 19.2	
466.3	 560.3	 NfkB1/NWATLAQK/+2/y5	 130	 22.2	
466.3	 459.3	 NfkB1/NWATLAQK/+2/y4	 130	 21	
663.4	 961.6	 NfkB1/NIHLHAHSLVGK/+2/y9	 130	 33	
663.4	 848.5	 NfkB1/NIHLHAHSLVGK/+2/y8	 130	 34.2	
663.4	 711.4	 NfkB1/NIHLHAHSLVGK/+2/y7	 130	 37	
530.3	 702.4	 Rel	A/DLEQAISQR/+2/y6	 130	 25.4	
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530.3	 574.3	 Rel	A/DLEQAISQR/+2/y5	 130	 24.7	
530.3	 503.3	 Rel	A/DLEQAISQR/+2/y4	 130	 25.9	
511.7	 687.4	 Rel	A/GDYDLNAVR/+2/y6	 130	 21.4	
511.7	 572.4	 Rel	A/GDYDLNAVR/+2/y5	 130	 25.5	
511.7	 459.3	 Rel	A/GDYDLNAVR/+2/y4	 130	 26.9	
522.8	 931.4	 Rel	B/IC[alk]FQASYR/+2/y7	 130	 24.3	
522.8	 771.4	 Rel	B/IC[alk]FQASYR/+2/y6	 130	 24.4	
522.8	 624.3	 Rel	B/IC[alk]FQASYR/+2/y5	 130	 27.5	
465.7	 559.3	 Rel	B/EIEAAIER/+2/y5	 130	 21.5	
465.7	 488.3	 Rel	B/EIEAAIER/+2/y4	 130	 20.4	
465.7	 417.2	 Rel	B/EIEAAIER/+2/y3	 130	 19.6	
793.9	 947.4	 c-Rel/LVSINLENPSC[alk]NAR/+2/y8	 130	 37.5	
793.9	 818.4	 c-Rel/LVSINLENPSC[alk]NAR/+2/y7	 130	 37.1	
793.9	 704.3	 c-Rel/LVSINLENPSC[alk]NAR/+2/y6	 130	 37.1	
575.3	 903.4	 c-Rel/FVLNDWEAR/+2/y7	 130	 25.5	
575.3	 790.3	 c-Rel/FVLNDWEAR/+2/y6	 130	 26	
575.3	 561.3	 c-Rel/FVLNDWEAR/+2/y4	 130	 27.6	
469.6	 684.4	 Traf6,	mouse/HLQENTQLHMR/3+/y10	 130	 24.8	
469.6	 622.3	 Traf6,	mouse/HLQENTQLHMR/3+/b5	 130	 25.1	
469.6	 556.3	 Traf6,	mouse/HLQENTQLHMR/3+/y4	 130	 25.5	
477.6	 700.4	 Traf6,	mouse/HLQENTQLHMoxR/3+/y10	 130	 24.8	
477.6	 622.3	 Traf6,	mouse/HLQENTQLHMoxR/3+/b5	 130	 25.1	
477.6	 572.3	 Traf6,	mouse/HLQENTQLHMoxR/3+/y4	 130	 25.5	
686.4	 1044.6	 Traf6,	mouse/LTILDQSEALIR/2+/y9	 130	 35	
686.4	 816.5	 Traf6,	mouse/LTILDQSEALIR/2+/y7	 130	 35	
686.4	 931.5	 Traf6,	mouse/LTILDQSEALIR/2+/y8	 130	 35	
567.3	 905.4	 Traf2/DLAMADLEQK/2+/y8	 130	 22.6	
567.3	 834.4	 Traf2/DLAMADLEQK/2+/y7	 130	 23	
567.3	 703.4	 Traf2/DLAMADLEQK/2+/y6	 130	 23.3	
575.3	 921.4	 Traf2/DLAMoxADLEQK/2+/y8	 130	 22.6	
575.3	 850.4	 Traf2/DLAMoxADLEQK/2+/y7	 130	 23	
575.3	 703.4	 Traf2/DLAMoxADLEQK/2+/y6	 130	 23.3	
516.3	 801.4	 Traf2,	mouse/ETFQDHVR/2+//y6	 130	 29.1	
516.3	 654.3	 Traf2,	mouse/ETFQDHVR/2+//y5	 130	 29.6	
516.3	 411.2	 Traf2,	mouse/ETFQDHVR/2+//y3	 130	 34.5	
595.8	 917.4	 IKKγ/C[alk]LEENQELR/2+/y7	 130	 28.7	
595.8	 788.4	 IKKγ/C[alk]LEENQELR/2+/y6	 130	 27.6	
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595.8	 659.3	 IKKγ/C[alk]LEENQELR/2+/y5	 130	 30.5	
486.8	 744.5	 IKKα/VEVALSNIK/2+/y7	 130	 20.4	
486.8	 645.4	 IKKα/VEVALSNIK/2+/y6	 130	 20.9	
486.8	 574.4	 IKKα/VEVALSNIK/2+/y5	 130	 23	
487.3	 773.4	 IKKα/SIQLDLER/2+/y6	 130	 20.6	
487.3	 645.4	 IKKα/SIQLDLER/2+/y5	 130	 19.9	
487.3	 532.3	 IKKα/SIQLDLER/2+/y4	 130	 25.2	
545.8	 977.5	 IKKβ/LGTGGFGNVIR/2+/,	y10	 130	 29	
545.8	 762.4	 IKKβ/LGTGGFGNVIR/2+/,	y7	 130	 29	
545.8	 705.4	 IKKβ/LGTGGFGNVIR/2+/,	y6	 130	 29.4	
507.8	 830.5	 IKKβ/ALDDILNLK/2+/,	y7	 130	 18.9	
507.8	 715.4	 IKKβ/ALDDILNLK/2+/,	y6	 130	 23	
507.8	 600.4	 IKKβ/ALDDILNLK/2+/,	y5	 130	 26.7	
477.3	 727.4	 Histone	H2B/LLLPGELAK/+2/y7	 130	 26	
477.3	 614.4	 Histone	H2B/LLLPGELAK/+2/y6	 130	 26	
477.3	 517.3	 Histone	H2B/LLLPGELAK/+2/y5	 130	 26	
872.4	 1126.5	 Histone	H2B/AMGIMNSFVNDIFER/+2/y9	 130	 43.4	
872.4	 1039.5	 Histone	H2B/AMGIMNSFVNDIFER/+2/y8	 130	 43.4	
872.4	 892.4	 Histone	H2B/AMGIMNSFVNDIFER/+2/y7	 130	 43.4	
888.4	 1126.5	 Histone	H2B/AMoxGIMoxNSFVNDIFER/+2/	y9	 130	 43.4	
888.4	 1039.5	 Histone	H2B/AMoxGIMoxNSFVNDIFER/+2	y8	 130	 43.4	
888.4	 892.4	 Histone	H2B/AMoxGIMoxNSFVNDIFER/+2/	y7	 130	 43.4	
403.2	 706.4	 GAPDH/VGVNGFGR/+2/y7	 130	 22.7	
403.2	 649.3	 GAPDH/VGVNGFGR/+2/y7	 130	 22.7	
403.2	 550.3	 GAPDH/VGVNGFGR/+2/y7	 130	 22.7	
435.3	 770.4	 GAPDH/VIPELNGK/+2/y7	 130	 24.1	
435.3	 657.3	 GAPDH/VIPELNGK/+2/y7	 130	 24.1	
435.3	 560.3	 GAPDH/VIPELNGK/+2/y7	 130	 24.1	
585.7	 1055.5	 IκBα/DEEYEQSMK/+2/y8	 130	 30.7	
585.7	 926.4	 IκBα/DEEYEQSMK/+2/y7	 130	 30.7	
585.7	 797.4	 IκBα/DEEYEQSMK/+2/y6	 130	 30.7	
593.8	 1071.5	 IκBα/DEEYEQSMoxK/+2/y8	 130	 30.7	
593.8	 942.4	 IκBα/DEEYEQSMoxK/+2/y7	 130	 30.7	
593.8	 813.4	 IκBα/DEEYEQSMoxK/+2/y6	 130	 30.7	
495.2	 852.4	 IκBα/HDSGLDSMK/+2/y9	 130	 26.8	
495.2	 737.3	 IκBα/HDSGLDSMK/+2/y8	 130	 26.8	
495.2	 650.3	 IκBα/HDSGLDSMK/+2/y7	 130	 26.8	
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503.2	 989.4	 IκBα/HDSGLDSMoxK/+2/y9	 130	 26.8	
503.2	 989.4	 IκBα/HDSGLDSMoxK/+2/y8	 130	 26.8	
503.2	 989.4	 IκBα/HDSGLDSMoxK/+2/y7	 130	 26.8	
 
Table 2.2 SRM method parameters for NF-κB pathway proteins.  
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3.2   The Protein-protein interaction network of NF-κB precursor 
p100. 
SILAC SRM-MS analysis of the non-canonical NF-κB reponse led to the observation 
that two populations of the precursors p100 and p105, the pre-existing L-Arg-0 and the 
newly translated M-Arg-6, undergo distinct dynamics. The pre-existing L-Arg-0 
population is preferentially degraded, with 90% of this population disappearing over 
the 12h time course, while the de novo synthesized M-Arg-6 precursors undergo a 
preferential processing process to transform them into the transcriptionally active p52 
and p50 products. It was theorized that each form of precursor exists in a unique 
physicochemical context such that the cellular machinery can distinguish them and 
direct each down the appropriate enzymatic avenues. One possible scenario that 
might lead to such a distinction between the L-Arg-0 and M-Arg-6 population are 
differences in the p100-p105 complex, with each unique population being incorporated 
into a unique complex, whereby the set of interacting proteins are the distinguishing 
feature. Another potential scenario creating these differences is a chemical change to 
the precursor molecules themselves in the form of post-translational modifications. 
The discovery nature of this means that analytical approaches addressing these 
questions rely on data-dependent (shotgun) mass spectrometry, rather than targeted 
proteomics.  
 
3.2.1   Determination of p100 interactome by immunoprecipitation. 
Evidence abounds for an interaction between p100 and p105. On the physical side, 
co-immunoprecipitation of one precursor with the other indicates a close cellular 
proximity. The gel-filtration seen in Figure 1.2C shows both precursors migrating 
together in a high molecular weight complex, a complex that appears to shift to lower 
molecular weight upon stimulation with α-LTβR, suggesting a change in the 
complex’s membership. Mechanistically, the contrasting p100 KO and p105 KO MEF 
phenotypes (Figures 1.2B & 2.24) show that p100 plays a crucial role; its absence 
abolishes the response, while the absence of p105 enhances the kinetics of p100 
depletion. Mathematical modelling of this system has also supported the contention 
that p100 and p105 form a signal-responsive complex. Isolation of either precursor 
from the cell should be sufficient to enrich the other as well as complex components. 
The SRM-MS analysis of wild-type MEF cell lysate has determined the absolute 
levels of the precursors and products in basal and stimulated states; in both cases 
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p100 is shown to be in excess of p105, making p100 a better target for isolation by 
immunoprecipitation. The general approach to an MS-based interactome 
determination is to compare the identity and quantity of proteins between an 
experimental and a control pull-down, whereby normalization of the data reveals 
those proteins enriched in the pull-down of the target protein. In proteomics, two 
approaches for this normalization are utilized. Using a SILAC approach, one 
prepares cell lysates from differentially labeled cells and performs an experimental IP 
on one label type and a control IP on the other with an equivalent amount of input 
lysate. For example, cells labeled with light Lys0/Arg0 isotopes might be used for an 
experimental IP with a p100 antibody, while the heavy Lys8/Arg10 labeled cells are 
used for a control immunoprecipitation with IgG. A label-swap experiment in which 
the heavy-labeled cells are used for the experimental pull-down is also performed. 
Following elution from the beads, the pull-downs are combined and measured 
simultaneously in a single LC-MS run. The differential isotopic labels distinguish 
which proteins are derived from which pull-down, and each identified protein has an 
associated Intensity value for each label type, reflecting its abundance in the sample. 
The ratio of the Intensities of the two isotopic labels (i.e heavy/light or light/heavy) 
facilitates normalization and gives a measurement of relative enrichment between 
experiments. In contrast, the label-free quantitation (LFQ) approach does not utilize 
isotopic labelling of cells. Rather, equivalent pools of cell lysate are used for 
experimental and control pull-downs and the eluates measured separately by LC-MS. 
A minimum of three replicates of each condition are required for the MaxQuant LFQ 
algorithm to normalize the ratios. Each approach has its relative advantages. The 
SILAC methodology requires less instrument time as both conditions are measured 
simultaneously, and the isotopic labeling simplifies normalization. However sample 
complexity is effectively doubled by the isotopic labelling; identical heavy and light 
peptides will often both be sequenced, a redundancy that can limit the depth of 
protein identifications returned. 
Please note that this project was in collaboration with Inbal Ipenberg of AG 
Scheidereit at the Max Delbrück Center, who performed all cell culture and 
immunoprecipitations.  The SILAC methodology was chosen for initial experiments in 
p100 interactome determination due to its relative simplicity and the computational 
instability of early MaxQuant LFQ algorithms. Cells are grown in a special media 
supplemented with either L-Lys-0/L-Arg-0 or H-Lys-8/H-Arg-10 amino acids. Multiple 
passages are required to ensure the extent of incorporation of the heavy amino acids 
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approaches 100%. A portion of cells are lysed and the extracted protein digested 
with trypsin and measured by LC-MS as a quality control to determine the extent of 
labeling before proceeding with the planned immunoprecipitations. Figure 31 
indicates an incorporation of 91.7%, sufficient to proceed with the SILAC experiment.  
 
 
Figure 2.34 Incorporation of H-Arg-10 and H-Lys-8 residues in MEF cells by SILAC.  
Twenty micrograms of MEF protein lysate was processed and digested with trypsin and the 
peptides measured by data-dependent analysis on a Q-Exactive mass spectrometers. Plotted 
is a histogram of the distribution of the H-Lys-8/H-Arg-10 in the detected tryptic peptides. 
*MEF cell culture and isotopic labeling performed by Inbal Ipenberg. 
 
Proteins bound to the p100 antibody were eluted with a chaotropic buffer containing 
6M urea/2M thiourea and could be directly processed for LC-MS measurement, 
undergoing in-solution digest to convert them to tryptic peptides. Following a data-
dependent shotgun analysis, the raw files were analyzed with MaxQuant. The 
intensities of proteins found in either the control (IgG, L-Lys-0, L-Arg-0 label) and 
experimental (anti-p100 H-Lys-8, HArg-10 label) pull-downs, measured in parallel in 
a single LC-MS run, were used to generate a Heavy/Light SILAC ratio. In total, 2953 
protein groups were found in the MaxQuant analysis, what can be considered a high 
background. The Normalized Heavy/Light SILAC Ratios from MaxQuant Protein 
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Groups output file were converted to a Log2 scale and the MS1 intensities are 
represented on a Log 10 scale. Plotted together they create a so-called Christmas 
tree plot, found in Figure 32. The central cluster of proteins at a Log2 of 0 represents 
the majority, those proteins that have equal affinity to IgG as they do p100.  The 
upper right hand portion of the plot is where the gene products enriched in the 
experimental immuoprecipitation can be found, in this case those proteins binding 
specifically to p100 and with an enrichment factor greater than 2 and an MS1 
intensity greater than 1e9 counts per second (cps). The presence of p100 (NFkB2) at 
a high intensity and degree of enrichment is an indication that the 
immunoprecipitation was successful; absence of the bait protein would suggest 
problems with the experiment, such as poor antibody affinity or incomplete elution. In 
addition to the bait, all core members of the NF-κB transcription factor family have 
been enriched in the pull-down, including Rel B, p105 (nfkb1) and Rel A (nfkb3). The 
fifth member, c-Rel (mCG-8770), also appears in the plot, albeit with a lesser degree 
of enrichment. The ATPase p97/VCP previously implicated in the conversion of the 
precursors p100 and p105 into the products p52 and p50 was detected as well with a 
similar intensity as p100 (6e10 cps) but with a SILAC ratio of only 0.95, meaning it 
was not enriched in the p100 pull-down relative to the IgG control experiment.  
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Figure 2.35 SILAC p100 interactome Christmas tree plot. 
The eluted proteins in urea buffer that coimmunoprecipitated with p100 were subjected to an 
in-solution digest and the peptides measured in data-dependent mode on a Q-Exactive mass 
spectrometer. The data file was analyzed by MaxQuant 1.5.2.8 and the protein group file 
used to plot the Log10 transformed Intensities versus the Log2 transformed ratios. Enriched 
proteins with a Log2 fold-change greater than 1.5 are coloured in red with their gene name 
while background binders are indicated as gray circles.  
*MEF cell culture and p100 immunoprecipitation performed by Inbal Ipenberg. 
The lack of novel interactors found in the SILAC experiment prompted approaching 
the experiment using a LFQ approach. While this requires significantly more 
instrument time, measuring each experimental and control replicate separately, the 
absence of labels means the complexity of the analytes is reduced by half; each 
peptide exists only in the natural L-Lys-0/L-Arg-0 light format. Additionally, due to the 
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undersampling associated with shotgun measurements, repetitive analysis can 
augment the number of protein hits. The raw data for the label-free quantitation 
experiment was analyzed using the LFQ settings in MaxQuant 1.5.2.8. In total it 
returned 3030 protein groups, similar to the previous SILAC experiment. The log2 
fold-change of proteins found in the control and experimental pull-downs (each 
measured in triplicate, six runs total) were plotted versus the –Log t-test p-value in 
Figure 33. Once again all transcription factors of the NF-κB pathway had a 
statistically significant enrichment in the p100 pull-down. The level of enrichment is 
comparable to the SILAC experiment presented above, with p100, p105, RelA and 
RelB clustering together and c-Rel (mCG_8770) enriched to a lesser extent. 
p97/VCP does not appear as a significant interactor of p100 under these conditions.   
Figure 2.36 LFQ p100 interactome volcano plot. 
The eluted proteins in urea buffer that coimmunoprecipitated with p100 were subjected to an 
in-solution digest and the peptides measured in data-dependent mode on a Q-Exactive mass 
spectrometer. The data file was analyzed by MaxQuant 1.5.2.8 with LFQ activated. 
*MEF cell culture and p100 immunoprecipitation performed by Inbal Ipenberg. 
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3.3   MS screening for radiation-induced interactors of NEMO/IKKγ. 
The classical immunoprecipitation approach to identify protein-protein interactors 
must be refined when shifting from Western blot to MS methods for the detection and 
analysis. While the advantages of MS over Western blotting in interactome studies 
are manifest, with hundreds of proteins routinely identified in eluates, care must be 
taken to avoid chemical additives common to molecular biology but having a 
deleterious effect in proteomics workflows. The tryptic digestion of proteins to form 
peptides and the conversion of these peptides into gas-phase ions in the MS ion 
source are critical junctures in the analysis that are susceptible to chemical 
interference. The search for protein interactors of IKKγ/NEMO, illustrates such a 
refinement of this approach. Please note that in this section all cell culture and 
immunoprecipitations were performed by Nadine Mikuda of AG Scheidereit at the 
Max Delbrück Center. 
The non-canonical NF-κB activates gene transcription in response to many stimuli, 
among them genotoxic stress such as DNA double-strands breaks caused by 
exposure to radiation. It was previously demonstrated in the Scheidereit group that 
the response to DNA damage includes formation of a cytoplasmic complex involving 
NEMO that directs NF-κB activation 126. The SILAC method was chosen as the basis 
for identifying inducible interactors of NEMO upon irradiation of cells in culture where 
NEMO is present at endogenous levels. Cells are labeled with light Lys0/Arg0 or H-
Lys-8/H-Arg-10, with one label type exposed to radiation and the other not, as well as 
a label swap in a reverse experiment. Initial trial experiments were performed in MEF 
cells due to their ready availability in the lab with SILAC labeling already in place. 
The histogram in Figure 34 illustrates the incorporation of the H-Lys-8/H-Arg-10 
labels into MEF proteins.   
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Figure 2.37 Incorporation of H-Arg-10 and H-Lys-8 residues into the MEF 
proteome.  
Twenty micrograms of MEF protein lysate was processed and digested with trypsin and the 
peptides measured by data-dependent analysis on a Q-Exactive mass spectrometers. Plotted 
is a histogram of the distribution of the H-Lys-8/H-Arg-10 in the detected tryptic peptides. 
*MEF cell culture and isotopic labeling performed by Nadine Mikuda. 
 
 
3.3.1   Optimization of immunoprecipitation and MS conditions to 
improve enrichment of NEMO. 
In the pilot experiments in MEF cells, protease inhibitors (Pefablock) were included in 
the IP wash buffer, a useful step to prevent background proteolysis that might alter 
the precipitated proteins and interfere with downstream antibody detection. However, 
as this eluate was prepared by an in-solution digest and analyzed by MS, carryover 
of these reagents into the subsequent digestion steps resulted in a poor preparation. 
The activity of trypsin was unsurprisingly inhibited, resulting in many missed 
cleavages (over 50% of peptides with one or more missed cleavages, 20% with two 
or more, compared to a typical overall rate of 20%).  While NEMO was identified in 
this experiment, few of the other known interactors were found. After discussion of 
the results, it was decided that future IPs would omit Pefablock from the wash step. 
Additionally the cells would be fractionated and only the cytoplasmic portion used for 
the pull-down, as NEMO is partitioned in this compartment and including the 
complement of nuclear proteins would only serve to increase the background. Lastly, 
3			Results.	
	 69	
incubation of the Dynabeads used with tRNA for 1h before use was designed to 
block non-specific binding to the beads. The next experiments with HepG2 cells were 
abandoned after the cells responded poorly to the SILAC culture media, forming 
large vacuoles and appearing unhealthy, raising concerns about whether such cells 
could be relied upon to respond normally to the radiation. However, analysis of these 
experiments was not entirely fruitless, revealing the detriment of another common 
additive in molecular biology and highlighting fundamental differences in sample 
preparation approaches between molecular biology and MS-based proteomics. NP-
40, a polymeric detergent that aids in cellular fractionation by lysing outer plasma 
membranes but leaving the nuclear envelope intact, was included in one experiment 
and processed by an in-gel digest. A second equivalent experiment used douncing of 
the cells to shear the outer membrane and effect the fractionation. A comparison of 
the outcomes of MS analysis (Table 2.3) shows that the combination of NP-40 and 
in-gel digestion resulted in far fewer protein identifications (505) relative to douncing 
coupled to in-solution digest (1435). The number of NEMO peptides identified serves 
as a useful measure of the success of the immunoprecipitation. Additionally, the co-
immunoprecipitation of known interactors of NEMO can be used to benchmark the 
experiments, as maintenance of these interactions is a promising indication that the 
IP and wash conditions were not unduly harsh.  
 
Trial Cell line Cell lysis agent 
Digestion 
protocol 
Number 
of total 
protein 
groups 
Number 
of IKKγ/ 
NEMO 
peptides 
Percentage 
missed 
cleavages 
P3 MEF NP40 In solution 943 28 56.9* 
P5 HepG2 NP40 In solution 1865 8 26.6 
P6 HepG2 NP40 In gel 505 32 22.4 
P7 HepG2 Douncing In solution 1435 29 28.5 
U1/U2 U2OS Douncing In solution 1822 20 33.5 
U7/U8 U2OS Douncing In gel 1697 33 24.2 
Table 2.3 Summary of IKKγ/NEMO IP optimization.  
All samples measured on a Q-Exactive MS and raw data analyzed with MaxQuant 1.2.2.5. 
Asterisk (*) indicates that the protease inhibitor Pefablock was present during sample 
processing. Trial names are arbitrary. 
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Trial IKK
ϒ 
IKK
α 
IKK
β 
Sharpin HOIP HOIL NFκB1 NfκB2 Rel
A 
EDC4 
P3 28 3 0 0 0 0 0 0 1 3 
P5 8 1 2 0 3 3 8 5 3 9 
P6 32 31 18 1 0 1 0 0 0 0 
P7 29 1 1 0 2 0 0 3 4 4 
U1/U2 21 3 5 1 1 0 4 3 3 5 
U7/U8 33 23 23 0 4 0 14 15 10 23 
Table 2.4 Number of peptides of related IKKγ/NEMO proteins found in MS 
screens127. 
 
The known interactors of NEMO had SILAC ratios around 1 in both the forward and 
reverse experiments, indicating their association with NEMO was not altered upon 
irradiation. A subset of the 1867 proteins identified in the U1/U2 screen had SILAC 
ratios greater than 2, indicating their association to NEMO was enhanced upon 
irradiation. Figure 2.38 represents these DNA-damage induced interaction partners 
of NEMO in a heatmap, with additional verification of the specificity of the interaction 
achieved using the protein frequency library (PFL) and the CRAPome database, 
comprised of 400 affinity-pull-down experiments, both of which aid in the correct 
categorization of known contaminants. The percentage listed refers to the occurrence 
of each interaction partner in these contaminant databases; therefore interaction 
partners with a lower percentage can be considered less likely to be associated non-
specifically. The fourth column is an in silico prediction of which partners are likely to 
be targets of IKK phosphorylation, with more than half of the interactors returning a 
positive result.  
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Figure 2.38 Radiation-inducible interactors of NEMO. 
Interactors of NEMO enriched in forward (Lys8/Arg10 labeled cells irradiated) and reverse 
experiments. Frequency of occurrence in databases of non-specific interactors found in 400 
affinity pull-down screens analyzed by LC-MS. Interactors predicted to be substrates of the 
IKK complex. 
*Courtesy of Nadine Mikuda. 
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The inducible interactors were also subjected to a Gene Ontology analysis (Figure 
2.39) to identify the biological processes most enriched. As expected, “Response to 
DNA damage stimulus” is near the top of the list, but it was the presence of “mRNA 
metabolic processes” which turned attention on to enhancer of mRNA-decapping 
protein 4 (EDC4), which is involved in the degradation of mRNA. Further investigation 
revealed that upon irradiation, IKK binds and phosphorylates EDC4.  This leads to an 
increased formation of p-bodies, cytosolic structures that are the sites of mRNA 
processing, as well as recruitment of mRNA decapping enzymes Dcp1a and Dcp2. 
Ultimately, this work was able to show that the stability of a significant number of 
transcripts is regulated by the IKK and EDC4 signaling axis, ascribing a new role to
IKK in protein regulation that extends beyond transcriptional regulation.  
Figure 2.39 Gene ontology analysis of the inducible interactors of NEMO. 
*Courtesy of Nadine Mikuda. 
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3.4   Analyzing polyubiquitination by mass spectrometry. 
 
3.4.1   Ubiquitin linkage profiling by SRM-MS. 
The mode of polyubiquitination on a substrate is a critical feature in determining the 
downstream fate of that protein. Primary ubiquitination sites on a target protein can 
be identified using mass spectrometry by looking for the lysine residues with a diglycl 
moiety (K-GG), appearing in a MS/MS spectrum as a lysine augmented by 114.03 
Da. Ubiquitin’s internal lysines are modified by diglycyl moieties by the process of 
polyubiquitination, with seven lysines (K6, K11, K27, K29, K33, K48 and K63) and 
the N-terminus (M1) possessing the primary amine functionality required for 
conjugation.  Upon digestion with trypsin, eight unique peptides are formed, each one 
specific to a particular linkage type. SRM-MS methods for these peptides were 
published by Mirzaei et al 128 and adapted for use in our laboratory, with the 
exception of the M1/linear peptide which was developed in-house for these studies. 
Table 2.5 lists the transitions for the detection of endogenous ubiquitin linkage-
specific peptides; transitions for heavy-labeled peptides were also published but are 
not listed here. Analysis of a whole cell lysate in the presence of a known amount of 
heavy internal standard can show global levels of each linkage type across the 
proteome. However, it is more informative to assess the polyubiquitination chain type 
conjugated to a single substrate, and therefore an immunoprecipitation to enrich this 
particular target is the starting point for further analysis in each of the studies 
presented below.  
 
Q1	 Q3	 Ubiquitin	linkage	type;	Sequence	 DP	(V)	 CE	(eV)	
460.6	 305.2	 K6,	MQIFV[K_GG]TLTGK	 130	 27	
460.6	 519.3	 K6,	MQIFV[K_GG]TLTGK	 130	 24	
801.4	 1002.5	 K11,	TLTG[K_GG]TITLEVEPSDTIENVK	 130	 38	
801.4	 1131.6	 K11,	TLTG[K_GG]TITLEVEPSDTIENVK	 130	 38	
701.0	 944.0	 K27,	TITLEVEPSDTIENV[K_GG]AK	 130	 28	
701.0	 802.4	 K27,	TITLEVEPSDTIENV[K_GG]AK	 130	 36	
408.7	 503.3	 K29,	A[K_GG]IQDK	 130	 28	
272.8	 390.2	 K29,	A[K_GG]IQDK	 130	 15	
546.6	 643.3	 K33,	IQD[K_GG]EGIPPDQQR	 130	 36	
546.6	 740.4	 K33,	IQD[K_GG]EGIPPDQQR	 130	 29	
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487.6	 617.8	 K48,	LIFAG[K_GG]QLEDGR	 130	 19	
487.6	 347.2	 K48,	LIFAG[K_GG]QLEDGR	 130	 33	
748.7	 1015.5	 K63,	TLSDYNIQ[K_GG]ESTLHLVLR	 130	 32	
748.7	 1067.6	 K63,	TLSDYNIQ[K_GG]ESTLHLVLR	 130	 46	
520.3	 740.4	 Ub	internal,	EGIPPDQQR	 130	 29	
520.3	 643.3	 Ub	internal,	EGIPPDQQR	 130	 30	
440.2	 506.3	 M1/Linear,	GGMQIFVK	 130	 27	
440.2	 634.4	 M1/Linear,	GGMQIFVK	 130	 27	
793.4	 978.5	 K11	yeast,	TLTG[K_GG]TITLEVESSDTIDNVK	 130	 40	
793.4	 891.4	 K11	yeast,	TLTG[K_GG]TITLEVESSDTIDNVK	 130	 40	
698.4	 940.0	 K27	yeast,	TITLEVESSDTIDNV[K_GG]SK	 130	 29	
698.4	 804.4	 K27	,	TITLEVESSDTIDNV[K_GG]SK	 130	 36	
416.7	 503.3	 K29	yeast,	S[K_GG]IQDK	 130	 25	
416.7	 262.1	 K29	yeast,	S[K_GG]IQDK	 130	 25	
896.0	 802.4	 actin	(ACTB_HUMAN),	SYELPDGQVITIGNER,	y7	 130	 36	
896.0	 1086.6	 actin	(ACTB_HUMAN),	SYELPDGQVITIGNER,	y10	 130	 47	
Table 2.5 Polyubiquitin linkage specific SRM methods adapted from literature.  
The linear/M1 linkage-specific peptide was not used in the Mirzaei et al, Method parameters 
were developed manually on an ABI Sciex 5500 Q-Trap using the approach detailed for the 
precursors and products of NF-κB.  
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3.4.2   Polyubiquitin and parkin. 
 
3.4.2.1   Parkin promotes linear polyubiquitination of NEMO by LUBAC. 
Parkin is an E3 ubiquitin ligase linked to Parkinson’s disease with a role in 
neuroprotective pathways. In vitro, parkin prevents cell death in response to 
mitochondrial and endoplasmic reticulum stress, while in vivo mutations in the parkin 
gene resulting in a loss of function cause autosomal-recessive parkinsonism. With 
regard to mitochondrial stress, parkin has been linked to a pathway that removes 
damaged mitochondria by mitophagy	 129, and it was theorized that this role is the 
foundation for parkin’s prosurvival function. Please note that this project was in 
collaboration with Dr. Anne-Kathrin Müller-Rischart of AG Winklhofer at the Ludwig 
Maximilians University  , who performed all cell culture and immunoprecipitations. In 
MEF cells where parkin was knocked-out, Dr. Müller-Rischart observed a significant 
increase in apoptotic cell death, implicating the mitophagy pathway	 130. 
Systematically knocking out other components of the mitophagy pathway, PINK1, 
ATG5 and p63, did not hinder parkin’s ability to block apoptosis, but removal of the 
ubiquitin-like (UBL) domain from parkin’s N-terminus did. These findings indicated 
that parkin’s roles in mitophagy and stress protection are regulated by different 
pathways. Parkin is known as a stimulator of the canonical NF-κB pathway	 131, itself 
linked to anti-apoptotic activity, and therefore a possible link between them was 
pursued. As NEMO is an essential mediator of the canonical NF-κB response, MEF 
cells with NEMO knocked out are deficient in responding to canonical stimuli. It was 
shown that in these cells mitophagy was unaffected but parkin’s ability to block 
apoptosis was prevented, and that this activity is restored upon rescuing the cells by 
expressing NEMO by transient transfection. Parkin is an E3 ligase and the NF-κB 
pathway is highly dependent on ubiquination, both degradative and non-degradative, 
in order to propagate signals, including linear ubiquination of NEMO	 103. The only 
other protein known to undergo linear ubiquitination is RIP1	 132, a kinase also 
associated to the NF-κB pathway. Linear polyubiquitin chain formation is catalyzed 
by the linear ubiquitin assembly complex (LUBAC), comprised of the E3 ligases 
HOIL-1L and HOIP and Sharpin as an adaptor protein	 133	 134. A link between parkin 
and LUBAC was therefore investigated using SRM-MS as a tool to quantitate 
changes in the various polyubiquitin linkage types. This was facilitated by using the 
UBAN domain of NEMO, known to have affinity for linear ubiquitin chains and can 
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therefore be exploited to enrich them	135. 
HEK293T cells were transfected with the LUBAC components HOIL-1L and HOIP, as 
well as a wild-type parkin or a mutant form lacking the UBL domain. Lysates of these 
cells were incubated with a recombinant UBAN domain with a Strep tag to enrich for 
linear ubiquitin chains, which were then relatively quantified by SRM-MS using 
heavy-labeled analogues of the internal polyubiquitin linkage peptides listed in Table 
2.5. Figure 2.40A illustrates that the expression of wild-type parkin in these cells is 
associated with a three-fold-increase in linear ubiquitination, while this activity is 
severely compromised when parkin’s UBL domain is removed. The effect that 
endogenous parkin has on linear ubiquitination was investigated by knocking-down 
parkin levels with siRNA in the same cell system (HEK293T), and Figure 2.40B 
shows that suppression of endogenous parkin expression is associated with an 
approximately three-fold decrease in linear ubiquitination.  
 
Figure 2.40 Parkin promotes the linear ubiquitination of NEMO.  
A. SRM-MS relative quantitation of linear (M1), K48- and K63-linked polyubiquitin following 
affinity-purification of HEK293T lysates with Strep-linked UBAN. Samples measured in 
triplicate with top two transitions used for quantitation with standard deviation indicated.  
B. Relative quantitation of linear polyubiquitin in HEK293T cells treated with siRNA to knock 
down parkin. Measured by SRM-MS as in A. 
*HEK293T cell culture and immunoprecipitation performed by Dr. Anne-Kathrin Müller-
Rischart. 
A B
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3.4.2.2   Parkin is a component of LUBAC and binds preferentially to 
HOIP. 
Parkin’s effect on linear ubiquitination was further compounded by showing that it 
physically interacts with the LUBAC complex. Two cell lines of HEK293T cells were 
made overexpressing the LUBAC components, one with HOIP, HOIL-1L-HA and 
parkin, the other with HOIP-HA, HOIL-1L and parkin, with the HA tag used to enrich 
these proteins and their interactors. After analysis of the two pull-downs by shotgun 
mass spectrometry following an in-gel digestion, the data was analyzed by MaxQuant. 
Figure 2.41 reveals that Parkin binds preferentially to HOIP. Strikingly, it does so to 
an even greater extent than the known LUBAC component Sharpin, itself also 
exhibiting a preferential binding to HOIP. Other known interactors of HOIP and HOIL-
1L (TRIM25, PSMD2, PSMD7, PSMC4) appear in the central cluster and do not 
favour binding to one LUBAC component over the other. 
Figure 2.41 Parkin is a component of LUBAC and binds preferentially to HOIP.
HEK293T cells were transfected with HOIP-HA, HOIP-1L and parkin, or HOIP, HOIL-1L-HA 
and parkin and subjected to immunoprecipitation with α-HA antibody. Proteins bound to HOIP 
or HOIL-1L were measured and quantified on a Q-Exactive MS and the Log2 ratio of HOIP 
and HOIL-1L plotted versus the Log10 transformed normalized MS intensity. Known 
interactors of the bait proteins are coloured in red.  
*HEK293T cell culture and immunoprecipitation performed by Dr. Anne-Kathrin Müller-
Rischart. 
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3.4.3 Ubiquitin and protein kinase A signalling. 
 
3.4.3.1   ARHGAP36 induces K63-linked polyubiquitination of PKAC. 
Cyclic adenosine monophosphoate (cAMP), a derivative of adenosine 
monophosphate, acts as an intracellular signal transduction agent and is involved in 
several biological processes, acting as a second messenger downstream of G-
protein coupled receptors. One such function is the activation of protein kinase A 
(PKA), a serine/threonine kinase with roles in regulating diverse activities such as 
development, proliferation and metabolism	 136. PKA is composed of a dimer of 
regulatory subunits (PKAR) each bound to a catalytic subunit (PKAC), occupying its 
active-site cleft and inhibiting its function. Upon binding of cAMP to PKAR, PKAC 
dissociates and is rendered active, facilitating phosphorylation of PKA targets. Tight 
regulation of this activity is achieved through multiple means, including by small 
protein kinase inhibitor proteins (PKI) that act as pseudosubstrates blocking the 
kinase site	 137, or a mechanism by which PKAR is subjected to proteasomal 
degradation in a cAMP-dependent manner	138.  A ubiquitin-dependent degradation of 
PKAC was also suspected as this is a typical pathway for turning off protein kinase 
activity.  
Please note that this following project was carried out in collaboration with Dr. 
Rebecca Eccles of AG Rocks at the Max Delbrück Center. In a previous MS screen 
for interactors of PKAC, a Rho-GTPase-activating protein family member ARHGAP36 
was identified. Further co-immunoprecipitation studies confirmed the interaction, and 
it was demonstrated that ARHGAP36 inhibits the activity of PKAC by binding to its 
active site cleft via a pseudosubstrate motif. Beyond simple inhibition to 
downregulate the kinase activity, it was observed in HEK293T cells that expression 
of ARHGAP36 coincides with depletion of PKAC, as measured by Western blotting, 
evidence pointing towards a degradation pathway. A SRM-MS analysis of linkage-
specific polyubiquitin peptides was performed, measuring their levels in a PKAC 
immunoprecipitation in HEK293T cells transfected with PKAC-YFP in the presence or 
absence of co-expressed Flag-ARHGAP36. Figure 2.42 demonstrates that their 
coexpression leads to an accumulation of K63-linked polyubiquitin with no change in 
levels of the K48-linkages classically associated with protein degradation. While 
inhibition of the proteasome by epoxomicin had no effect on PKAC levels, inhibition 
of endolysosomal acidification by bafilomycin partially restored PKAC.  
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Figure 2.42 Coexpression of PKAC and ARHGAP36 results in increased levels 
of K63-linked polyubiquitination.  
HEK293T cells were transfected with PKAC-YFP with or without FLAG-ARHGAP36 and a 
immunoprecipitation performed with an α-GFP antibody. Eluates were processed and SRM-
MS analysis was used to quantify the relative levels of K48 and K63-linked polyubiquitination
after normalizing protein loading  based on PKAC levels determined by data-dependent 
measurement of a portion of sample on a Q-Exactive MS. SRM-MS Samples injected twice 
and the top two transitions used for quantitation and standard deviation calculated. 
*Cell culture and immunoprecipitations performed by Dr. Rebecca Eccles. 
3.4.3.2   Intensity-based quantification of neuroglioblastoma proteins.  
A shotgun MS analysis of a neuroglioblastoma (NGP) whole cell lysate was 
quantified by a method known as Intensity-based absolute quantification (IBAQ)	 139. 
In this approach, the overall MS intensity of each protein detected is normalized by 
dividing this intensity by the number of theoretically observable tryptic peptides each 
protein can yield, a value converted to an absolute via calibration with a spiked in 
protein standard mix. In the absence of this calibration. this method enables a 
relative quantitation of all of the proteins found in the data set, ranking them 
according to their abundancy in the sample. In Figure 2.43, a histogram shows the 
distribution of relative abundance for all of the measured proteins (n = 4448).  
ARHGAP36 and PKAC appear in the same bin, indicating that they have a similar 
abundance. The  accompanying bar plot shows the log10 abundance of several 
proteins relative to ARHGAP36; PKAC is at 0.95 fold, and therefore essentially 
equimolar to ARHGAP36. These findings confirm that ARHGAP36 is a viable 
regulator of PKA kinase activity. On a short-term time scale, endogenous and 
equimolar levels of ARHGAP36 block the kinase activity with its PKAC 
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pseudosubstrate motif, while on a longer-term time scale it promotes its K63-
polyubiquitin mediated endolysosomal degradation.  
Figure 2.43 Intensity-based quantification shows ARHGAP36 and PKAC found 
in equimolar amounts in neuroglioblastoma cells. 
Data-dependent MS analysis of whole-cell neuroblastoma lysate subjected to an IBAQ 
quantitation to sort proteins by relative abundance. Histogram (right) indicates the abundance 
distribution of all measured proteins (n = 4448) with the bin that ARHGAP36 and PKAC co-
occur in coloured pink. PKAC is the sum of the two subunits of PKAC, PRKACA and 
PRKACB. Bar plot (left) indicates the abundance of the proteins relative to ARHGAP36. 
PKAC has a 0.95 fold abundance relative to ARHGAP36.  
*Cell culture performed by Dr. Rebecca Eccles. 
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4   Discussion 
 
4.1   Inception and evolution of proteomics. 
The term “proteome”, first coined in 1994	140, referred to the entire observable protein 
complement of a cell. This was a time when MS-based proteomics was still in its 
infancy, indeed before the word proteomics was even used, and the ultimate goals 
must have seemed lofty and idealistic. Although the identification of a handful of 
proteins might take months of work, the awesome potential of the nascent technology 
had clearly been recognized for its ability to transform protein science. Ten years 
later Mann and Tyers put forth an updated definition, describing proteomics as 
“almost everything post-genomic: the study of the proteome in any given cell and the 
set of all protein isoforms and modifications, the interactions between them, the 
structural description of proteins and their higher-order complexes”	 141. This 
expanded definition reflected the massive leaps forward that had already occurred in 
MS-based proteomics, driven by innovations in technology and informatics, and 
adopted in droves by researchers persuaded at the sheer power of MS-based 
proteomics approaches.  
Ten years further onward and the once-lofty goals are beginning to become routine, 
with complete proteomes of organisms starting to come within grasp. Starting with 
lower-order organisms	142 all the way up to human proteomes	143	144, what was once a 
fantasy can now be achieved readily, often in as little as a day. This exponential rise 
in the power of proteomics parallels that of the genomic field	 145.  The Human 
Genome Project, a massive global effort to sequence the three billion nucleotide 
base pairs of our genetic code, took 13 years and cost $3 billion, reaching completion 
in 2003	 146. Thanks to next-generation sequencing technology, the same goal could 
be achieved in days for a tiny fraction of the cost. In proteomics the development of 
highly-sensitive instrumentation and robust methodologies has propelled widespread 
growth in the field, offering immense advantages over the direct and indirect protein 
identification and characterization methods that came before. Foremost of these is 
the specificity with which proteins are identified by the detection and sequencing of 
multiple peptide proxies. Over the last 20 years, the basic workflows of proteomics 
have become increasingly standardized, with similar sample preparation and 
instrumental analysis methods adopted by groups around the globe. In most shotgun 
or data-dependent analyses, the measurements proceed in an unbiased way; the 
4			Discussion	
	 82	
researcher does not have control over what peptides are being selected for 
sequencing. Generic workflows and common instrumentation makes the sharing of 
raw data in public repositories an aid in research projects worldwide	147.   
With the advent of deep-proteome sequencing and approaching full proteome 
coverage, one surprising observation has been just how similar the proteomes of 
different tissues are. Rather than being differentiated on the basis of the types of 
proteins expressed, in practice there are very few proteins that are unique to a given 
tissue	 148. This pervasive proteome expression was confirmed by the Human Protein 
Atlas, a global antibody-based effort to map protein expression and produce 
validated anti-bodies for each protein-coding gene	149. Differentiation of these tissues 
must therefore be realized by differential protein abundances and arrangements, how 
many molecules there are and with what other molecules they interact. Hence, the 
ability of MS to precisely quantify proteins emerged as a vital property, as only 
through quantitation will we characterize these differences and reach a deeper 
understanding. Quantitative proteomics strategies involving the use of stable-isotope 
coded peptides and proteins dominate for their ability to correct for a number of 
experimental and instrumental variations, though label-free approaches have also 
steadily gained traction.  
In the context of a discovery shotgun experiment, the instrument operates in an 
unbiased manner, sampling whatever peptide ions are most abundant at any given 
time during the chromatographic elution for MS/MS sequencing. While many 
thousands of peptides can be identified this way, there are also inherent problems. 
First, due to its data-dependent nature and the size of the digested proteome, the 
instrument samples a slightly different subset of this population each run, leading to a 
level of irreproducibility even between identical samples.	Second, sampling only the 
most abundant ions means the less abundant signals are neglected, resulting in a 
systematic underrepresentation of these analytes in data sets	 112	 110. This is 
particularly true for the transcription factor class of proteins, which tend to be 
expressed at low levels in the cell	150	151	152. How, then, to reliably measure them? 
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4.2   Targeted proteomics for analytically challenging scarce 
protein species. 
Targeted proteomics strategies address both of these problems. Focusing the MS 
analysis on a pre-determined list of peptide analytes means they will be reproducibly 
sampled each time, even when other more abundant species are co-eluting from the 
chromatographic column. While not generating the same volume of data as discovery 
proteomics, targeted methods allow researchers to answer the specific questions 
they are interested in. SRM-MS on a triple-quadrupole MS is the most mature 
method in the targeted proteomics toolbox, and the method of choice for reliable and 
robust quantitative measurements across many samples and even between different 
labs and instrument platforms. SRM-MS has long been a “gold standard” for small-
molecule drug candidate quantitation	 153, measurements that need to be precise and 
reproducible if they are to satisfy powerful regulatory bodies like the Food and Drug 
Administration (FDA) in the U.S.A. Continuous development and refinement in QQQ 
technology brought the sensitivity of these instruments to a level matching the needs 
of proteomics. Early examples of SRM on plasma proteins	 154 and Streptococcal 
virulence factors	 155 demonstrated its feasibility, but it was the massive studies 
targeting the complete yeast proteome undertaken by the group of Rudi Aebersold, 
that demonstrated the power of the technique to the proteomics community. Picotti et 
al detected and quantified yeast proteins across the entire abundance range with a 
success rate of 90%	 156. Following this breakthrough, and spurred on by the 
concurrent creation of databases to share SRM methods, other groups started to 
apply this technique and publish their work, including groups interested in quantifying 
transcription factors such as the NF-κB family. Xiang et al quantified all NF-κBs, with 
the exception of c-Rel, as part of a project to characterize a model system of drug 
resistance in multiple myeloma, after first fractionating proteins using SDS-PAGE	157. 
Zhao and colleagues measured activated Rel A molecules present in nuclear 
fractions following enrichment using a single-stranded DNA aptamer that binds free 
Rel A with high affinity	 158. In a different publication, the same group measured 
protein markers of the innate immune response in cellular fractions	159. Simicovic et al 
probed the levels of key transcription factors during the terminal phase of 
adipogenesis	 160. What the above studies have in common is employing a 
fractionation or enrichment scheme in order to first reduce the complexity of the 
measured proteome, and as such should refrain from making claims of absolute 
quantitation. In two cases, cell lysates were resolved by SDS-PAGE before being 
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subjected to an in-gel digestion to convert embedded proteins into tryptic peptides, 
with heavy peptide internal standards spiked in later. Provided this SDS-PAGE 
procedure involves completely efficient processes to get the proteins into the 
polyacrylamide matrix and a lossless extraction of the resultant peptides, this could 
be true. However, the systematic efforts by the group of Schevchenko using isotope-
coded peptides has shown that peptide recovery from the gel varies from 13 to 40% 
and is both protein- and peptide-dependent	 121. As it is not feasible to measure the 
extraction efficiency for all peptides in this way, the quantitation of in-gel preparations 
should be considered as relative, not absolute. Likewise, for affinity enrichment of a 
target protein, the efficiency of the pull-out is highly variable and sub-stoichiometric, 
so a claim of absolute quantitation would require a precise characterization of this 
pull-down process for each sample to define what percentage of the total population 
was captured.  
In the present work, SRM-MS methods were designed and optimized to perform 
absolute quantitation of the NF-κB precursor molecules, p100 and p105, and their 
respective products, p52 and p50, following an in-solution digest of a protein solution 
derived from lysis of intact MEF cells. Such a preparation represents a maximum of 
sample complexity in proteomics, a level of complexity that is not fully defined	 109. 
While the number of protein-coding genes an organism possesses can be 
approximated, the number of discrete protein products actually present in a cell is 
complicated by alternate splice forms and post-translational modifications, a limitless 
landscape of possibilities further amplified by the ever-changing dynamics of biology. 
Faced with such a significant analytical challenge, taking measures to reduce sample 
complexity via fractionation or affinity enrichment are understandable steps to 
improve the chances of detecting one’s target in the downstream MS measurement. 
However, such manipulations are difficult to quantify for the above-mentioned 
reasons, and introduce unknowns into the process that make absolute quantitation a 
challenge unless carefully controlled and monitored. In addition, fractionation or 
affinity enrichment is generally not reproducible across many samples and would 
therefore introduce further uncertainties. The goal here was a method that could 
probe hundreds of samples generated from time course experiments; after activating 
the non-canonical NF-κB pathway by treatment with a lymphotoxin B receptor 
agonist and sampling cells over a 6-12 h time window. In previous studies this 
detection was accomplished via Western blot, the standard technique for protein 
detection in biology labs, as evidenced by over 54,000 citations of the original 1979 
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publication	 161. Here the authors noted in the abstract that the transfer of proteins 
from gels to nitrocellulose was not quantitative. Coupled with antibodies of dubious 
specificity and non-linear detection properties, a Western blot is not the ideal tool for 
making precise quantitative measurements.  
 
4.3   Critical facets of the SRM-MS method development process. 
The selection of tryptic peptides on which to build an SRM method is a crucial step 
as it will ultimately determine the sensitivity of the assay. The signal response from 
tryptic peptides derived from the same protein can differ by 100-fold	 162, a fact that 
could make the difference between a confident detection or a signal indistinguishable 
from the background noise. Unfortunately it is very difficult to predict any given 
peptide’s MS performance based on the sequence alone. Some computational tools 
do exist, trained by existing data resources	 163	 164	 165, with some incorporating up to 
500 properties in their scoring algorithm	 118. The non-cohesiveness of results among 
platforms pushes some in the direction of public data repositories, such as 
PeptideAtlas	 166	 167 and SRMAtlas	 113, to simply adapt the methodologies already 
used by others. At the time of method development for this project, no information 
about NF-κB peptides was available, and indeed the majority of entries in these 
databases arose from yeast as a result of the work of Picotti et al. Data from shotgun 
experiments can also be used to identify peptides that are reproducibly detected, but 
these data generally come from non-QQQ instrument platforms, where the mode of 
fragmentation results in differing fragmentation patterns	 168. In this study, the in-
house availability of a solid-phase peptide synthesizer provided the means acquire 
MS/MS spectra on the Sciex 5500 Q-Trap, the QQQ platform to be used.  
The first step in the development of an SRM-MS assay is the characterization of the 
peptide’s MS traits, such as the precursor m/z and charge state, as well as the 
MS/MS fragmentation pattern. Even in the presence of synthetic by-products (and 
contaminants), steady infusion of the synthetic peptides directly into the MS via 
electrospray source to give a stable signal made it possible to confirm the success of 
the synthesis by the presence of the expected m/z and to determine the charge state 
of the peptide under experimental conditions. While this is generally a straightforward 
calculation for a small peptide, the Enhanced Resolution scan of the peptides in Figs. 
2.4 and 2.9 makes visualization of the spacing of the 13C isotopes simple. When 
comparing the two types of precursor scans, EMS and ER (Figs 2.3, 2.8 vs. 2.4, 2.9), 
4			Discussion	
	 86	
one observes the trade-off for the higher resolution in terms of intensity, with a loss of 
nearly 10-fold. In SRM mode, the instrument allows one to set a resolution on the Q1 
and Q3 m/z signals, filtering the selected ion through a window 0.35 (High), 0.7 (Unit) 
or 1.0 (Low) m/z units wide. A narrow bandwidth (high) on Q1 allows more precision 
in precursor ion selection, but the reduced ion transmission means less sensitivity for 
that target and therefore must be considered carefully. It is also noteworthy that a 
wider selection bandwidth offers a higher tolerance for drift in the calibration of the 
quadrupole, drift that might otherwise reduce ion transmission by sampling an m/z 
value off-centered from the maximum. For this study, the resolution was set to Unit 
for both Q1 and Q3.  
The product ion or MS/MS spectra (Figs 2.5 and 2.10) are the foundation of any 
SRM-MS method development. Here the collision-induced dissociation (CID) 
fragmentation pattern is revealed, making selection of the most abundant fragments 
straightforward. Also valuable is the relative fragment abundance, as the same 
hierarchy of signals will be present in the nested peaks characteristic of SRM-MS 
data. Referring to Fig. 2.14, one sees the ranking y7 > y6 ≈ y8 seen in the MS/MS 
spectrum replicated in the nested peaks for the p100 peptide. Likewise, comparing 
the MS/MS of the p105 peptide in Figure 2.10 with the SRM trace in Figure 2.19, y6 > 
y9 ≈ y7. The relative abundance of fragments is a useful characteristic to support a 
signal’s identity. In the absence of a heavy reference peptide co-eluting, more 
transitions should be included in the method to increase confidence, in essence by 
reproducing more datapoints of the MS/MS fragment spectrum.  
In the next step various adjustments to the instrumental parameters are made, 
particularly the MS/MS collision energy, in order to maximize the method’s sensitivity. 
Optimization of the declustering potential yielded a relatively flat response (Fig. 2.6) 
across the range, making selection of a single value for all transitions a sensible 
choice. Similar flat optimization of this ion source voltage has been noted for other 
QQQ systems such as the Thermo Quantiva	 158. An advantage of using a single 
value across the transition list is that the ion source remains in a constant state 
throughout the acquisition. Such voltage switching on the 5500 system requires 5 ms 
of settling time for the electronics before the next transition can be monitored. This 
penalty can quickly consume valuable duty cycle, the time required to cycle through 
all transitions in the method and record a data point for each. The duty cycle is 
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restricted so that sufficient data points are recorded to adequately define the 
chromatographic peak	116.  
Repetitive acquisition of the SRM transitions while ramping the collision energy 
provides the best opportunity for tuning the method to increase sensitivity. 
Mathematical equations exist to predict collision energy, but these only take into 
account the peptide’s precursor mass and charge state	 120	 169. The influence of 
amino acid composition and sequence is neglected, meaning a single collision 
energy value is assigned for all transitions from a peptide (gray dashed line in Figs. 
2.7 and 2.11). However this is not the true case, as the different amino acid side-
chains with their varying chemical properties do exert an influence on the lability of 
the peptide bond, as the curves in the CE ramp plots indicate that breaking the 
different peptide bonds requires different voltages to achieve maximum signal. The 
optimization of the collision energy should be considered essential in cases where 
sensitivity is a concern, and while a synthetic peptide to perform these scans may be 
considered a luxury, early effort spent in method development is rewarded 
downstream with improved detection. The Dynamic SILAC-SRM study strained the 
methodology in two ways. First, additional transitions were added to the method to 
monitor the new species, the M-Arg-6 labeled peptides produced from de novo 
synthesis, which reduced the dwell times for each transition by 1/3 to maintain a fixed 
duty cycle. Second, the earliest-possible detection of de novo M-Arg-6 peptides and 
conversely the latest-possible detection of L-Arg-0 precursors p100 and p105 in the 
stimulation time course demands the maximum sensitivity to confidently distinguish 
these weak signals from the background.  
 
4.4   The advantages of SRM-MS over Western blotting. 
In a 2013 editorial for Molecular and Cellular Proteomics	 170, Aebersold et al 
compared and contrasted Western blotting to SRM-MS assays, arguing that the data 
derived from the MS-based targeted proteomics technique surpasses that from 
Western blotting on several grounds. Regarding the detection and quantification of 
the NF-κB precursors and their products, SRM-MS is superior to Western blotting 
with respect to :  
i) The Quality of the Assay, including its performance characteristics, and  
ii) The Quality of the Results.  
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4.4.1   SRM-MS vs. Western blotting: Quality of the assay. 
Detection of the precursors p100 and p105 and their products p52 and p50 for the 
vast majority of studies has depended upon antibodies. Antibodies specific to the 
protein N-termini detect both the precursor/product pairs as the target epitope is 
shared between them, and they can be distinguished by their apparent molecular 
weight on the gel. C-terminal specific antibodies detect only the full-length precursor 
molecules. These are commercial antibodies sourced from major suppliers, but little 
information is provided about their properties and the consumer generally has no 
quality control but faith. Variations between batches of antibody as well as how it is 
handled and stored within the laboratory can lead to shifting performance traits, such 
as effective concentration and affinity	 171. Meanwhile, the synthetic peptides 
purchased from JPT were aliquotted in precise amounts, facilitated by the fluorescent 
tag at the C-terminus, and arrive with an MS spectrum and LC-UV trace to support 
identity and purity. An independent verification of the identity of the peptide is easily 
achieved on the user’s end, as MS and MS/MS spectra will be ample proof of the 
peptide’s sequence and purity.  The linearity of the SRM assay is demonstrated in 
Figure 2.13, as the quantified synthetic peptides allow a precise titration of the 
instrument’s detector response. While other groups commonly employ standard 
addition	 158, supplementing different amounts of protein digest to a fixed amount of 
internal standard, the reverse standard addition method employed here maintains a 
constant background of whole cell digest, so the same amount of protein is injected 
onto the column each time	 172. This negates effects that increasing amounts of 
protein would have on column capacity and ionization efficiency. The SRM method’s 
superior sensitivity relative to antibody-based detection is evident for the p100 
peptide in the context of the p105 KO MEF stimulation time course (Western blot in 
Figure 1.2B vs. bar plot in Figure 2.24A). The band assigned to p100 vanishes after 
4h of LTβR stimulation, while the SRM-MS method detects p100 in this assay up until 
the endpoint of 6h. In this case the Western blot had led to the incorrect interpretation 
that p100 had been largely depleted from the cell.  
The Dynamic SILAC-SRM experiments are an ideal example of the additional value 
one obtains using MS analysis that cannot be supplied by immunoblotting. In a single 
measurement, two populations of proteins, the pre-existing L-Arg-0 and the de novo 
synthesized M-Arg-6 are not only distinguished but also quantified. In the multiplexed 
analysis, 12 peptide species (L-Arg-0, M-Arg-6, and H-Arg-10) are monitored with 
three transitions each, with dwell times ranging from 50 to 100 ms, a total of 36 
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channels measured for every 2.5 s duty cycle. It should be noted that SRM-MS 
permits much higher levels of multiplexing, depending on the target proteins. 
Monitoring a peptide from an abundant structural protein such as actin requires far 
less time: 2 ms is sufficient to acquire a strong signal of 1e5 cps or greater. 
Assuming the same duration of duty cycle, one could monitor hundreds of equivalent 
transitions in a single run, a level of multiplexing unrivalled by any classic 
immunoblotting approach.  
 
4.4.2   SRM-MS vs. Western blotting: Quality of the results. 
SRM-MS detection and quantification of proteins through tryptic peptide proxies 
generates datasets richer in information and more confident than those derived from 
Western blotting. The latter depends upon a single signal, manifested as a band 
appearing in a position that corresponds to the molecular weight, or more correctly 
the electrophoretic mobility, which is externally calibrated via a molecular weight 
ladder in another lane. It is not at all unusual for more than one band to appear in a 
lane, although this may not be shown in a published figure. At best, additional bands 
are an example of the antibody’s non-specificity, and they can simply be disregarded 
based on their apparent molecular weight. At worst, these false positives cast doubt 
upon a band’s true identity and complicate discussions about how to interpret the blot.  
With SRM-MS, detection of the proteotypic peptide proxy for a protein depends on 
multiple parameters. One could consider the retention time of a peptide as a parallel 
to the electrophoretic mobility. They are of course unique: the first is a function of a 
peptide’s affinity to non-polar stationary phase, while the second a function of the 
physical size of a denatured intact protein. When considered simply as fractionation 
methods, it is clear that the retention time is a characteristic measured at a higher 
resolution and therefore more precise. Whereas a typical lane in an SDS-PAGE gel 
might be divided into 10-20 molecular weight slices or bins, reversed-phase nanoflow 
chromatography might resolve hundreds of peaks over the course of a gradient 
elution, tuneable by manipulation of the gradient’s profile and duration, making the 
retention time a more meaningful piece of information.  
The ions isolated by Q1 and Q3 are another parameter to be weighted. Each SRM 
transition itself is essentially a dual mass filter, the first quadrupole isolating peptide 
precursors through a 0.7 m/z window, and after fragmentation of the ions transmitted, 
the third quadrupole allows fragments matching another 0.7 m/z wide window to 
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reach the detector. While this confers substantial selectivity, the complexity of a 
digested proteome is so extreme that despite these tight restrictions many other 
signals arise from other non-target peptides. Inspection of any of the chromatograms 
in Figures 2.14 through 2.23 illustrates the noise in these measurements, as each 
transition trace yields multiple peaks across the gradient. Monitoring multiple 
transitions per peptide and having knowledge of the relative intensity of each 
transition increases this selectivity further, and coincidence of all transitions when the 
targeted peptide elutes gives rise to the characteristic nested peaks in the correct 
proportions. This identification becomes indisputable when an isotopically-labeled 
heavy reference peptide has been spiked in, as it co-elutes with the exact retention 
time and peak pattern. The exquisite selectivity of the method to monitor the 
precursors p100 and p105 and their products p52 and p50 was demonstrated in this 
work by applying the SRM-MS methods to the analysis of whole cell tryptic digests of 
wild-type MEFs, where all proteins are present, as well as knockout cell lines where 
one target has been deleted (p100-/-, nfkb2-/-, p105-/-, and nfkb1-/-). The complete 
absence of nested peaks at the indicated retention time windows in Figures 2.16, 
2.18, 2.20 and 2.22 is the supreme evidence for the method’s selectivity, 
demonstrating that no underlying signal is contributing noise to the measurement.  
The clearest advantage of SRM-MS over Western blotting is the ease with which 
precise quantification is facilitated when employing a heavy reference peptide. In 
terms of internal standards, a co-eluting molecule that is identical in every way save 
for the addition of a few neutrons cannot be matched, and is certainly superior to 
using a potentially misleading housekeeping protein such as actin or tubulin	 173	 174. 
The peak area of each analyte transition is normalized to the peak area of its 
corresponding internal standard transition. As the heavy peptides were spiked in to 
the protein lysate, their signal can correct for sample preparation parameters such as 
non-specific binding losses and digest efficiency, as well as variables at the 
instrument level such as injection volume and detector response. Quantitating a 
Western blot can be achieved	175	176, but it requires significant work to control factors 
such as the linear detection range and sample loading, and relies on densitometry, 
the counting of pixels, that is itself highly variable 177. However studies have shown 
that it is the operator itself that is the biggest source of error due to differences in 
sample handling	178. 
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4.5     Dynamic SILAC SRM-MS analysis of LT-βR stimulated MEF 
cells. 
The successful quantitation of the NF-κB precursors and products in MEF wild-type 
and knockout cell lines was a proof-of-concept to show that SRM-MS analysis can 
achieve what Western blot analysis had done previously. This is best demonstrated 
by the 12 h stimulation time courses in Figure 2.25. In whole cell extracts from wild-
type MEF cells, a gradual, stimulation-dependent decrease in the levels of p100 and 
p105 are clear, adhering to the established hallmarks of non-canonical signaling. 
This is matched by the slow rise of the products p52 and p50. For each species 
every timepoint is comprised of six data points representing two transitions quantified 
for three separate injections, the clustering of the data points a measure of the 
precision of the measurement. Precisely quantified signals permit the calculation of 
fold-changes for a single species between any time points, and importantly the 
absolute nature of the quantification means the levels of the different species can be 
compared directly. Absolute quantification transforms the qualitative thinking about 
the system, that a band in lane 1 on an immunoblot is stronger or weaker than that in 
lane 2, into a capacity to think about the very real molecules that are the actual 
players in this cellular signaling mechanism. With absolute quantification a 3-fold 
excess of p100 over p105 becomes apparent, and one can observe a loss of 200 
million molecules of p100 (per μg protein) between 0 and 12 h, with a rise in its N-
terminal product p52 by an approximately equal magnitude. In the p100 KO and 
nfkb2-/- MEF cell lines (Figure 2.24B), SRM-MS measurements of the basal and 
stimulated levels of p105 and p50 reveals significant differences that are not obvious 
from Western blotting, ultimately leading to a better-informed mechanistic 
understanding of the cell lines.  
The expanded capabilities of the Dynamic SILAC SRM-MS experiment is the most 
convincing demonstration of the value of this approach, exploiting the power of 
isotopic labeling for the dual purpose of absolute quantification and to mark protein 
populations relative to the initiation of non-canonical activation. This strategy further 
transformed our interpretation of the mechanism of p100/p105 activation and 
presented a new viewpoint that would have eluded our detection otherwise. 
Preferential degradation of the old L-Arg-0 precursors combined with preferential 
processing of de novo M-Arg-6 precursors can account for the slow kinetics of the 
activation, as it is only after new precursor has been translated at the ribosome and 
processed by the proteasome that the rise in products occurs and the transcriptional 
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response to the stimulus enacted. This is also consistent with a co-translational 
mechanism that was proposed within the Scheidereit group 14 years ago by 
Mordmueller et al.	 179, as the kinetics would suggest that the nascent precursor 
polypeptide chain emerging from the ribosome is immediately acted upon by the 
proteasome, p97 and unknown cofactors to generate the product. The requirement 
for protein synthesis to upregulate NIK and the essential role of the proteasome have 
been established	16	15 so it was unsurprising that inhibition with cycloheximide or MG-
132, respectively, should prevent the accumulation of the products p52 and p50, but 
through Dynamic SILAC it became clear that it was specifically the de novo M-Arg-6 
products that are affected. The investigation into p97’s role in this process was the 
most illuminating and opens up new avenues for ongoing investigations. Blocking the 
p97 ATPase activity by inhibition with DBeQ significantly reduced the generation of 
de novo products, leading to a speculative mechanism for a long-standing question in 
the NF-κB world: the mechanical force created by p97 hydrolysis of ATP is 
harnessed and used to pull the N-terminal halves of the precursors p100 and p105 
free of the proteasome before they are completely degraded; this force may also be 
required in separating the tightly-bound NF-κB dimers 
 
4.6     Modelling predicts a signal-responsive precursor complex.  
The interaction and interdependence of the precursors p100 and p105 in non-
canonical signal propagation pointed to the possibility of a functional p100-p105 
complex existing. The development of a mathematical model to describe this aspect 
of non-canonical signaling, the conversion of the free or complexed precursors p100 
and p105 into their respective products, benefitted greatly from the absolute 
quantitation of protein species through a 12 h time course. Previous models 
published on NF-κB have focused on canonical signaling alone	180	181, with modelers 
compiling data and deriving rate constants for reactions in the pathway from across 
the literature. This means that ultimately the data is sourced from different 
researchers in different groups working in different labs with different cell lines at 
different times and different places. In our work, all of the data inputted into the model 
was derived from our own measurements, performed with careful coordination and 
consistency. As has been discussed, the absolute data from SRM-MS analysis is of a 
higher quality, and measurements of whole cell lysates in endogenous systems 
brings us closer to the physiological truth. The proposed models in Figure 2.31 were 
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kept simple, focused on this single aspect of precursor conversion and omitting 
upstream processes like receptor activation and downstream processes such as 
nuclear translocation of the products. SRM-MS measurement of cells with and 
without stimulation provided the concentration changes that occur over time, so 
kinetic parameters could be estimated by fitting each model to this absolute, time-
resolved data. The mathematical modeling efforts supports the concept that p100 
and p105 form a complex and that this complex responds to the non-canonical 
stimulation. Model M3 emerged as the most probable model, in which a p100-p105 
complex forms and responds to the non-canonical stimulus by undergoing 
proteasomal processing. Simulations performed with this model were predictive and 
agreed well with the experimental data as evident in Figure 2.33, and the model also 
predicted that 14% of total p100 and 42% of total p105 participate in a p100-p105 
complex. Matthias Wilm once wrote	182: “A model remains a model, it never describes 
the reality in an absolute way. A good model should explain experimental data and 
should have a good predictive power for experimental results in a qualitative or even 
quantitative way. A model is not true because it is believed to be true. It is even 
difficult to say that certain experimental findings confirm the model description. It is 
more accurate to say that the experimental data can be interpreted within the 
framework of a specific model.” While Wilm was referring to models of electrospray 
ionization, this concept is equally apt here.  While the model alone cannot be taken 
as proof of a functional p100-p105 complex, it is a useful step, and provides a 
framework for evaluating future findings. Much like models of the canonical system	
181, this model of non-canonical NF-kB activation will be subject to ongoing evolution 
and challenge as future experiments attempt to further dissect an elaborate 
mechanism and generate data that may support or refute the model’s fundamental 
construction.  
The success of these efforts encourage the continued development of mathematical 
models to explain aspects of NF-κB signaling involving more of the upstream and 
downstream proteins. To this end SRM methods have been created to cover other 
transcription factors (Rel A, Rel B, c-Rel) as well as the IKK kinase complex. It would 
be interesting to incorporate Dynamic SILAC SRM-MS data of stimulation time 
courses in other cell types or with different stimuli. Ultimately, a larger and more 
comprehensive model of the non-canonical NF-κB pathway that gives deeper 
mechanistic insights into the kinetics could find utility in the development of therapies 
targeting this system, pinpointing reactions that might be pharmacologically 
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manipulated to achieve a desired correction to pathway misregulation occurring in 
disease states	183	184	185.  
 
4.7     Protein-protein interaction analysis of p100 and IKKΥ/NEMO. 
Analysis of a LTBR stimulation time course in MEF cells by Dynamic SILAC SRM 
presents an interesting question: if the two populations of precursors, old and new, 
exhibit distinct behaviours, how does the cellular machinery distinguish one from the 
other? One possibility is that in each context the precursors associate with different 
proteins, and this protein interaction network guides them down the appropriate 
pathway. An MS-based proteomics approach to find significant interactors of p100 
was not able to shed much light on this question. Either SILAC or LFQ was used as 
the basis for normalization to quantify differences between the immunoprecipitations 
with an anti-p100 anitbody versus a control IgG. Both approaches pointed to the 
other NF-κB molecules as the primary significant interactors of p100: p105 (nfkb1), 
Rel A (nfkb3), Rel b and, to a lesser extent, c-Rel. That p105 was identified as a 
significant interactor is expected given their previous co-occurrence in Co-IP 
experiments, the known interdependency of processing of the two precursors, and 
our mathematical model’s assertion that they form a functional complex. It is known 
that the C-terminal ankyrin repeat domain of p100 plays an inhibitory role by binding 
to the NF-kB transcription factors and masking their nuclear localization signals to 
maintain them in the cytoplasm in an inactive state	 14. It is clear from these data that 
no other protein binds p100 with as much affinity. The AAATPase p97 was equally 
abundant in both the experimental and control pull-downs, therefore it cannot be 
classified as a significant interactor of p100 according to this approach. Considering 
that p97 has been demonstrated here as having a functional connection to p100 
biology, regulating the proteasomal processing of the two precursors, this might 
seem surprising. However, a failure to enrich p97 in the p100 pull-down relative to 
IgG could be explained by the difference in abundance. While p97 is highly abundant, 
by some measures accounting for 1% of total protein mass	 186, p100 is relatively 
scarce. Even if p100 bound to p97 with high affinity and equal stoichiometry, this 
would not decrease the pool of unbound p97 in a significant way. It is likely that p97 
mediates its interaction with p100 through an as-yet-unknown cofactor, although the 
MS screen did not enrich for any likely candidates.  
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The MS-based screening for interactors of IKKγ/NEMO successfully identified a p-
body protein, enhancer of decapping 4 (EDC4), which was subsequently shown to 
undergo an IKK-mediated phosphorylation in response to DNA damage caused by 
radiation, and has a function in regulating mRNA transcript stability (Mikuda et al, 
submitted). This exciting finding points to new roles for the IKK complex in cellular 
regulation of mRNA that extend beyond its classical roles in NF-κB signaling, with 
RNAseq data pointing to hundreds of affected transcripts, the large majority of which 
are not known NF-κB target genes. The identification of EDC4 would not have been 
possible without an MS analysis of the eluate from the co-immunoprecipitation of 
NEMO. The MS-based detection of proteins pulled down by affinity enrichment is 
completely unbiased; the bound proteins are eluted, digested and their peptides 
measured by a data-dependent shotgun analysis. Detection by Western blot, 
conversely, is necessarily biased, as specific antibodies are required to probe the 
blot for proteins suspected of having an interaction with the bait. Cost and practical 
limits on how many times a blot can be probed restrict these to a handful of 
interactors. This limitation also shields an ugly truth of Co-IP experiments, that the 
total number of proteins pulled down routinely exceeds 1000 and often many more. 
In the p100 examples here, nearly 3000 proteins occupy the central cluster of non-
enriched background proteins, while for the NEMO screen this number exceeded 
1800. Optimization of experimental conditions, particularly the composition of the 
post-IP washing buffer, can help to reduce this number but such efforts are often 
offset by fear of washing away something important. The high number of binders 
pulled down is not surprising considering how the protein input for the IP is prepared. 
For both the p100 and NEMO IPs, cells are harvested from culture and lysed by 
shearing outer membranes in a douncer, after which the cytoplasmic fraction was 
isolated. At this stage the cellular context in which the proteins existed has been 
destroyed: the contents of various compartments intermingle, protein structures and 
scaffolding have collapsed, and the remaining protein soup is assayed to try and fish 
out the bait protein and whatever proteins are bound to it, or bound to the anti-body, 
or to the beads to which the antibody is linked. Proteins that might never share a 
cellular locale can co-precipitate, resulting in the aforementioned massive 
background and possibly confounding researchers with false positive hits. This 
protein lysate is far removed from the original cellular conditions, in which the protein 
concentration is estimated to be between 100-300 mg/mL 124, an astonishing figure 
achieved by the tight packing and compartmentalization of the cell. 
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Alternative approaches allow researchers to get closer to a protein’s interactors 
under in vivo conditions. Labeling proteins with fluorescent groups and performing 
microscopic imaging to demonstrate co-localization	 187, this method suffers from a 
similar bias, in that only those proteins so tagged can be studied. Such fluorescent 
proteins are often overexpressed and that, in combination with the tagging, means 
the system can no longer be classified as endogenous. Furthermore, the low 
resolution attained by imaging is not definitive proof of an interaction. Both of these 
issues are addressed with the proximity ligation assay	 188	 189, a technique to image 
protein-protein interactions in a cell, whereby antibodies to two proteins are tagged 
with short DNA strands. If the two proteins come into contact, when they are 
recognized by their respective antibodies the two DNA strands can participate in a 
rolling circle synthesis, generating circular DNAs amplified hundreds of times. 
Detection occurs through hybridization with fluorescently labeled oligonucleotide 
probes, yielding a signal visible to the microscope. While addressing proximity at 
endogenous levels, the requirement for antibodies to proteins being investigated 
makes this approach biased.  
Protein cross-linking to preserve complexes or investigate protein structure has been 
present in the literature for some years, but needed refinement on the technical and 
bioinformatics fronts to make it feasible	 190	 191	 192. It is an MS-based approach 
whereby cells in culture are treated with a small-molecule chemical reagent that 
covalently links proteins together. Typically these are based on bifunctional 
molecules such as two aldehydes or two NHS esters connected by a short 
hydrocarbon linker	 193	 194. The functional groups form a bond to protein primary 
amines (N-terminus, Lys) that have the correct proximity to each other, through a 
reductive methylation or simple substitution reaction. After cross-linking, the cells are 
lysed and the target enriched through affinity purification, after which the proteins are 
prepared for a standard shotgun analysis by tryptic digestion. Where crosslinks 
between two proteins formed, digestion yields two tryptic peptides connected by the 
short hydrocarbon linker. MS/MS fragmentation of such species gives complex 
patterns, but computational tools have been developed to aid in their interpretation	195. 
Proteins cross-linked together is evidence of a primary interaction, and one can map 
the peptides onto known structures to determine the domains making contact. A core 
of the complex can be described and re-asssembled outwards as secondary and 
tertiary cross-links are defined. Unlike the MS-based approaches utilized in the 
present work, significantly enriched interactors can be further ranked according to 
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their proximity to the target. This methodology has been used to characterize protein-
protein interactions within the 50 mDa yeast nuclear pore complex	 193, sorting 
interactions as local, distant and transient. A similar approach to elucidation of the 
interactome of p100 might meet with more success, capturing binding weak or 
transient interactors at different points during a LTBR stimulation time course. As 
recent reports indicate that the majority of cellular protein networks are governed by 
weak interactions with very few stable core complexes	 196, cross-linking may be the 
only way to preserve these interactions for study.  
 
4.8     Polyubiquitination in cell signalling networks.  
The modification of proteins with ubiquitin polymers is a critical PTM, controlling the 
fate of marked proteins and acting as a major regulator within signaling networks	101, 
with NF-κB the archetype. In fact, it was the first system in which the degradative role 
of K48-linked polyubiquitination was described, activating the canonical pathway by 
down-regulating the inhibitory IkBα, or suppressing NIK and activating p100 
processing in the non-canonical pathway	 197	 198	 199. While K48-linked polymers are 
the classical example, other major polyubiquitin types exist within this system. Non-
degradative K63 chains are needed for canonical NF-κB response to the chemokine 
IL-1B	 200, while K63 chains form on TRAF6 following genotoxic stress and are 
essential to the DNA damage transcriptional response by promoting IKKβ 
phosphorylation	126. K11 chains can act as degradative signals, as with the anaphase 
promoting complex	 201 or, conjugated to RIP1, are also involved in NF-κB activation	
202. As for linear (M1) polyubiquitin, one of the only substrates shown has been 
IKKΥ/NEMO, where it is involved in the response to TNFα	133. Identification of chains 
via Western blot is possible, but the antibodies available are generally of low affinity 
and specificity	 203. Methods based on SRM-MS detection have been developed that 
can overcome these limitations using isotope-coded reference peptides that both 
increase confidence and aid in quantification	 128. One drawback of such a proteomic 
approach is the loss of context that occurs upon tryptic digestion, separating the 
chain from the substrate and thereby obscuring its identity. Here a combination of 
Western blotting and MS-analysis can be useful to pinpoint the primary substrate.  
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4.8.1     Linear ubiquitination and parkin. 
SRM-MS analysis of ubiquitin linkages enriched from HEK293T cell lysate through 
affinity to a recombinant NEMO UBAN domain was used as evidence for parkin’s role 
in M1 chain formation	 130. Cells over-expressing wild-type parkin in combination with 
the LUBAC components HOIP and HOIL had 3 times as much linear chain formation, 
an effect abolished by deleting parkin’s UBL domain.  Importantly, knockdown of 
parkin by RNA interference could demonstrate that this was also the case at 
endogenous levels. Parkin’s involvement in linear ubiquitination was further 
cemented by it displaying higher affinity for HOIP than a known component of 
LUBAC, Sharpin	 133, via an MS-based interactomics experiment that compared 
proteins enriched through co-immunoprecipitation with HOIP or HOIL.  Overall, this 
work linked NF-κB signaling, activated by linear ubiquitination of NEMO, to a stress-
protective pathway and mitochondrial integrity through up-regulation of OPA1, an NF-
κB target gene.  
 
4.8.2     Novel regulation of protein kinase A signalling. 
Mass spectrometry was key in elucidating two new regulatory mechanisms inhibiting 
signaling through Protein Kinase A (PKA), an important signaling hub whose 
misregulation has implications in disease	 187. A previous proteomics experiment 
identifying binding partners of the catalytic subunit of PKA, PKAC, motivated 
investigations into what role one of these binders, ARHGAP36, plays in PKA 
signaling. Imaging studies indicated that the presence of ARHGAP36 led to 
lysosomal degradation of PKAC. An SRM-MS analysis of a PKAC pull-down showed 
enhanced formation of K63-linked chains in the presence of ARHGAP36, with these 
chains later proven essential to targeting PKAC to the lysosome for destruction. A 
second mode of inhibition is through ARHGAP36 acting as a pseudosubstrate to bind 
and block the catalytic site of PKAC. Here a quantitative shotgun MS experiment 
based on IBAQ	 139 could show that the two proteins exist in the same abundance 
range. This is an important finding as an equivalent stoichiometry is a prerequisite for 
pseudosubstrate inhibition to be a feasible mechanism.  
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4.9     Quantitative proteomics and unbiased biology. 
Quantitative MS-based proteomics has revolutionized protein biology over the last 
three decades. The scale on which proteins are reliably detected and confidently 
identified has greatly expanded the protein universe, facilitated by the arrival of 
complete genome databases	66. Quantitation of proteins is an important way to study 
a protein’s function, its protein interactors, and how perturbation of the system can 
alter its expression	 111. Confined to classical molecular biology techniques with their 
reliance on antibody-based detection, such studies were necessarily confined to a 
limited scope. Such biased approaches often meant that one did not detect a protein 
unless they are actively looking for it. Modern MS-based proteomic studies analyzed 
by a data-dependent acquisition scheme are unbiased and capable of monitoring 
many thousands of protein species in a single measurement.  
Quantitation in MS-based proteomics, including the majority of studies presented in 
this thesis, utilize an isotope-coding strategy to synthesize peptide analogues that 
are identical to the target peptide in every way except for their mass. As an internal 
standard this strategy is unparalleled, as normalizing to this signal can correct for a 
number of parameters covering sample preparation as well as the measurement 
itself	204. When the goal is relative quantitation, the internal standard need only act as 
a fixed signal, a constant magnitude that does not waver across multiple samples 
and, ideally, has an MS intensity similar to the target. This is the most common form 
of quantitation and was employed in the present work in the search for protein 
interactors and for profiling polyubiquitin linkage types. Absolute quantitation, on the 
other hand, interprets the fixed signal as representing a defined amount and 
therefore takes the normalization further and uses it to assign concentration units to 
the measurement. Absolute quantitation is more powerful than relative quantitation. 
By assigning units, one can directly compare the levels of different proteins across 
samples. In the mathematical modeling of the precursors-to-products mechanism in 
non-canonical NF-κB signaling, the absolute values of the precursors and products 
were used to estimate the kinetic parameters governing the various reactions: 
synthesis, degradation, complex formation, and processing	 25. However, it is 
important to be aware that absolute quantitation by MS-based proteomics has its 
limitations, ranging from specific technical issues to the broader picture of cell biology.  
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4.10    Caveats of absolute quantitation.  
Absolute quantitation of NF-κB proteins p100, p105, p52 and p50 was achieved 
using isotopically-heavy peptides purchased from a vendor	 205. A proprietary 
fluorescent C-terminal tag facilitated accurate aliquotting of peptides, delivered as 1 
nanomole lyophilized in plastic tubes. The user re-solubilizes the peptides and 
prepares a stock solution according to a vendor-supplied protocol. During sample 
preparation these reference peptides are added to a solution of whole cell lysate, 
prepared by a Wessel-Fluegge methanol-chloroform extraction	 122, prior to reduction 
and alkylation of protein sulfhydryl groups and tryptic digestion. At this point in the 
process several assumtions have already been made that impact absolute 
quantitation. The first is that the actual amount of lyophilized peptide in the tube 
corresponds with the amount claimed, and the second is that the resolubilization is 
100% efficient. While the first assumption is reasonable enough to make, in my 
experience the process of resolubilization should not be taken for granted.  Method 
development work on the peptides for the expanded NF-κB SRM study encountered 
significant problems with this seemingly straightforward step. Despite following 
dissolution protocols, unexpectedly weak peptide signals during MS characterization 
prompted the discovery that these measures were insufficient. Increasing the shaking 
times as well as increasing the organic solvent content improved the yield, but it is 
challenging to assess the extent of losses. Loss of internal standard peptide, either 
due to vendor error or solubilization problems, will lead to a systematic over-
estimation of the target peptide in the sample. The perfect internal standard would be 
an entire protein labeled with heavy isotopes, quantified accurately, and existing in a 
stable solution	 206. Such a protein could be introduced earlier in the sample 
processing, alongside the initial cell pellet, and therefore correct for all handling steps 
including fractionation, boosting sensitivity for low-abundance molecules. 
 On the sample side, the protein solution the peptides are added to has already 
undergone several manipulations, including ultrasonication, vortexing, precipitation of 
proteins and resolubilization. Cumulatively, these steps alter the proteome through 
heterogeneous extraction, with loss of membrane proteins the most severe	 207. Such 
losses cannot be reasonably assessed and are therefore neglected from 
consideration. One also makes an assumption that the enzymatic digestion is 100% 
efficient, that the target peptides are completely liberated from their parent 
polypeptide. While Schevchenko et al demonstrated efficiencies of ~90%	 121, each 
peptide exists in a unique context determined by the surrounding protein sequence. 
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Secondary protein structures as well as unfavourable residues adjacent to cleavage 
sites affect digest efficiency, although issues with the latter can be avoided with 
careful peptide selection during method development. One can also avoid peptides 
with known PTMs, but there remains a distinct possibility of an undiscovered PTM 
altering the peptide mass and making it invisible to the targeted MS method. From 
the moment the target peptide is released into solution, its isotopically-coded 
analogue acts as a perfect internal standard. Non-specific losses, sample loading, 
chromatography and instrument response will affect both peptides equally	 204. 
However, the number of assumptions that have been made up until this point will 
influence any absolute quantitation efforts. Incomplete protein extraction and 
digestion will lead to an underestimation of the target peptide concentration. 
Compounding the technical difficulties of absolute quantitation is the influence of the 
scientist doing the work. In one study, efforts to quantify the same proteins from 
identical sample solutions using identical protocols saw a 25% variation across 
different research institutes	208.  
It is clear that the very nature of biology itself introduces significant variability 
into an experimental outcome. The behaviour of cells and the expression of proteins 
depend on their environment, and this can change tremendously from lab to lab. Cell 
lines with the same nominal identity may have undergone genetic divergence 209 or 
have been contaminated by other cells or viruses 210. In the present work, the same 
MEF cells grown in normal growth media versus those grown in a depleted SILAC 
media responded differently to the LTβR stimulation. In terms of p100 levels, the 
former reached an endpoint about 3 times lower than the basal levels, while the 
SILAC cells underwent a 2-fold decrease in p100 levels.  
With so much variability derived from the technical and biological aspects of 
this work, how can one know what the best strategy is? The concept of “absolute” 
quantitation is suggestive of some kind of universal truth that will be obtained, that 
Protein X will be found in Cell Y at a concentration of Z. It is impossible to know for 
certain. The best that can be hoped for in absolute quantitation is that the data itself 
will guide the way to the truth. If multiple measurements by multiple labs using 
multiple techniques arrive at a similar number, then eventually this will be accepted 
as being accurate. However one can easily imagine the alternative case, and the 
resulting disputes in the literature justifying one number over another. Given the 
broad dynamic range of protein expression in cells, perhaps absolute quantitation 
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should be approached with broader strokes. Confining a protein’s absolute 
concentration to an order of magnitude can already be quite informative. The IBAQ 
technique used to determine the approximate stoichiometry of PKAC and 
ARHGAP36 in HEK293T cells is a good example of this, distributing proteins across 
the proteome into abundance bins. An advantage of this shotgun approach is that it 
is unbiased and generates a deeper dataset that could be revisited in the future. 
However, a targeted approach such as SRM-MS will provide a more robust 
measurement, and more data points acquired better outline the chromatographic 
peak. Such an approach is necessary for quantifying low-level protein species 
reliably across many samples, such as time courses or clinical samples from large-
scale studies. The ease and robustness of this form of quantitation offsets the 
expense incurred for synthetic reference peptides. An SRM-like technique used on 
quadrupole-Orpitrap instruments may come to dominate in the future	211	212. It follows 
the same principles but the Orbitrap measurement offers higher resolution, mass 
accuracy and the simultaneous measurement of all peptide fragments. While triple-
quadrupole instruments are more affordable, the quadrupole Orbitrap has already 
found a home in many labs specialized in shotgun proteomics.  
 
4.11     Concluding remarks. 
If the past two or three decades are any indication, the future is sure to bring 
new mass spectrometers with faster scanning that offer more sensitivity, mass 
accuracy and resolution. Proteomes will be characterized more completely and 
permit a deeper mechanistic understanding of protein function, particularly in critical 
cell-signaling pathways such as NF-κB that attract considerable interest for links to 
disease and therefore their therapeutic potential. Proteomic approaches will continue 
to be adopted on a larger scale in labs worldwide, though the expense and expertise 
required will still limit it to more specialized groups. These factors have always meant 
the proteomic community is relatively young and small, and this has fostered a 
certain amount of consistency to how this work is executed. What started as a Wild 
West of experimental strategies and bioinformatics approaches was eventually 
tamed and standardized, aided by the collaboration of several top labs in producing 
guideline publications, first for shotgun	 213	 214 and later for targeted proteomics	 204, of 
what constituted sound practices and acceptable data. A perusal of the literature 
shows that proteomics labs around the world now prepare routine samples using the 
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same protocols and measure them with similar chromatographic and instrumental 
settings. There is no question that this has met with tremendous success but it also 
represents a stagnancy that is out of step with the innovative spirit that has driven 
proteomics from the beginning. Indeed, there are groups disrupting these norms by 
exploring things like alternative enzymes to trypsin	 215, MS-friendly detergents	 216, or 
alternative chromatographic stationary phases and flow-rates. Uncovering the 
remainder of the proteome may require a re-examination of some of these 
fundamental practices that may systematically mask protein populations from 
detection.  
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5     Summary 
Activation of the NF-κB precursor protein p100 and p105 by a specific proteasomal 
truncation to yield the active products p52 and p50 is a distinct feature of the non-
canonical pathway but the mechanism governing it remains elusive. A novel mass 
spectrometry-based proteomics strategy was developed, using the targeted selected 
reaction monitoring technique in conjunction with stable isotope labeling for both 
absolute quantitation of proteins and to mark precursor protein populations relative to 
the application of the lymphotoxin β stimulation. In an endogenous murine embryonic 
fibroblast system, we have shown that both precursors are processed to the 
respective products in a parallel and interdependent manner in response to a 
lymphotoxin β receptor agonist. Our Dynamic SRM-SILAC method allowed distinction 
of pre-stimulation protein populations from proteins synthesized de novo post-
stimulation, and revealed a tendency for older precursor molecules to undergo 
degradation while the de novo molecules went on to be processed to the products, 
accounting for the slow and persistent kinetics that are a hallmark of the non-
canonical NF-κB pathway. In addition, the hydrolytic activity of the AAA ATPase 
VCP/p97 was implicated in the generation of de novo p52 and p50. 
An MS-based proteomics screen for specific, radiation-induced protein interactors of 
another key NF-κB player, the regulatory subunit of the IKK complex, IKKγ/NEMO, 
turned up the Enhancer of mRNA Decapping 4 (EDC4). This unexpected finding has 
expanded the known role of NF-κB regulation of protein levels beyond transcription 
into mRNA stability. Separate investigations into the ubiquitin E3 ligase, parkin, 
connected it to the NF-κB pathway through a linear ubiquitination it helps catalyze on 
IKKγ/NEMO. Proteomic analysis of polyubiquitin in the protein kinase A (PKA) 
signalling pathway helped to identify two novel modes of regulation: a lysosomal 
degradation pathway; as well as a pseudosubstrate inhibition mechanism. 
Keywords: 
Targeted proteomics, NF-κB signalling, selected-reaction monitoring mass 
spectrometry, mathematical modeling, polyubiquitination. 
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6 Zusammenfassung 
Die Aktivierung des NF-kB Vorläuferproteins p100 und p105 erfolgt durch eine 
proteasomale Trunkierung, um die aktiven p52 und p50 zu erzeugen. Zur 
Erforschung wurde eine Massenspektrometrie-basierende Proteomik-Strategie 
entwickelt, die mit der gezielten Reaktionsüberwachungstechnik plus einer 
Isotopenmarkierung verwendet wurde. In einem endogenen murinen embryonalen 
Fibroblasten-System konnte gezeigt werden, dass beide Vorläufer zu den jeweiligen 
Produkten in einer parallelen und sich einander bedingenden Weise in Reaktion auf 
einen Lymphotoxin-β-Rezeptor-Agonisten verarbeitet werden. Unsere SRM-SILAC-
Methode erlaubte die Unterscheidung von Prä-Stimulationsprotein-Populationen aus 
Proteinen, die de novo nach der Stimulation synthetisiert wurden, und zeigte eine 
Tendenz für ältere Vorläufermoleküle, sich einer Degradation zu unterziehen, 
während die de novo-Moleküle auf die Produkte verarbeitet wurden. Die langsame 
und anhaltende Kinetik, die ein typisches Merkmal des nicht-kanonischen NF-κB-
Weges ist. Darüber hinaus, konnten wir beobachten, dass die hydrolytische Aktivität 
der AAA ATPase VCP / p97 in der Bildung von de novo p52 und p50 eine Rolle spielt. 
Durch ein MS-basiertes Screening für strahlungsinduzierte Protein-Interaktoren eines 
weiteren NF-κB-Players, der die regulatorische Untereinheit des IKK-Komplexes 
IKKγ / NEMO bildet, konnte der Enhancer von mRNA Decapping 4 (EDC4) entdeckt 
werden. Durch die zusätzliche Untersuchung der E3-Ligase, Parkin, konnte eine 
Verbindung mit dem NF-κB-Weg durch eine lineare Ubiquitinierung hergestellt 
werden. Es konnte gezeigt werden, dass Parkin ist Hauptkomponenten des linearen 
Ubiquitin-Ketten-Assemblierungskomplexes (LUBAC). Die Proteomanalyse im 
Proteinkinase A (PKA) -Signalisierungsweg konnte zwei neuartige 
Regulationsformen identifizieren: K63-verknüpfte Polyubiquitinierung die katalytische 
Untereinheit von PKA, PKAC in Richtung eines lysosomalen pathways führt, und 
auch durch einen Pseudosubstrat-Hemmungsmechanismus. 		
Stichworte: 
 
Gezielte Proteomik, NF-κB-Signalisierung, selektierte Reaktionsüberwachung 
Massenspektrometrie, mathematische Modellierung, Polyubiquitinierung. 
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7     Materials and methods. 
 
7.1     Materials. 
 
7.1.1     Chemicals. 
Acetic anhydride (Sigma-Aldrich, Germany) 
Acetonitrile, Chromasolv LC-MS grade (Fluka, Germany) 
Ammonium bicarbonate (Roth, Germany) 
Ammonium persulfate (Sigma Aldrich, Germany) 
Arginine 13C6 & 13C615N4 (Cambridge Isotope Laboratories, USA) 
Benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate, PyBOP (Merck, 
Germany). 
T-butyl methyl ether (Sigma Aldrich, Germany) 
2-chloroacetamide (Merck, Germany) 
Dimethylformamide (Sigma Aldrich, Germany) 
Dithiothreitol (Sigma Aldrich, Germany) 
Empore C18 solid-phase extraction disc (3M, Germany) 
Formic acid (Sigma Aldrich, Germany) 
Fmoc amino acid derivatives (Intavis, Germany) 
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, HEPES (Sigma Aldrich, 
Germany) 
Isopropanol, Lichrosolv (Merck, Germany) 
L-Lysine-D4 (Cambridge Isotope Laboratories, USA) 
L-Lysine 13C615N2 (Cambridge Isotope Laboratories, USA) 
Methanol, LC-MS grade (Merck, Germany) 
N-methylmorpholine (Intavis, Germany) 
N-methyl-2-pyrrolidone (Sigma Aldrich, Germany) 
Piperidine (Sigma Aldrich, Germany) 
Reprosil-Pur AQ C18 chromatography beads (Dr. Maisch, Germany) 
Rotiphorese acrylamide solution, 30% (Roth, Germany) 
Sodium dodecylsulfate (Merck, Germany) 
SpikeTides TQL synthetic peptides (JPT Peptide Technologies, Germany) 
Tetramethylethylenediamine, TEMED (Sigma Aldrich, Germany) 
Thiourea (Roth, Germany) 
Tris(2-carboxyethyl)phosphine, TCEP (Sigma Aldrich, Germany) 
Trifluoroacetic acid (Sigma Aldrich, Germany) 
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Urea (VWR, Belgium) 
Water, LC-MS grade (Merck, Germany) 
 
7.1.2     Enzymes. 
 
Benzonuclease (Pierce, USA) 
Endoproteinase Lys-C (Wako, Japan) 
Sequencing-grade trypsin (Promega, USA) 
 
7.1.3     Laboratory equipment 
 
Analytical balance XA105DU (Mettler Toledo, Germany) 
Benchtop Centrifuges 5415D and 5430R (Eppendorf, Germany) 
Capillary tubing laser puller (Sutter Instruments, USA) 
Cold trap solvent recovery system (Thermo Savant, USA) 
Fused-silica capillary tubing (Polymicro technologies, USA) 
Hamilton syringe needle, point style 3 & plunger (Hamilton, Switzerland) 
Heating block DB2A (Techne, UK)  
Microscope Sedival (Carl Zeiss, Germany) 
Mini-PROTEAN electrophoresis system (Bio-Rad, Germany) 
Pipet-lite XLS pipets: P2, P10, P20, P200, P1000 (Rainin, USA) 
Pressure bomb for capillary column packing (Biostep, Germany) 
Sonifier 450 ultrasonic cell homogenizer (Branson, USA) 
Thermomixer incubator/shaker (Eppendorf, Germany) 
Vortex Genie 2 (Scientific Industries, USA) 
 
7.1.4     Instrumentation. 
 
Nano-LC-ultra 1D plus (Eksigent, USA) 
PAL HTC-xt autosampler (CTC, Switzerland) 
Proxeon Easy nanoLC1000 (Thermo Scientific, Denmak) 
Q-Trap 5500 triple quadrupole MS (Sciex, Canada) 
Q-Trap 6500 triple quadrupole MS (Sciex, Canda) 
Q-Exactive (Thermo Scientific, Denmark) 
ResPep SL solid-phase peptide synthesizer (Intavis, Germany) 
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7.2     Methods 
 
7.2.1     Solid-phase peptide synthesis of candidates for NF-κB assay. 
Synthetic peptides were prepared to aid in the development of selected-reaction 
monitoring (SRM) MS methods using a solid-phase synthesis approach on an 
automated peptide synthesizer, the ResPep SL (Intavis). The chosen solid-support, 
Tentagel Amide resin, has a modified polystyrene core and is used to generate 
peptide carboxamides. At a scale of 5 μmols synthesis target, a slurry of 22 mg of 
the Tentagel Amide resin (capacity 0.23 mmol/g) in 200 μL dimethylformamide 
(DMF) was required for each peptide. Peptides are synthesized from the C-terminus 
towards the N-terminus in a cycle involving activation of the carboxylic acid with 
benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate (PyBOP) 
followed by deprotection with piperidine to prepare the added residue for the next 
amino acid in the sequence. Acetic anhydride is introduced to scavenge and react 
with and neutralize any unreacted amine groups, and extensive washing with DMF is 
performed between each cycle step to eliminate carryover of reagents and amino 
acid derivatives. The amino acids used are Fmoc-protected derivatives, a chemistry 
used to block the reactivity of amino acid amine groups. The derivatives were all 
prepared as 0.5M stocks in DMF, with the exception of His, Phe and Pro which are 
dissolved with the aid of a sonication bath in N-methyl-2-pyrrolidone. The carboxylic 
acid activator, PyBOP was dissolved in DMF and a fresh solution prepared after 30 h 
to compensate for degradation effects.  Following coupling, deprotection of backbone 
amines is achieved with piperidine. Upon completion of synthesis, the resins with 
peptides bound were washed extensively with ethanol and dried, followed by 
treatment with a solution of 92.5% TFA and 5% triisopropylsilane that cleaves the 
peptide from the solid-phase support to yield the peptide amide, while simultaneously 
deptrotecting reactive side-chains blocked with t-butyl and Boc groups. Following 
cleavage from the resin, peptides were precipitated from solution with cold t-butyl-
methyl ether and the white solids washed with multiple aliquots of more ether.  
 
7.2.2     Quantified SpikeTides TQL peptide standards. 
Peptides were delivered as 1 nmol lyophilized aliquots, the quantitation achieved 
through a proprietary C-terminal fluorescent tag. All peptides are tryptic and have a 
C-terminal lysine or arginine residue isotopically coded as either Lysine 13C615N2 
(Lys8) or Arginine 13C615N4 (Arg10) and a typical proteomic workflow with trypsin 
digestion will cleave off the fluorescent tag. Peptides were dissolved at a 
concentration of 10 pmols/μL in 20% acetonitrile (ACN) with 100 mM ammonium 
bicarbonate buffer (ABC, pH 7). Longer peptides with more hydrophobic character 
were dissolved in 50% ACN/100 mM ABC. Vortexing and sonication in a water bath 
were employed to promote complete dissolution and peptide stocks stored at -80 °C. 
 
7.2.2.1     SpikeTides in an in-solution digest.  
The required amount of SpikeTide was added to the protein lysate at the beginning of 
the workflow. For the absolute quantitation of the precursors and products in the NF-
κB pathway, a working solution of the heavy peptides at 25 fmols/μL was prepared 
and 4.8 μL of this was spiked into 120 ug of MEF cell lysate.  
7					Materials	and	methods.	
	 110	
7.2.2.2     SpikeTides in in-gel digest workflow.  
The SpikeTides are introduced at the end following peptide desalting, as they are too 
small to be retained by the polyacrylamide matrix. In this context the SpikeTides are 
used for relative quantitation and must be pre-digested with trypsin to remove the C-
terminal tag. A portion of the 10 pmol/μL stock solution was diluted with 50 mM ABC 
buffer to a final ACN content of 7%, which is within the tolerance of trypsin. Add 1 μg 
of trypsin and incubate with gentle shaking for 4 h at room temperature. Stop digest 
by adding TFA to a final concentration of 1%, then capture and desalt peptides using 
a StageTip. Wash peptides and elute with 80% ACN, lyophilize and reconstitute 
peptides in a buffer containing 3% ACN and 0.1% formic acid at a concentration of 2 
pmols/μL. To use for relative quantitation, reconstitute samples with buffer containing 
50-100 fmols/μL of heavy SpikeTides. 
 
7.2.3     StageTips for peptide enrichment and desalting. 
Stop-and-Go Extraction Tips are homemade soild-phase extraction devices prepared 
according to Rappsilber et al 217. Punch three discs from 3M Empre C18 material with 
a Hamilton blunt-tipped syringe needle and deposit discs in a P200 pipet tip, using 
the syringe plunger to tamp them down and secure a leak-proof fit. Liquids are 
introduced through the top and the tip is placed through a hole punched in the lid of 
an Eppendorf tube acting as a receiver. Centrifugal force generated by spinning for 2 
min at 5000 rpm in a benchtop centrifuge pushes liquid through the C18 material and 
it collects as flow-through in the receiving tube. Prior to use, the tip is wetted with 50 
μL methanol and equilibrated with 100 μl 2% ACN/1% TFA. Samples (e.g. cell lysate 
digest) are acidified to 1% TFA and spun at maximum speed in a benchtop centrifuge 
to pellet insoluble material. After sample loading, the captured peptides are washed 
with 2% ACN/1% TFA prior to elution with 80% ACN/0.1 % formic acid. Following 
lyophilization in a SpeedVac, samples are reconstituted with 3%ACN/0.1% FA.  
 
7.2.4     Preparation of cell pellet for enzymatic digest. 
Cells derived from experiments in culture were harvested, washed with PBS, 
centrifuged and delivered as pellets in a sample tube. The pellet was solubilized in 
denaturation buffer (6M urea/2M thiourea) using 50 μL for every 1x106 cells. Samples 
are kept chilled on ice, though it should be noted that the concentrated urea solution 
tends to precipitate upon cooling. Vortex vigorously to break up large pieces, then 
use an ultrasonic homegenizer and pulse 8-10 times with the maximum output. This 
improves solubility as well as shearing genomic DNA into smaller fragments to lower 
sample viscosity. Vortex samples again prior to centrifugation to pellet any cell debris 
and remaining insoluble material. Transfer solution to a fresh tube and assay protein 
concentration by Bradford.  
 
7.2.4.1     Wessel-Fluegge extraction of cell lysate. 
Wessel-Fluegge extraction is a liquid-liquid extraction technique designed to 
fractionate biomolecules between immiscible methanol/water and chloroform122. 
Small molecule metabolites and lipids partition to the polar and non-polar phases 
respectively, while protein precipitates out and collects at the interphase region. This 
form of extraction is effective at removing small amounts of detergent that may be 
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present in the sample, as well as removing undesired background molecules that 
may interfere with the protein analysis. Following the ultrasonic homogenizer step in 
the previous protocol, add 400 μL each of chilled methanol, water and chloroform to 
the sample. Place on a shaker at 4 C and shake vigorously for 20 min. Centrifuge 
samples for 10 min at maximum speed to separate the phases. Remove the polar 
upper phase with a pipet, avoiding disruption of the interphase region where a white 
protein precipitate should be visible. Add 600 μl chilled methanol and shake again for 
10 min. Centrifuge again to pellet precipitate and decant off supernatant carefully. 
Air/dry the pellet for 5-10 min in a fume hood, then solubilize in denaturation buffer 
and assay protein content by Bradford.  
 
7.2.5     Bradford determination of protein concentration. 
Dilute protein solution 10 times with water to ensure readings remain within linear 
range of detector. Combine 2 μL of sample with 498 uL of water and 500 μL of 
Bradford reagent in a cuvet. Vortex briefly. Measure absorbance at 595 nm after 
blanking spectrophotometer. Measure absorbance of a serial dilution of bovine serum 
albumin (BSA) spanning 0.1 to 2 mg/mL and use the linear regression analysis to 
convert sample absorbances to protein concentrations.   
 
7.2.6     NanoDrop determination of peptide concentration. 
A protein sample subjected to a typical proteomic workflow of reduction, alkylation, 
digestion and desalting is likely to undergo considerable loss of material due to a 
number of factors, including non-specific binding effects and incomplete C18 capture. 
It is desirable to measure the concentration of peptides in a sample eluted from a 
StageTip that is destined to be injected into an LC-MS/MS system to control for either 
under or or overloading. This can be achieved with the NanoDrop using only 1 μL of 
sample by measuring the absorbance of the peptide bond at 205 nm with an 
extinction coefficient of 31 L mol-1 cm-1. 
 
7.2.7     SDS-PAGE preparatory gel prior to in-gel enzymatic digestion. 
For samples derived from immunoprecipitations where the eluent contains detergents, 
such as Laemmli sample buffer that has been employed to effect the elution, 
embedding the proteins in a polyacrylamide matrix provides a means of immobilizing 
them for the purpose of washing away these MS-incompatible contaminants. Prepare 
a single-phase 8% gel in a 1.5 mm slab with a 5-position comb. Load sample (up to 
80-100 μL volume) and run at a fixed amperage of 55 mA for approximately 10 
minutes, time for the sample to migrate completely into the gel and penetrate 1-2 mm. 
Stain gel for 30 min with Coomassie Plus Imperial stain. Destain with deionized water 
overnight with multiple changes.  
 
7.2.8     In-gel protein digest. 
After the samples have been run on 8% SDS-PAGE preparatory gels, stained and 
destained, the bands are excised with a razor blade and cut into cubes of 
approximately 1-2 mm. The gel pieces are washed with 1 mL volumes of 1:1 
ethanol/50 mM ABC, 50 mM ABC, and again with 1:1 ethanol/ABC for 20 minutes 
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each with vigorous shaking, with the aspirated to waste between each step. The 
pieces are then dehydrated in 1 mL ethanol for 20 min and the solvent aspirated to 
waste before being placed under vacuum (SpeedVac) for 10 min to remove any 
remaining ethanol. The dried gel pieces are rehydrated with 250 μL 10 mM 
dithithreitol (DTT) and incubated at 56 °C for 45 min to reduce disulfide bonds. The 
solution is removed and replaced with 250 μL 55 mM 2-chloroacetamide (CAA), the 
gel pieces protected from light and incubated for 45 min at room temperature. The 
CAA solution is aspirated to waste and the gel pieces washed with 1 mL volumes of 
50 mM ABC and 1:1 ethanol:ABC. The gel pieces are dehydrated again with 1 mL 
ethanol and dried in the SpeedVac before being rehydrated in 300 μL 50mM ABC 
with 1.5 μg of sequencing-grade trypsin and incubated overnight (16 h) at 30 °C. 
After digestion, the supernatant is collected in a fresh tube and the gel pieces 
subjected to extraction with 250 μL volumes of 30% ACN/3% TFA and ACN to 
retrieve the peptides. The combined volumes of 750 μL are placed in the SpeedVac 
and the volume reduced to 100-150 μL before being collected and desalted on a C18 
StageTip device.  
 
7.2.9     In-solution protein digest. 
Protein extract solutions derived from  Wessel-Fluegge extraction of MEF cell pellets 
and assayed by Bradford for protein concentration are subjected to an in-solution 
digest of proteins. Once the required volume of protein solution equivalent to 120 μg 
of protein is placed in a fresh 0.5 mL Eppendorf tube, denaturation buffer is used to 
adjust volumes of all samples in the set (e.g. time course) so that they are equivalent, 
such that all subsequent volumes and sample handling steps are common. 
SpikeTides are prepared as a 25 fmol/μL working stock solution and 4.8 uL added to 
each sample. Tris(2-carboxyethyl)phosphine (TCEP) is added to a final concentration 
of 5 mM and the samples incubated for 30 min at room temperature to reduce 
disulfide bonds. CAA is added to a final concentration of 15 mM and the samples 
incubated for 45 min in the dark. Endoproteinase Lys C is added to each sample at a 
ratio of 1:40 (w/w) and incubated at 30 °C for 2 h. A volume of 50 mM ABC 
equivalent to three times the current total volume is added to reduce the urea 
concentration below 2 M, and then sequencing grade trypsin is added at a ratio of 
1:40 (w/w) and the samples incubated at 30 °C overnight (16 h). The sample 
solutions are acidified by adding 10% TFA to a final concentration of 1% and then 
subjected to a StageTip extraction, with the volume for a single 120 ug sample 
divided across six three-disc StageTips. 
 
7.2.10     LC-SRM-MS analysis of NF-kB in MEF cells. 
Following the in-solution digestion, the peptides were eluted from the StageTip with 
50 μL of 80% ACN/0.1% formic acid into a 96-well plate. The eluate was evaporated 
under vacuum in a SpeedVac and the sample reconstituted with 20 μL 3% ACN/0.1% 
formic acid. An Eksigent nanoLC Ultra1D pump coupled with a CTC-PAL HTC-xt 
autosampler were used to inject 5 μL of sample and resolve it on the self-made 
reversed-phase analytical column emitter with a gradient from 3% to 36% ACN over 
38 minutes at a flow-rate of 250 nL/min. The total gradient length including 
equilibration time was 60 min, chosen to keep the overall measurement of the 
complete batch of samples as short as possible to prevent a technical failure of the 
MS or column from interrupting the analysis. The column eluent was electrosprayed 
into a Sciex 5500 Q-trap triple-quadrupole mass spectrometer operating at an 
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ionization potential of 2.3 kV and an interface heater temperature of 150 °C, with a 
sheath gas setting (GS1) of 15 and a curtain gas setting of 40 to minimize source 
contamination. The declustering potential (DP) was maintained at 150 V for all SRM 
transitions, with a . The resolution of quadrupoles 1 and 3 was kept at “Unit”, a peak 
half-width of 0.7 Da. All samples were measured in triplicate, and the raw data files 
in .wiff format were analyzed with Sciex MultiQuant v1.1. Using this software, the 
peaks corresponding to the selected peptides were integrated manually, drawing a 
baseline between the valleys bounding it on each side. The data was unsmoothed  to 
prevent loss of intensity and to make the peak boundaries more apparent. The peak 
area for each transition was divided by the peak area for the corresponding transition 
from the reference SpikeTide to give a ratio. The ratios for all transitions and all 
injections were averaged and a standard deviation calculated.  Five fmols of 
reference peptide were injected with each sample, and this value was used to 
convert peak area ratios into absolute values. The absolute values were normalized 
to the amount of initial total protein represented by the injection, 5 μg, to allow 
comparison between the wild-type MEF cells and the mutant cell lines which had 
variable cell volumes. The peptide signals representing the N-terminal products, p50 
and p52, were adjusted by subtracting the signal from the C-terminal peptide, which 
represent the intact p105 and p100, respectively.  
 
7.2.11     LC-MS/MS measurement of peptides derived from in-gel 
digestion of immunoprecipitations, and bioinformatic analysis of raw 
data. 
Following in-solution or in-gel digestion of proteins derived from whole cell lysates or 
immunoprecipitations, peptides were eluted from the StageTip with 50 μL of 80% 
ACN/0.1% formic acid into a 96-well plate. The eluate was evaporated under vacuum 
in a SpeedVac and the sample reconstituted with 20 μL 3% ACN/0.1% formic acid. A 
Proxeon nLC nanoflow HPLC with integrated autosampler was used to inject 5 μL of 
sample and form a gradient from 3 to 38% ACN over 118 min at a flow-rate of 250 
nL/min,  with a total gradient legth of 155 min including column equilibration. The 
column eluent was electrosprayed directly into the Q-Exactive operating at an 
ionization potential of 1.8kV. A Top 10 data-dependent acquisition method was 
employed, collecting MS1 fullscan spectra from 300 to 1800 m/z at a resolution of 70, 
000, an automatic gain control (AGC) target of 1e6 ions and a maximum injection 
time of 120 ms. The ten most abundant peptide precursor ions were selected for 
MS/MS via an isolation window of 2 m/z and fragmented by Higher-energy collisional 
dissociation (HCD) at a normalized collision energy of 26 eV. Fragments were 
collected for 60 ms (120 ms for lower-complexity immunoprecipitations) with an AGC 
target of 1e5 ions and scanned by the Orbitrap at a resolution of 17,500 between 200 
and 2000 m/z. Once measured, precursor ions were excluded from MS/MS selection 
for 30 s to avoid redundancy.  
Data files from the measurements in .raw format were analyzed by MaxQuant 
v1.2.2.5 218 for the NEMO IP samples, and by v1.5.2.8 otherwise. Samples subjected 
to SILAC labeling used a multiplicity of 2 with Lys8 and Arg10 labels selected. 
Methionine oxidation and protein N-terminal acetylation were chosen as variable 
modifications and carbamidomethylation of cysteine residues as a fixed modification. 
The maximum number of missed cleavages was set at 2 and the digestion mode was 
set to Trypsin/P. Unlabeled samples measured in triplicate were subjected to a label-
free quantification by selecting the LFQ settings with a minimum ratio count of 2. 
Human samples were analyzed against Uniprot database HUMAN.2014-10.fasta and 
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mouse samples against Uniprot database MOUSE.2014-10.fasta. Fragment mass 
tolerance was set to 20 ppm and the false-discovery rate set to 1%. In all cases, 
match between runs with a window of 0.7 min was enabled to increase coverage. 
Visualization of data in the output file Protein Groups was achieved using the open-
source R Project for Statistical Computing. 
 
7.2.12     In-house manufacture of reversed-phase analytical columns 
with emitters.  
The analytical columns used for all LC-MS measurements were prepared from fused-
silica capillary with a polyimide coating from Polymicro Industries and had an outer 
diameter of 365 μm and an inner diameter of 75 μm. 50 cm lengths of tubing were 
cut and the polyimide coating in the center 2 cm removed by briefly burning with a 
flame and rubbing away with an isopropanol-wetted laboratory wipe. The emitters 
were formed using a Laser Puller P-2000 machine (Sutter Instruments) that softens 
the fused-silica with a laser and applies force along the capillary’s axis to stretch the 
tubing into a fine point. A Heat setting of 275, a Velocity of 6, and a Delay of 255 ms 
were used to pull the 50 cm length of tubing into two 25 cm empty columns. The 
columns were packed with Dr. Maisch Reprosil-Pur C18 material that had a particle 
size of 3 μm and internal pores of 100 Å using a pressure-injection cell (Biostep, 
GmbH). After packing the column bed length was cut to 20 cm and the column stored 
in methanol until use.  
 
7.3     Collaborator contributions: cell culture, 
immunoprecipitations, and mathematical modelling. 
Dr. Buket Yilmaz of the Max Delbrueck Centre for Molecular Medicine (MDC) 
performed cell culture of MEF cells, including stimulation time courses, Dynamic 
SILAC labeling, inhibition of ribosome, proteasomes and p97, and analyzed samples 
in parallel by Western blotting. Mathematical modeling, including calculations and 
simulations were performed by Dr. Bente Kofahl, Dr. Katherina Baum and Dr. Jana 
Wolf, with relevant details published in Yilmaz et al, Cell Reports, 2014 25. Inbal 
Ipenberg (MDC) labeled MEF cells with SILAC amino acids and performed p100 
immunoprecipitations according to the protocol established by Dr. Yilmaz. Nadine 
Mikuda (MDC) performed cell culture of HepG2, MEF and U20S cells and 
immunoprecipitations for the interactomics investigations of IKKγ/NEMO . Anne-
Kathrin Mueller-Rischart of the Ludwig Maximilians University performed all cell 
culture of MEF cells for the investigations into Parkin, including pull-downs of 
transfected cell lines as well as RNA silencing of wild-type MEFs 130. Rebecca Eccles 
(MDC) performed cell culture, transfections of HEK293T and NGP neuroblastoma 
cells for the investigations into PKA inhibition by ARHGAP36 187. 
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8.1 Abbreviations 
 
AAA   ATPaSE associated with diverse cellular activities 
AICc   Akaike information criterion 
ARD   Ankyrin repeat domain 
AUC   Area under curve 
cAMP   Cyclic adenosine monophosphate 
CE   Collision energy 
CI   Chemical ionization 
CID   Collision-induced dissociation 
CoIP   Protein complex immunoprecipitation 
DBeQ   N2,N4-dibenzylquinazoline-2,4-diamine 
DDA   Data-dependent analysis 
DNA   Deoxyribonucleic acid 
DP   Declustering potential 
EDC4   Enhancer of mRNA decapping protein 4 
EI   Electron impact 
EMS   Enhanced MS 
ER   Enhanced resolution 
ERAD   Endoplasmic reticulum associated degradation 
ESI   Electrospray ionization 
FAB   Fast-atom bombardment 
Fmoc   Fluorenylmethyloxycarobonyl 
H-Arg-10  Heavy arginine 13C615N4 
H-Lys-8  Heavy lysine 13C615N2 
HPLC   High-performance liquid chromatography 
IBAQ   Intensity-based absolute quantitation 
IKK   Inhibitor of κB kinase 
IKKΥ   Inhibitor of nuclear factor kappa-B kinase subunit gamma 
K-GG   Lysine with diglycyl remnant from ubiquitin 
KO   Knockout 
L-Arg-0  Light arginine 12C614N4 
L-Lys-0  Light lysine 12C614N2 
LC-MS/MS  Liquid chromatography tandem mass spectrometry 
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LFQ   Label-free quantitation 
LT   Lymphotoxin 
LTβR   Lymphotoxin beta receptor 
LUBAC  Linear ubiquitin assembly complex 
M-Arg-6  Medium-heavy arginine 13C614N4 
MEF   Murine embryonic fibroblast 
MS   Mass spectrometry 
MS/MS  Tandem mass spectrometry 
NaF   Sodium fluoride 
NaV   Sodium vanadate 
NEM   N-ethylmaleimide 
NF-kB   Nuclear factor κB 
NGP   Neuroglioblastoma 
NIK   NF-κB inducing kinase 
PFL   Protein frequency library 
PINK1   PTEN-induced putative kinase protein 1 
PKA   Protein kinase A 
PKAC   Protein kinase A catalytic subunit 
PKAR   Protein kinase A regulatory subunit 
PKI   Protein kinase inhibitor 
Q1,2 or 3  Quadrupole 1, 2 or 3 
QQQ   Triple quadrupole 
qRT-PCR  Quantitative real-time polymerase chain reaction 
RHD   Rel homology domain 
RIP1   Receptor interacting protein kinase 1 
RNAseq  Ribonucleic acid sequencing 
SDS-PAGE  Sodium dodecyl sulfate polyacrylamide gel eletrophoresis 
SILAC   Stable isotope labeling in cell culture 
siRNA   Small interfering RNA 
SRM   Selected reaction monitoring  
TFA   Trifluoroacetic acid 
TNF   Tumor necrosis factor 
TOF   Time-of-flight 
TRAF   TNF receptor associated factor 
Ub   Ubiquitin 
UBAN   Ubiquitin binding in ABIN and NEMO 
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UBL   Ubiquitin-like  
UFD   Ubiquitin fusion degradation 
VCP/p97  Vasolin-containing protein 
WT   Wild-type 
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